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ABSTRACT 
Two clinical trials investigating the effect of modulating two dietary components, tea 
containing polyphenols and vitamin D aimed at improving non-haem iron absorption 
and iron status recovery, were carried out in a cohort of healthy and iron deficient 
UK women, respectively.  
Tea has been shown to be a potent inhibitor of non-haem iron absorption but it 
remains unclear whether the timing of tea consumption relative to a meal influences 
iron bioavailability, with limited published evidence, especially in human trials. The 
aim of the first study was to investigate the effect of tea consumption on non-haem 
iron absorption and to assess the effect of time interval of tea consumption on non-
haem iron absorption relative to an iron-containing meal, in a cohort of healthy 
female participants using a stable iron isotope (57Fe).  
Twelve participants (mean age (± S.D): 24.8 ± 6.9 years) were administered a 
standardised breakfast porridge meal, extrinsically labelled with 4 mg of 57FeSO4 on 
3 occasions consecutively, with a 14-day time interval between each test meal (TM). 
The isotope-labelled test meal was administered with (i) water (TM I); (ii) tea 
administered simultaneously with a meal (TM II); and (iii) tea administered 1 hour 
post-meal (TM III). A reference iron dose was also administered (3 mg 57FeSO4 with 
35 mg ascorbic acid) without a test meal 14-days after the final test meal (TM III). 
Fasted venous blood samples were collected for iron isotopic analysis and 
measurement of iron status biomarkers, including plasma hepcidin concentration. 
Iron isotopic analysis was carried out using ICP-MS, and fractional iron absorption 
was estimated by the erythrocyte iron incorporation method.  
Mean (± S.D) fractional iron absorption was 5.69 ± 8.5% (TM I), 3.57 ± 4.2% (TM II) 
and 5.73 ± 5.4% (TM III). Mean fractional iron absorption was found to be 
significantly higher (2.2%) with TM III compared to TM II (p = 0.046).  Mean total iron 
absorbed was also found to be significantly higher (0.043 mg) when tea was 
consumed 1-hour post-meal (TM III) compared to when tea was administered 
simultaneously with test meal (TM II) (p= 0.049). A 2-fold reduction in the inhibition 
effect of tea (relative to water) was observed, from 37.2% in TM II to 18.1% in TM III. 
Plasma hepcidin concentration was found to be associated with fractional iron 
absorption (r=-0.475, p=0.007) and total iron absorbed (r=-0.560, p=0.004). 
This study demonstrates that tea consumed with an iron-containing test meal 
simultaneously leads to decreased iron absorption, and that a 1-hour time interval 
between a meal and tea consumption attenuates the inhibitory effect, resulting in 
increased iron absorption. These findings are not only important in relation to the 
management of iron deficiency, but should also influence dietary advice, especially 
to those at risk of iron deficiency. 
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Vitamin D has recently been suggested to be involved in regulating iron absorption 
by its action on hepcidin suppression, but there is paucity of supporting literature, 
especially in human trials. The objective of the second study was to investigate the 
effect of an 8-week high dose of daily vitamin D3 supplementation (1500 IU) 
consumed with 60-grams of iron-fortified breakfast cereal containing 9 mg iron on 
haematological indicators and hepcidin response in a cohort of marginally and iron 
deficient premenopausal UK female participants. A total of 50 participants (mean 
age (± S.D): 27.4 ± 9.4 years) were randomised to receive either 1500 IU (38 µg) of 
vitamin D3 or placebo. Both groups were instructed to consume iron-fortified 
breakfast cereals with 200 ml of semi-skimmed milk, with either vitamin D3 or a 
placebo daily according to the group assigned. Participants attended 3 clinics at 
baseline, 4 weeks and 8 weeks, and fasted venous blood samples were collected 
for measurement of iron and vitamin D status biomarkers at each time point. 
Anthropometric measurements were performed at each time point, and a 3-day food 
diary was provided at baseline and post-intervention. Mixed model repeated 
measures analysis of variance (ANOVA) was performed to determine the effect of 
intervention and the interaction with time points for all iron and vitamin D status 
biomarkers.  
There was a significant increase in the two main iron status biomarkers: 
haemoglobin concentration and haematocrit % from baseline (Week 0) to post-
intervention (Week 8) in the vitamin D group, but not in the placebo group. It was 
demonstrated that mean (±S.D) haemoglobin concentration increase by 0.36 ± 0.71 
g/dl from baseline to post-intervention in the vitamin D group was significantly higher 
than the placebo group (p=0.037). Mean (±S.D) haematocrit % increase from 
baseline to post-intervention was also significantly higher in the vitamin D group 
(1.82 ± 3.12 %) compared to the placebo group (p=0.032). It was also established in 
the present study that baseline concentrations of haemoglobin and plasma 25(OH)D 
had a significant effect on participants’ response to the intervention. Interestingly, it 
was also observed that improvement in plasma vitamin D binding protein 
concentrations were strongly associated with the recovery of the red blood cell 
(r=0.653, p=0.002), mean corpuscular volume (r=0.612, p=0.004), haematocrit 
levels (r=0.751, p=0.0001), haemoglobin (r=0.638, p=0.002) and mean corpuscular 
haemoglobin concentrations (r=-0.592, p=0.006).  
This study demonstrates that vitamin D3 supplements (1500 IU), consumed daily 
with iron-fortified breakfast cereal is a novel iron absorption enhancer in 
premenopausal women with marginal and low iron stores. An upregulation in plasma 
vitamin D binding protein concentration was demonstrated to be associated with the 
restoration of participants’ iron status, however, the underpinning mechanism was 
unclear, which needs further investigations. These findings are clinically relevant, 
especially in the UK where iron deficiency prevalence is currently 16% in women of 
child-bearing age with vitamin D deficiency prevalence that could reach up to 39% in 
adults during the winter months.  
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1.0 INTRODUCTION 
1.1 IRON 
Most living organisms require iron, which is one of the essential trace elements 
(Ganz, 2013) that plays a role in numerous important biochemical functions at the 
cellular level, including biosynthesis, cell proliferation, oxygen transportation and 
energy metabolism (Wang & Pantopoulos, 2011). Iron exists in two main oxidation 
states, the ferrous (Fe2+) or ferric (Fe3+) state, and ferric iron is readily converted to 
ferrous iron with the presence of reducing agents, or ferrous iron is converted to the 
ferric form facilitated by molecular dioxygen (Aisen, Enns, & Wessling-Resnick, 
2001). Due to it’s ability to occur in two different states, reduced and oxidised iron is 
capable of transferring electrons, facilitating reactions, forming complexes with 
proteins, and binding to oxygen (Aisen et al., 2001), but the ferric form of iron has 
low solubility that leads to poor bioavailability (Wang & Pantopoulos, 2011). 
However, the free form of iron can be lethal, resulting in significant cell and tissue 
damage due to the production of radical scavengers known as reactive oxygen 
species (ROS) (Silva & Faustino, 2015). Humans developed their own mechanism 
to take advantage of the presence of iron by utilising it for metabolism purposes 
whilst diminishing the ROS activities. This manipulation of iron, however, requires 
specific proteins to facilitate iron homeostasis processes which include intestinal 
absorption, and transportation to circulatory system, body utilisation, storage and 
functional sites (SACN, 2010; Silva & Faustino, 2015).  
A typical adult human comprises of approximately 3-4 g iron, and the largest iron 
depot (2-3 g) is in haemoglobin of the erythrocytes (Ganz, 2013). The incorporation 
of body iron into haemoglobin is required for the development of erythroid 
precursors or mature red blood cells (RBC) (Andrews, 1999) and transportation of 
oxygen (Wang & Pantopoulos, 2011). Figure 1.1 illustrates the iron distribution in 
different human tissues, which shows that about 1-2 mg of iron is mobilised across 
the human body daily in the non-pathological state. The distribution begins with the 
absorption of dietary iron by the intestinal enterocytes which enters the circulation, 
and forms iron-transferrin complexes to be distributed to various tissues (Andrews, 
1999). Iron is distributed for utilisation in muscle fibres that exists in myoglobin form 
(300 mg), in the bone marrow (300 mg), and the greater proportion in erythrocytes 
as haemoglobin (1.8 g). The repository form of iron can be found in parenchymal 
hepatocytes of the liver (1 g) or in the macrophages of reticuloendothelial system 
(600 mg) (Andrews, 1999). Macrophages are responsible for iron recycling from the 
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degraded senescent RBCs (Knutson & Wessling-Resnick, 2003). As iron has an 
immediate turnover and rapid changes in the utilisation, the mobilisation of the 
recycled iron into plasma is tightly controlled to ensure that plasma iron 
concentrations are constantly in a balanced state (Ganz, 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Iron distribution in typical adults - adapted from Andrews (1999) 
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1.2 IRON METABOLISM 
As iron is not routinely excreted by specific mechanisms, iron metabolism does not 
involve typical pathways, as with other metals. Iron metabolism is different in that a 
greater amount of the daily iron requirement (~90%) is obtained endogenously, from 
the breakdown of circulating RBCs. Iron losses, especially for premenopausal 
women occur from the monthly menstrual cycle, in addition to average obligatory 
losses from various sources such as skin, the urinary tract, airways and the intestine 
(Hurrell & Egli, 2010). It was reported that a healthy man will lose an average of 
nearly 14 µg/kg body weight from gastrointestinal and urinary tracts, bile or dermis, 
which is estimated to be between 0.9 to 1.0 mg/day (Green et al., 1968). Taking into 
account these losses and the physiological needs for growth, iron must be obtained 
from the diet in order to maintain optimal iron balance (Hurrell & Egli, 2010).  
Tightly-regulated iron homeostasis exists to ensure sufficient body iron content and 
plasma iron concentrations by controlling intestinal dietary iron uptake and 
regulating  iron release from the macrophages (Ganz, 2013). Different transporter 
proteins and enzymes are specifically required for the transportation and handling of 
iron, as well as for the iron homeostatic control (Andrews & Schmidt, 2007), 
described further in Table 1.1. There are 3 prime cells that are individually vital in 
iron homeostasis including; (i) duodenal enterocytes which are involved in iron 
uptake, (ii) macrophages which are involved in iron recycling and (iii) hepatocytes 
which are involved in iron storage (Ganz, 2013). The key step in iron metabolism is 
the transfer of iron from enterocytes, macrophages and hepatocytes to the plasma, 
which is regulated by a peptide hormone, known as hepcidin that is produced in 
liver. Hepatocytes and macrophages are the iron depot for the proportion of iron not 
transported into plasma, whilst iron that is retained in enterocytes will be sloughed 
off after 2-5 days (Ganz, 2013). For this reason, iron body content is indicated by the 
segregation of iron between enterocytes and the plasma (Donovan et al., 2005).  
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1.2.1 Intestinal dietary iron absorption at duodenal enterocytes 
A substantial proportion of physiological iron can be obtained from two sources; via 
the placenta during the foetus stage of life, or through intestinal uptake after birth. 
Dietary iron becomes the chief source of iron, as the iron accumulated during the 
foetus phase is rapidly utilised in the first few months postpartum (Fuqua, Vulpe, & 
Anderson, 2012). Dietary iron can be classified into haem or non-haem iron, which 
has different pathways of absorption. However, the absorption of haem iron is poorly 
understood, whilst non-haem iron absorption has been extensively discussed (Ganz, 
2013). Additionally, the bioavailability of non-haem iron is influenced by the 
presence of iron enhancers such as meat and ascorbic acid, or iron inhibitors such 
as tannins or phytates that are predominantly found in plants (Abbaspour, Hurrell, & 
Kelishadi, 2014).  
As excess of iron may lead to release of the ROS, intestinal iron uptake is tightly 
regulated to; (i) supply an adequate amount of iron needed for regular human body 
functions, (ii) rapidly respond to physiological requirements, such as pregnancy, and 
(iii) restrain iron uptake when there is a sufficient amount of iron in a human body. 
The disruption in regulation of intestinal iron absorption may result in clinical 
outcomes such as iron overload, that are characterised by increased iron uptake in 
spite of replete iron stores (Fuqua et al., 2012). This iron loading, or hereditary 
haemochromatosis (HH) is caused by a genetic mutation, affecting hepcidin 
antimicrobial peptide (HAMP) gene expression that results in low hepcidin 
concentration (Gulec, Anderson, & Collins, 2014). On the contrary, there are few 
syndromes or diseases that can cause a lowered intestinal iron absorption. One of 
the most described types of this disorder is iron-refractory iron deficiency anaemia 
(IRIDA), which is characterised by increased concentration of hepcidin due to a 
mutation in gene transmembrane protease, serine 6 (TMPRSS6), and the presence 
of anaemia, with no response to oral iron therapy (Heeney & Finberg, 2014).  
Intestinal iron absorption is comprised of a number of processes, including; (i) the 
transportation of iron across the apical membrane of the duodenum, (ii) the storage 
of iron as ferritin, or mobilisation from stores subject to requirements, (iii) 
transportation of iron across the enterocytes, and (iv) iron transfers across the 
basolateral membranes. Table 1.1 summarises the description of the key molecules 
and enzymes involved in the absorption process, including the functions of each 
molecule or enzyme in the steps involved in intestinal iron absorption. 
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Table 1.1 Molecules and enzymes involved in the regulation of intestinal 
iron absorption  
Molecules/Enzymes 
1. Duodenal cytochrome B (DcytB) 
 A ferric reductase brush border enzyme that reduces dietary iron ferric 
(Fe3+) into ferrous iron (Fe2+). 
 Assumed to be a haem protein that utilises ascorbic acid in the reduction 
process, and is highly expressed in the presence of iron deficiency & 
hypoxia (McKie et al., 2001).  
 
2. Divalent metal transporter 1 (DMT-1)  
 Transfers Fe2+ across cell membranes. 
 Acts as a proton symporter, which works effectively in a low pH 
environment (Gunshin et al., 1997). 
 
3. Haem carrier protein 1 (HCP-1) 
 Transports haem iron as intact into the enterocyte (Shayeghi et al., 2005). 
 The mechanism is not fully established. Postulated that haem iron is 
degraded by haem oxygenase and enters the same iron pool with non-
haem iron (Andrews & Schmidt, 2007). 
 
4. Ferritin 
 A protein that stores iron in the enterocytes in order to regulate the export of 
iron into circulation (Ganz, 2013). 
 There is no established mechanism on how iron is transported from ferritin 
to bind to iron exporter (Ganz, 2013). 
 
5. Ferroportin (FPN) 
 Exports iron from the enterocytes into the blood circulation via hephaestin 
that mediates the oxidisation of Fe2+ to Fe3+ (Vulpe et al., 1999). 
 Exists at the enterocytes membranes (Canonne-Hergaux, Donovan, 
Delaby, Wang, & Gros, 2006) and hepatocyte surface (Ramey et al., 2010). 
 
6. Transferrin (TF) 
 The iron carrier protein that primarily offers high-affinity binding sites for 
plasma iron which the concentrations depends on local conditions (Andrews 
& Schmidt, 2007).   
 High in concentration when there is high availability of iron in circulation due 
to recent duodenal uptake (Andrews & Schmidt, 2007).  
 Low in concentration when iron is used by erythroid precursor cells to 
produce RBCs in the bone marrow (Andrews & Schmidt, 2007).  
 
7. Hepcidin  
 Peptide hormone that is produced in the liver (Ganz, Olbina, Girelli, 
Nemeth, & Westerman, 2008). 
 Regulates iron relocation from enterocytes, macrophages and hepatocytes 
into plasma (Ganz, 2013).  
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Figure 1.2 shows the iron uptake process from the cell into the blood circulation, 
which involves several different transporters and enzymes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Haem and non-haem intestinal iron absorption pathways in 
humans 
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Non-haem iron is composed mainly from an inorganic form of iron (Fe3+) and is 
reduced to the absorbable form of ferrous (Fe2+) by duodenal cytochrome b (DcytB), 
a ferric reductase enzyme. Once reduced into ferrous form, divalent metal 
transporter 1 (DMT1) transports the iron into the intracellular iron pool in the 
enterocyte, known as labile iron pool (LIP). Unlike non-haem iron, haem iron is 
absorbed intact into the enterocyte via haem carrier protein 1 (HCP-1), degraded by 
haem oxygenase (HO) and released into the same pool (LIP) joining iron from the 
non-haem pathway. The absorbed iron will be at this point either (a) stored in 
enterocytes as ferritin, (b) utilised, e.g. for instance to produce haem, or (c) exported 
from the basolateral membrane into the blood circulation via the transporter 
ferroportin (FPN1). As transferrin will only receive a ferric form of iron, ferrous iron is 
re-oxidised into the ferric form via hephaestin and subsequently binds transferrin in 
blood circulation to be distributed to various tissues in the body (Gulec et al., 2014; 
Sharp & Srai, 2007; Steele, Frazer, & Anderson, 2005).  
1.2.2 Utilisation of iron at various tissues for cellular functions 
In a non-pathological state, 75% of iron is utilised in the development of erythroid 
precursors and RBC production (Andrews & Schmidt, 2007). Once iron is absorbed, 
it is bound to transferrin (TF) and forms transferrin-iron complexes (TF-I) (Andrews 
& Schmidt, 2007). Iron utilisation begins with the binding of TF-I complexes with 
transferrin receptor (TfR) that is expressed by the erythroid precursors, preparing for 
delivery to the required cells for cellular functions (Silva & Faustino, 2015). 
Subsequent to the binding, the TF-I/TfR complex undergoes a clathrin-mediated 
endocytosis, which causes changes in the shape of the complex that results in the 
release of iron (Fe3+) (Andrews & Schmidt, 2007; Hentze, Muckenthaler, & Andrews, 
2004).  
A ferric reductase known as six-transmembrane epithelial antigen of prostate 3 
(STEAP3) is found in high concentrations in haematopoietic tissues, which is 
responsible to reduce ferric iron to ferrous iron before transportation into a 
cytoplasm (Ohgami et al., 2005). After the iron is released, STEAP3 reduces the 
ferric iron (Fe3+) into the ferrous form (Fe2+) (Andrews & Schmidt, 2007; Silva & 
Faustino, 2015), before the iron transporter known as divalent metal transporter 1 
(DMT-1) (Table 1.1) transfers the reduced iron (Fe2+) into the cytoplasm across the 
endosome membrane (Fleming et al., 1998). Both TF and TfR are reused for 
another cycle of iron binding and absorption, following the recycling process to the 
cell membrane surface (Hentze et al., 2004). 
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Poly(rC) binding protein 1 (PCBP1) is an RNA-binding protein that is found in the 
cytosol and nucleus of mammal cells (Shi, Bencze, Stemmler, & Philpott, 2008). Iron 
that leaves endosomes will move into mitochondria, directly or mediated by PCBP1 
(Shi et al., 2008). A protein known as mitoferrin-1, encoded by the SLC25A37 gene 
is the chief iron importer which facilitates iron transport into the mitochondria 
membrane (Shaw et al., 2006). Once in the mitochondria, iron is then used to initiate 
haem synthesis and subsequently used to produce haemoglobin and RBC (Andrews 
& Schmidt, 2007). Iron is also utilised in the biosynthesis of iron-containing sulphur 
(ICS) protein that is needed for transfer of electrons (Silva & Faustino, 2015) and 
oxidative phosphorylation (Richardson et al., 2010). The mechanism through which 
muscle assimilates iron to produce myoglobin is unclear and poorly understood 
(Andrews & Schmidt, 2007).  
1.2.3 Storage and recycling of iron 
Since there is no mechanism in place to secrete iron, and intestinal uptake accounts 
for only 10% of iron requirements per day, iron recycling involves iron already 
available within the system, in order to ensure a satisfactory amount of circulating 
iron (Andrews & Schmidt, 2007). The amount of circulating iron is primarily a 
derivative of aged and deteriorated RBCs that are phagocytosed by splenic 
macrophages. The engulfed RBCs undergo lysis and iron is released and 
transported to plasma transferrin once haemoglobin is catabolised by haem 
oxygenase (Andrews & Schmidt, 2007). Whilst ferroportin (FPN) mediates the iron 
transport from macrophages to bind to transferrin and distribute to specific tissues 
(Hentze, Muckenthaler, Galy, & Camaschella, 2010), some iron is retained in 
macrophages as a depot (Andrews & Schmidt, 2007). Iron is stored predominantly 
as ferritin in hepatocytes to serve two key functions; to ensure the absence of free 
iron that may damage cells, and to ensure sufficient iron mobilisation when there is 
demand (Silva & Faustino, 2015). Ferritin is comprised of 24-subunits of both heavy 
and light polypeptide chains which forms a spherical shape capable of storing more 
than 4500 iron atoms inside the core of the sphere (Wang & Pantopoulos, 2011). 
Ferritin is not only found in serum, but also in the cell cytosol, mitochondria and 
nucleus. Iron is released to the required cells by degradation of lysosome and 
proteasome (Silva & Faustino, 2015), depending on the iron levels, whether it is 
depleted or sufficient (De Domenico, Ward, & Kaplan, 2009). 
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1.3 REGULATION OF IRON METABOLISM  
Iron levels are maintained homeostatically via several mechanisms, and iron uptake, 
recycling and storage are part of these mechanisms. However, iron uptake may be 
subject to changes, resulting in iron release from the storage and cells. Under 
increased demands, iron uptake, as well as released iron from macrophage storage 
will be rapidly increased. On the contrary, stored iron increases when there is iron 
overload due to increased iron absorption to avoid higher concentrations of free iron 
(Finch, 1994; Gavin, McCarthy, & Garry, 1994). Iron metabolism is strictly regulated 
at cellular and systemic levels (Silva & Faustino, 2015). Ferritin, the iron storage 
protein which is produced in all mammalian cells regulates iron metabolism at the 
cellular level by storing iron when there is excess, and releasing iron with demand 
(Andrews & Schmidt, 2007). Hepcidin has been reported to be a systemic iron 
regulator (Andrews & Schmidt, 2007).  
1.3.1 Role of hepcidin in regulating iron metabolism 
Hepcidin is produced in the liver and this peptide hormone is suggested to be partly 
responsible for regulating iron balance by obstructing intestinal iron absorption 
(Gulec et al., 2014). The HAMP gene which was first discovered at the long arm of 
chromosome 19, is where hepcidin is produced, consisting of a single peptide and 
25 acid amino sequence (Hunter, Fulton, Ganz, & Vogel, 2002). Hepcidin 
expression is triggered when ferritin concentrations are high, and also when there is 
inflammation or infection, which leads to a decrease amount of circulating iron. The 
iron transporter ferroportin is eventually degraded following the internalisation, which 
is caused by the interaction between hepcidin-ferroportin. Conversely, hepcidin 
production is downregulated in the presence of iron deficiency, pregnancy and 
tissue hypoxia (Gulec et al., 2014). In a normal and healthy individual, the 
downregulation process of iron uptake takes place when there are adequate iron 
stores, however, in hereditary haemochromatosis patients, iron will accumulate in 
various organs including, the pancreas, heart, liver or other tissues as a result of 
increased iron absorption (Gulec et al., 2014). Hepcidin expression is regulated by 
different stimuli occurs at systemic levels, including; (i) circulating iron 
concentrations, (ii) hypoxia, (iii) erythropoiesis, (iv) depleted or excess iron and (v) 
presence of inflammation. The expression is greater with the presence of infections 
or inflammations, iron overload and increased serum iron, whilst it reduced in 
response to erythropoiesis, hypoxia and iron deficiency (Lin et al., 2007; Nicolas et 
al., 2002; Vokurka, Krijt, Sulc, & Necas, 2006), described individually as follows.  
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1.3.1.1 Circulating iron concentrations: presence of iron overload or iron 
deficiency 
The expression of HAMP gene regulated by iron levels is necessary to avert the 
incidence of iron overload and iron deficiency in humans. There are different 
proteins involved in regulating hepcidin expression, and mutations in these proteins 
causes decreased hepcidin which leads to iron overload, or increased hepcidin, 
which results in iron deficiency (Ganz, 2011). The mutations in haemochromatosis 
(HFE), transferrin receptor 2 (TfR2), and hemojuvelin (HJV) genes are associated 
with a human hereditary haemochromatosis disorders, whilst the mutation in 
TMPRSS6 gene is related to severe iron deficiency (Ganz, 2011).  
1.3.1.2 Infection and inflammation 
Iron deficiency may be caused by infection due to utilisation of iron by pathogens to 
proliferate, and for survival. Further inflammation in the gut can reduce intestinal iron 
uptake and systematically iron can be retained iron in macrophages, mediated by 
hepcidin expression. The retained iron will subsequently lead to low circulating iron 
concentrations (Ganz, 2011). Different pro-inflammatory cytokines (IL-6, IL-22) are 
released when pathogens are identified as foreign substance by cells, such as 
macrophages (Silva & Faustino, 2015). The cytokine subsequently forms a ligand 
with its receptor that activates the Janus kinases (JAKs) which then triggers the 
pathway of transcription protein known as signal transducer and activator of 
transcription 3 (STAT3) that leads to transcription of HAMP gene expression 
(Wrighting & Andrews, 2006), rendering iron unavailable for pathogens to proliferate 
(Silva & Faustino, 2015). 
1.3.1.3 Hypoxia/anaemia and erythropoiesis 
Under hypoxia or oxygen deficits, hypoxia inducing factor (HIF) is postulated to 
downregulate HAMP gene expression (Nicolas et al., 2002), but the HIF mechanism 
of action in inhibiting hepcidin expression is not well-established (Silva & Faustino, 
2015). With hypoxia or anaemia, the production of the hormone erythropoietin, leads 
to the initiation of erythropoiesis. HAMP gene expression is reduced in parallel to 
this, to increase iron uptake in enterocytes, allowing an adequate amount of iron for 
erythropoiesis (Nicolas et al., 2002).  
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Suppression of HAMP gene expression in erythropoiesis has been shown to be 
facilitated by either erythropoietin hormone (Pinto et al., 2008), or molecules 
originating from the bone marrow known as growth differentiation factor 15 (GDF15) 
(Tanno et al., 2007) and twisted gastrulation protein homologue 1 (TWSG1) (Tanno 
et al., 2009).  
Figure 1.3 (A) and (B) describes the role of hepcidin in regulating iron absorption 
(Vyoral & Petrák, 2005). Figure 1.4 summarises the role of hepcidin in regulating 
iron metabolism. The liver is responsible for expressing hepcidin, a peptide hormone 
that functions to downregulate iron absorption in iron metabolism homeostasis 
(Tandara & Salamunic, 2012). The liver is considered the chief organ in iron 
metabolism homeostasis as it produces hepcidin and stores the majority of iron 
(Detivaud et al., 2005). The interaction of hepcidin-ferroportin causes internalisation 
of the iron exporter, which results in degradation by the lysosome. Since ferroportin 
is responsible for delivering iron to plasma, the uptake is reduced when there is a 
lower concentration of ferroportin at the membrane, causing the interference in iron 
flow from the main sites of circulating iron, such as macrophage, liver and 
enterocytes into blood circulation (Ganz, 2013). This then leads to decreased 
transferrin saturation and ultimately low iron availability (Nemeth et al., 2004; 
Tandara & Salamunic, 2012).  
To sum up, iron metabolism involves the process of (i) iron uptake at intestinal level, 
(ii) iron utilisation for the production of RBCs, and (iii) iron storage and iron recycling 
as there is no mechanism for iron to be excreted. Different proteins and enzymes 
are involved at each stage in iron metabolism, and iron homeostasis is regulated by 
a tightly-controlled mechanism at systemic level by the action of hepcidin, which is 
expressed depending on iron concentrations, presence of inflammation, hypoxia and 
rate of erythropoiesis.  
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Figure 1.3 Regulation of non-haem iron absorption with (A) low hepcidin 
expression (B) high hepcidin expression - adapted from Vyoral 
and Petrák (2005) 
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Figure 1.4 Regulation of iron metabolism by hepcidin - adapted from Tandara and Salamunic (2012)   
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1.4 IRON IN THE DIET 
1.4.1 Dietary iron bioavailability 
Iron bioavailability is defined as “the extent to which iron is absorbed from the diet 
and used for normal body function” (Hurrell & Egli, 2010) that is sometimes 
interchangeably used with the word “absorption”, which is defined by SACN as “the 
passage of a nutrient, or other dietary constituent, from the intestinal lumen into the 
body. It usually comprises the uptake of a nutrient into the enterocytes of the gut 
mucosa and its subsequent transfer across the cell and into the body” (SACN, 
2010). Iron will not be principally absorbed and transported unless there are 
systemic demands, thus, bioavailability is not as critical in dictating iron absorption. 
Nevertheless, bioavailability becomes fundamental when there is an increased iron 
requirement, as different type of diets or component within the diet will have an 
impact on the bioavailability (SACN, 2010). Iron is less bioavailable, particularly 
when there is unvaried diet pattern, for instance in the developing countries where 
the dietary intake comprised of legume and cereal-based food sources 
(Zimmermann, Chaouki, & Hurrell, 2005).  
Dietary-based iron sources exist in two major forms; haem or non-haem iron (Hurrell 
& Egli, 2010), and the differences between these forms are summarised in Table 
1.2. Iron can also be obtained from other sources, such as iron fortifiers, that are 
used for food fortification and iron supplements, which are available in tablet or 
capsule form (SACN, 2010). There is no established method to quantify the amount 
of haem iron, therefore, the difference between the amount of total iron content and 
non-haem iron is assumed to be the total amount of haem iron (SACN, 2010).  
Table 1.2 Comparison between haem and non-haem iron 
 Haem iron Non-haem iron 
1Primary food sources  
 
 
Meat, poultry and fish Fruit, vegetable, cereal, 
pulses, legumes, eggs 
2Bioavailability  
 
 
 
High, between 15-35% 
and not affected by 
dietary components 
Low, between 2-20% and 
greatly influenced by 
dietary components 
3Amount in diet 
 
Low High 
1FAO/WHO (2001); 2Hurrell and Egli (2010); 3Abbaspour et al. (2014) 
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1.4.2 Dietary iron intake of the UK adult population  
The NDNS provides data on dietary intake of the UK population. It was shown that 
the mean daily intake, in general, has reduced from 14 mg/day in the 1950s to 10 
mg/day in the 1990s, and remained unchanged (Fairweather-Tait, 2004). Mandatory 
fortification of wheat flour and breast milk alternatives are the currently implemented 
community health approach improving iron intake in the UK population (SACN, 
2010). However, it is evident in the NDNS population data that the dietary iron intake 
is lower in women as opposed to men, and premenopausal women in particular, are 
an at-risk groups susceptible to iron deficiency. A review on the quality of UK 
women’s diet by Ruxton and Derbyshire (2010) concluded that women aged 19-50 
years consumed a diet characterised by a low intake of vegetable, fruit and oily fish, 
but high in saturated fat and salt. Micronutrients which include folic acid, vitamin D, 
calcium, and iron intakes, in particular, are still below the recommended level, and 
women of child-bearing aged are at risk of developing iron deficiency (Ruxton & 
Derbyshire, 2010).  
Earlier NDNS population data has shown that a fifth of women of reproductive age 
failed to meet the requirement of lower reference nutrient intake (LRNI) for iron 
intake (Henderson et al., 2003). The percentage of women with LRNI for iron is 
increased when data was combined in the 4th year of the survey to 23% (Bates et 
al., 2014). Recent evidence from the NDNS data shows that the percentage of 
women with LRNI for iron has increased to 27% (Public Health England, 2016). 
Insufficient dietary iron intake increases individual risk of iron deficiency, particularly 
in women of childbearing-age, and iron deficiency may result in various health 
consequences demonstrated in previous studies in different settings (Ruxton & 
Derbyshire, 2010).  
Table 1.3 summarises the findings on dietary intake of iron for women and men 
aged 19-64 years from the UK NDNS carried out from 2008-2014. For women, in 
particular, it can be observed that the mean daily iron intake was less than 80% of 
the RNI, which is 14.8 mg for women aged 19-64 years. Almost 30% of women 
consumed iron below the recommended intake (LRNI). Cereal and cereal products 
represent the highest percentage of food contributes to iron intake.  
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Table 1.3 NDNS population data for dietary iron intake of UK men and women aged 19-64 years 
NDNS aMean (±S.D) daily iron intake 
(mg)/ b(Percentage of RNI) 
cPercentage of 
participants with 
LRNI 
dPercentage contribution of food groups  
12008/09-2010/11 (Year 1-3) Women Not available (79%) 20% Not available 
 
 
 Men Not available (137%) 1% 
22008/09-2010/12 (Year 1-4) Women 9.6 ± 3.0 mg (78%) 23% Cereal & products: Women (38%), Men (40%)  
Meat & products: Women (19%), Men (20%) 
Vegetable & potato: Women (17%), Men (16%) 
dOther groups : Women and men (1-5%) 
 
 Men 11.7 ± 4.0 mg (135%) 1% 
32012/13-2013/14 (Year 5-6) Women 9.4 ± 3.1 mg (76%) 27% Cereal & products: Women (39%), Men (41%)  
Meat & products: Women (17%), Men (22%) 
Vegetable & potato: Women (17%), Men (15%) 
dOther groups : Women and men (1-4%) 
 Men 11.5 ± 4.0 mg (133%) 1% 
RNI values: 14.8 mg/day; LRNI values: 8 mg/day for women aged 19-50 years; 8.7 mg/day; LRNI values: 4.7 mg/day for men aged 19-50 years 
Mean and/or SD represents the data for women and men aged 19-64 years 
aThe mean daily iron intake represents the mean daily intakes from food sources only (not including dietary supplements) 
bThe mean daily iron intake as a percentage of Reference Nutrient Intake (RNI) 
cThe proportion of participants with mean daily iron intake below the Lower Reference Nutrient Intake (LRNI) 
dThe percentage contribution of food groups to average daily iron intake : Other food groups include milk and its products; eggs and egg dishes; fish and fish dishes 
savoury snacks; nuts and seeds; fruits; sugars, preserves and confectionery 
1Henderson et al. (2003); 2Bates et al. (2014);3Public Health England (2016) 
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1.5 IRON STATUS 
Iron status can be described as a spectrum that ranges between the presence of 
iron overload and iron deficiency anaemia (IDA) at the lower end. The presence of 
IDA is due to a negative iron balance, as a result of a continuous iron depletion for a 
long period of time (UNICEF/WHO, 1999).  
Iron status is a measure of the individual’s body iron level characterised by 
physiological requirements. Both iron deficiency and iron overload occur due to the 
failure of iron homeostasis and results in flaws at functional and structural levels 
(SACN, 2010). Figure 1.5 represents the spectrum of iron status, indicated by 
principal iron status biomarkers, including ferritin, transferrin receptor and hepcidin.  
 
   
Ferritin Reduced Normal Increased 
Transferrin receptor Increased Normal Reduced 
Hepcidin Reduced Increased Increased 
Intestinal absorption Increased Reduced - 
 
 
 
Figure 1.5 Spectrum of iron status - adapted from SACN (2010) 
1.5.1 Anaemia 
Anaemia is one of the major worldwide public health concerns that generally affects 
not only population health, but also the social and economic development of both 
industrial and non-industrialised countries (WHO, 2008). A WHO report on anaemia 
prevalence across different countries worldwide reported that anaemia is present 
across all age groups, but is often observed amongst young children and pregnant 
women. Iron deficiency has been identified to be the main aetiology of anaemia and 
marked as one of the most prevailing micronutrient deficiencies, affecting 
approximately 2 billion individuals worldwide (UNICEF/WHO, 1999).  
 
 Deficiency Adequacy Overload 
Cell & tissue structure 
and functional damage 
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It was estimated that nearly 30-60% of non-pregnant women are anaemic in 
developing countries, with Asia and Africa being two of the leading countries 
affected by anaemia (UNICEF/WHO, 1999). Anaemia is the result of a combination 
of causes which could be considered separately, however, these anaemia 
aetiologies are more frequently linked to each other (WHO, 2008). Up to half of all 
anaemia cases are attributable to iron deficiency (WHO/UNICEF/UNU, 2001), and 
the proportions hinge on numerous factors, for instance, geographical aspects or 
different age groups (WHO, 2008).  
Anaemia can typically be diagnosed at the population level with the measurement of 
haemoglobin concentration that is straightforward and reasonably inexpensive. 
However, the sole use of haemoglobin concentration to determine the aetiology of 
anaemia should be interpreted cautiously (WHO, 2008). WHO normal threshold of 
haemoglobin concentrations of < 12 g/dl for non-pregnant women aged > 15 years 
to define anaemia have been internationally established and implemented 
(WHO/UNICEF/UNU, 2001). Anaemia prevalence of ≥ 40% is considered a public 
health issue, but not regarded as public health problem with the prevalence of ≤ 
4.9% (WHO/UNICEF/UNU, 2001). The prevalence of anaemia in Europe between 
1993 and 2005 in non-pregnant women was 19%, which approximates to nearly 41 
million women, which indicates a mild public health concern (WHO, 2008). Despite 
the multifactorial causes of anaemia, measuring haemoglobin concentration to 
establish anaemia may be used as an indirect means of detecting iron deficiency 
(WHO, 2008).  
1.5.2 Iron deficiency (ID) and iron deficiency anaemia (IDA) 
Iron deficiency is a condition that is characterised by depleted iron stores that either 
develop into iron deficiency anaemia or remain at depleted levels with no 
progression (Camaschella, 2015). Iron deficiency with the presence of anaemia 
signifies reduced iron stores, with the presence of smaller and paler RBCs 
characterised by low MCV and MCH levels (Camaschella, 2015). In order to 
appraise the global prevalence of iron deficiency, it is a common practice to use 
levels of anaemia as a surrogate and it is observed that prevalence differs in 
developed countries compared to developing countries (WHO/UNICEF/UNU, 2001).  
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ID and IDA occurrences in developing countries have been attributable to 
inadequate dietary iron intake, infection by a worm that leads to blood loss, or a 
combination of both. On the contrary, dietary patterns such as a vegetarian diet and 
pathological disorders such as gastrointestinal-related illness are the generic causes 
of ID and IDA in developed countries (Camaschella, 2015). The main factors that 
generally lead to the incidence of IDA are poor dietary iron consumption; low iron 
bioavailability from meals especially with the presence of polyphenols and phytates; 
and higher physiological demands during menstruating, pregnancy or puberty 
(WHO, 2008). 
The indications of ID in tissues are often elusive and treatment with iron may not 
lead to the restoration of iron stores. ID has been demonstrated to be associated 
with various health problems related to slowing development and cognitive 
impairment, particularly in children. As it is constantly recurring, IDA may also exist 
without distinct symptoms and typically may not be diagnosed. However, it is 
classically linked to disability in maintaining focus, reduced work output, fatigue and 
lethargy. A severe stage of IDA may increase individuals to risk of infection or heart 
failure, restless leg syndrome and affected numerous birth outcomes in pregnant 
mothers (Camaschella, 2015).  
The evaluation of iron status, by measuring arrays of iron parameters is fundamental 
to determine the specific stage, due to a broad spectrum of iron status. It was 
specified that the use of several parameters is necessary as the use of a single 
parameter to define deficiency, adequacy or excess is not appropriate 
(Camaschella, 2015; SACN, 2010).  
1.5.3 Measurement of iron status using different iron blood biomarkers 
Iron biomarkers can be classified into 3 different categories that indicate either (i) 
iron function; (ii) iron delivery; and (iii) iron stores. Functional iron can be used as 
biomarker indicating iron utilised in production of the RBCs; iron delivery and 
supplies represents the biomarkers that are associated with the supply of iron to 
tissues; whilst iron stores represents the biomarkers that specify the iron depot in 
tissues (British Nutrition Foundation, 1995; SACN, 2010). Haemoglobin 
concentrations, mean corpuscular volume (MCV) and mean corpuscular 
haemoglobin (MCH) levels give measurements of functional iron. Serum iron, 
transferrin saturation, and soluble transferrin receptor (sTfR) indicate the iron 
supplies to tissues, whilst ferritin and total iron binding capacity (TIBC) represents 
iron repository (British Nutrition Foundation, 1995).  
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The presence of anaemia can be confirmed with a single biomarker of haemoglobin 
concentration, however, diagnosing iron deficiency is more intricate and requires 
interpretation of combined iron status biomarkers (Lopez, Cacoub, Macdougall, & 
Peyrin-Biroulet, 2016). The diagnosis starts with observation of hypochromic and 
microcytic red cells indicated by reduced in MCH and MCV concentrations due to 
the effect of long-term iron deficiency (Lopez et al., 2016).  
Ferritin concentration has been demonstrated to be well-associated with iron 
storage, on condition that there is no presence of inflammation (WHO/CDC, 2004), 
and deemed to be the best measurement to identify iron deficiency (Lopez et al., 
2016). Iron stores to the level of below 15 µg/l, indicated by serum ferritin 
concentration, is reported as a depleted iron storage, however, a higher 
concentration of ferritin may be observed with inflammation despite low iron stores, 
causing the interpretation to be more complex (WHO/CDC, 2004). This, however, 
can be controlled by measuring acute phase protein (ACP) and a typical ACP is C-
reactive protein (CRP) which has a rapid response to infection but also rapidly 
diminishes in concentration (WHO/CDC, 2004).  
When iron deficiency is present, there will be a decline in serum iron and transferrin 
saturation but an increase in TIBC and sTfR signifies the total iron available to 
initiate erythropoiesis in response to iron deficiency (Lopez et al., 2016).  Finally, the 
use of bone marrow (Perls’ stain) aspiration is still regarded the benchmark method 
to detect iron deficiency. Despite its high specificity and that it is not influenced by 
infections, the method is costly, invasive, gives an unpleasant experience to the 
patients and the use of recombinant human erythropoietin affects the results (Lopez 
et al., 2016). Table 1.4 summarises the principal iron biomarkers typically used to 
define iron status in adults. 
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Table 1.4 Principal biochemical iron parameters with indications of iron status assessment in adults  
Iron parameters Indication Normal threshold Presence of ID Presence of IDA 
1. Hb Anaemia Males : 13-18 g/dl 
Females : 12-16 g/dl 
Normal Low 
2. MCV RBC size (micro or macrocytic) 80-96 fL Normal <80 
3. MCH Amount of hb in RBC (hypo or normochromic) 27-32 pg Normal <27 
4. Ferritin Proportions of iron storage  Males : 15-300 µg/l 
Females : 15-200 µg/l  
<30 <10 
5. Hepcidin  Iron intestinal-uptake regulator No established threshold Low Very low 
6. Iron  Amount of iron that binds to transferrin in blood 10-30 µmol/l Low Low 
7. TF saturation Amount of circulating transferrin/iron complex  16-50% ≥16 <16 
8. sTfR  Balance between iron demands and supplies No established threshold High High 
Hb: haemoglobin; MCV: mean corpuscular volume; MCH: mean corpuscular volume; TF: transferrin; sTfR: soluble transferrin receptor; ID: iron deficiency; IDA: iron deficiency 
anaemia  
Threshold of Hb, ferritin, iron, TF saturation : SACN (2010), adapted the values from British Nutrition Foundation (1995) 
Threshold of MCV,MCH: Kumar and Clark (2009), MCV threshold varies due to no established threshold 
Threshold of hepcidin, sTfR – varies depending on methods of measurement and assay manufacturer’s recommendation 
Presence of ID and IDA were based on review by Camaschella (2015) 
Indication of each parameter was based on report by WHO/CDC (2004) 
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Premenopausal women are an at-risk group with respect to iron deficiency (Gregory, 
Foster, Tyler, & Wiseman, 1990), and are more prone to mild iron deficiency in 
comparison to post-menopausal women (Heath, Skeaff, Williams, & Gibson, 2001). 
In the most recent combined population data of NDNS between 2008 - 2012, it was 
reported that 9.9% women aged 19-64 years were anaemic (haemoglobin 
concentration < 12 g/dl), 15.5% were ID (plasma ferritin concentration < 15 µg/l) and 
4.7% were IDA based on thresholds of both iron biomarkers (Bates et al., 2014). 
Apart from menstrual losses in premenopausal women, another factor that leads to 
iron deficiency is a lack of iron intake from the diet (Bendich, 2001). Whilst the iron 
RNI for females aged 19-50 years is 14.8 mg/day (Department of Health, 1991), 
dietary iron intake has constantly remained at borderline levels in the UK population 
(Gibson & Ashwell, 2003).  
1.5.4 Prevalence of anaemia, ID and IDA in the UK adult population 
Prevalence of anaemia, ID and IDA reported in the NDNS that represents the UK 
population used the threshold suggested by the WHO/UNICEF/UNU (2001). For 
non-pregnant women aged ≥15 years, in particular, anaemia was defined as 
haemoglobin concentration of < 12 g/dl, ID was defined as serum ferritin 
concentration of < 15 µg/l and IDA is the combination of both biomarkers. The 
determination of the iron status of the UK population, reported in the NDNS did not 
use multiple biomarkers due to different thresholds available for other biomarkers, 
recommended by manufacturers of assays or laboratories which are not 
internationally established. Iron deficiency is predominantly prevalent in women, as 
opposed to men (Fairweather-Tait, 2004), and it was evident in the recent NDNS 
population data. It was reported that 4% of men were anaemic (mean (±S.D) 14.8 ± 
10.3 g/dl), 2% was iron deficient (mean (±S.D) 139 ± 91.7 µg/l), and only 1% 
classified as IDA (Public Health England, 2016). It can be observed that the 
prevalence of anaemia and IDA in women did not substantially change, however, 
there was a decline in the prevalence of women with low serum ferritin concentration 
despite the overall normal concentration of both iron biomarkers (Table 1.5). 
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Table 1.5 NDNS population data for prevalence of anaemia, ID and IDA of 
women aged 19-64 years 
NDNS 12008/09-
2010/11 
(Year 1-3) 
22008/09-
2010/12 
(Year 1-4) 
32012/13-
2013/14 
(Year 5-6) 
Haemoglobin concentration     
     Mean ± SD (g/dl) 13.3 ± 9.8 13.2 ± 9.8 13.2 ± 9.5 
     % below threshold 9.8 9.9 9.0 
Serum ferritin concentration     
     Mean ± SD (µg/l) 56.0 ± 52.0 56.0 ± 53.6 56.0 ± 57.7 
     % below threshold 16.6 15.5 10 
Hb & serum ferritin concentrations     
     % below threshold 3.3 4.7 3 
1Henderson et al. (2003); 2Bates et al. (2014); 3Public Health England (2016) 
One of the many reasons that anaemia, ID or IDA are still prevalent is due to 
methodological difficulties in the execution of corrective measures of this 
widespread nutritional deficiency (Lynch, 2011). Hence, it is important to identify and 
implement the approach that is effective to tackle this nutritional deficiency.  
1.6 STRATEGIES FOR RECOVERY OF IRON STATUS 
In a review by Aspuru, Villa, Bermejo, Herrero, and López (2011), it was stated that 
the management of ID and IDA due to insufficient dietary iron intake involves the 
normalisation of iron intake in daily food consumption. The aim of preventive 
measures are to restore and sustain a sufficient level of iron status, predominantly in 
the highly susceptible group of young children, adolescents, premenopausal 
women, pregnant and lactating women (Milman, 2011) and ultimately improve the 
quality of life (Lopez et al., 2016). A report on the management of IDA by 
WHO/UNICEF/UNU (2001) summarised the corrective and preventive measures 
into 2 different categories of (i) a food-based approach that comprises dietary 
modification and iron fortification or (ii) iron supplementation.  
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1.6.1 Dietary modification  
Dietary modification involves strategies that are mainly focused on the education or 
dissemination of appropriate information, tailored specifically for iron. The emphasis 
should be on promoting and selecting iron-rich food sources; inclusion of iron 
absorption enhancers such as meat and ascorbic acid; exclusion of iron absorption 
inhibitors such as phytates and polyphenol; and appropriate ways of processing and 
cooking foods to retain the nutrient of interest (WHO/UNICEF/UNU, 2001). This 
dietary-based approach is not only specific to iron, but to the long-term overall diet 
as the aim is not only to increase the amount of iron in the diet but to improve overall 
bioavailability of the diet (WHO/UNICEF/UNU, 2001). Figure 1.6 summarises the 
steps to implement this strategy that can be implemented in different populations. 
 
 
 
 
 
Figure 1.6 Step-by-step dietary modification approach to recovery of iron 
status - adapted from WHO/UNICEF/UNU (2001) 
The first step in determining a specific meal pattern of the population can be 
achieved by using a food frequency questionnaire (FFQ), as the methods developed 
at step 4 are tailored specifically for a particular population or at-risk group. In 
developing countries where the iron intake is mostly derived from plant-based 
sources, or the majority of the population are vegetarians, ID is more prevalent 
(Zimmermann et al., 2005), therefore, promotion of the incorporation of iron 
absorption enhancers into the diet is crucial (Aspuru et al., 2011).  
However, one of the greatest limitations of dietary modification is that  this approach 
is demanding, as amending dietary patterns of the population can be challenging 
(Aspuru et al., 2011). In addition, women, in particular, have been reported to not 
have a tendency to alter their dietary intake to maintain optimal iron status despite 
higher physiological requirement, especially during pregnancy (Milman, 2011).  
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1.6.2 Iron fortification   
Iron fortification is one of the dietary-based approaches aimed at the general 
population and can be a practical, efficient, sustainable and cost-effective approach 
if appropriately implemented (Aspuru et al., 2011; WHO/UNICEF/UNU, 2001). 
However, this approach requires joined-up efforts from the legislation sector or 
government, food manufacturers and also the food users (the population). The 
success of this approach also depends on (i) the choice of food vehicles, which are 
selected specifically to suit intended population, easily accessed and vastly 
consumed; and (ii) iron fortifiers that do not change the sensory appeals of the food 
vehicle which are normally staples or commonly consumed food items such as flour, 
salt or sugar (WHO/UNICEF/UNU, 2001).  
For instance, mandatory iron addition into white and brown flour has been 
implemented in the UK since 1953, and the most used iron fortifiers are ferrous 
sulphate, elemental iron powder, and ferric ammonium citrate (SACN, 2010), which 
highlights the use of staple food items to cater for specific needs of UK population 
that use flour to prepare pasta or bread in their daily diet. The challenging aspect of 
this approach is to select the appropriate iron fortifiers to incorporate into the chosen 
food vehicles, as different fortifiers have their own pros and cons.  
Ferrous sulphate has always been used as a reference if the comparison is made 
with regards to the different bioavailability of iron fortifiers (Hurrell, 2002a). However, 
because of its tendency to cause colour changes and become rancid if the foods are 
stored for long periods, the use of ferrous sulphate as a fortifier is often limited 
(SACN, 2010). Compared to ferrous sulphate, elemental iron powders will not cause 
organoleptic changes but their bioavailability differs between individual elemental 
iron powders, depending on how they are processed. Processing will have an 
impact on their shape, surface area and porosity which will ultimately affect their 
solubility in gastric acid (Hurrell, 1997). Electrolytic iron, hydrogen/carbon monoxide 
reduced iron and carbonyl iron are among elemental iron powders that are 
commonly used in fortification of cereal products. Novel iron compounds, as 
opposed to these specified conventional iron compounds that are available and 
used in fortification studies, are summarised in Table 1.6. 
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Table 1.6 Novel iron compounds used as fortifiers in iron fortification  
Iron 
compound 
Description Cons 
NaFeEDTA  Highly absorbed compared to 
other iron compounds 
 Prevent complex formation 
between iron & inhibitors 
 
Costly, may cause colour 
changes in certain food 
vehicle 
Ferrous bis-
glycinate 
 Manufactured by independent 
company (Albion Laboratories, 
Utah, USA) with unknown 
composition 
 Claimed to be capable of 
preventing iron having contact 
with inhibitors 
 
Expensive, may lead to 
change in colour and also 
cause fat oxidation in 
certain food vehicles 
 
Haemoglobin  Add to foods as a fortifier in a 
dried bovine RBC form 
 Highly absorbed and 
inaccessible to inhibitors 
Demanding in terms of 
production and storage, 
unattractive red colour to 
be used in food vehicle 
 
Encapsulated 
iron 
compounds 
 The outer coatings function to 
avoid organoleptic changes 
associated with the use of 
conventional compounds such as 
ferrous sulphate and fumarate 
 The frequently utilised coating 
substances are maltodextrin, 
ethyl cellulose or hydrogenated 
oils 
 
Heat labile  
NaFeEDTA: sodium iron ethylenediaminetetraacetec acid 
Information extracted from review by Hurrell (2002b) 
 
In the UK, there is no population data available on the contribution of iron-fortified 
foods from the total daily iron intake, as this information was not assessed in the 
NDNS. It is known that main food items that are mandatorily fortified with iron 
fortifiers in the UK are white and brown wheat flours and most breakfast cereals 
which are frequently iron-fortified voluntarily by a number of food manufacturers 
(SACN, 2010). In general, it was reported in the NDNS that cereal and cereal 
products contributed to approximately 50% of daily iron intake across all age groups 
(Bates et al., 2014).  
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1.6.3 Iron supplementation   
Iron supplementation has been used predominantly in developing countries, to 
manage ID in at-risk groups such as women, adolescents, young children 
(WHO/UNICEF/UNU, 2001), and has been advocated to be the primary corrective 
measure to be utilised to stabilise haemoglobin concentration and iron depletion if 
IDA is present (Aspuru et al., 2011). Iron supplementation for adults including 
premenopausal women can be classified into 2 categories; (i) correction of ID 
without anaemia as preventive measures at community level with 12-weeks of 60 
mg/day of iron supplementation and (ii) therapeutic supplementation of IDA at health 
care level with 12-weeks of 120 mg/day of iron supplementation 
(WHO/UNICEF/UNU, 2001). Administration of iron supplements is frequently linked 
to a low compliance due to classically-associated adverse effects of gastrointestinal 
discomfort, nausea and black stool (WHO/UNICEF/UNU, 2001).  
Ferrous sulphate has been suggested to be primarily used as an oral iron 
supplement, with other commercially available ferrous salts (ferrous fumarate, 
ferrous glutamate, ferrous lactate, ferrous succinate) as options if intolerant to 
ferrous sulphate, as these specified ferrous salts have comparable bioavailability 
(Aspuru et al., 2011). To enhance the absorption, it was advocated that the 
administration of oral iron supplements should be followed by ascorbic acid-rich 
juice and consumed following the meal (Aspuru et al., 2011). Iron supplements can 
be consumed with a meal to avoid the undesirable adverse effects, but it has been 
shown that this will result in decreased absorption by approximately 40%, and 
efficiency may be enhanced by taking the supplements in separate small doses 
(Lopez et al., 2016). This approach aims to replenish the depleted iron stores, and 
results may not be observed in a short amount of time, hence the need for high 
adherence (Aspuru et al., 2011). Following the administration of iron supplements, 
an increase in reticulocyte counts should be observed at the earliest at 4 days and is 
optimised after 7 to 10 days. A recovery of 2 g/dl of haemoglobin concentration is 
expected following iron supplementation, and the increment in concentration is 
typically established beginning the second week, hence the suggestion of 12-weeks 
of supplementation to continually replenish the iron stores (Lopez et al., 2016). 
However, the response to supplementation differs between individuals, depending 
on several other factors such as baseline haemoglobin concentration and overall 
iron status; the proportion of physiological-related losses; iron uptake; or other 
factors such as the presence of infections (Pavord et al., 2012).  
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The administration of intravenous iron supplements such as iron sucrose or the 
recently developed, iron carboxy maltose (Aspuru et al., 2011) is recommended 
typically in patients who have poor tolerance and low adherence to oral supplements 
(Clark, 2008). Parenteral iron supplements should only be considered when the oral 
iron supplements show no progression after thorough investigations have been 
conducted, considering the possible causes including poor compliance, 
malabsorption, or presence of infection (Lopez et al., 2016).  
In the UK, evidence from NDNS population data shows that the intake of iron 
supplements in women aged 19-64 years represents only approximately 3%, with 
the approximately 15% for all single supplements including vitamin C and vitamin D 
(Bates et al., 2014; Henderson et al., 2003). The guideline to manage ID and IDA 
during pregnancy has been published after a joint review by several organisations 
representing UK-based medical experts recommending the consumption of ferrous 
salts, instead of ferric salts due to higher bioavailability (Pavord et al., 2012).  
Pasricha et al. (2010) regarded a dietary-based approach as secondary to 
supplementation, as dietary iron intake as a single approach is insufficient in the 
treatment of IDA. However, it was evident that iron supplementation has low 
adherence as a result of it’s adverse effects despite its efficacy in the recovery of 
haemoglobin and ferritin concentrations (Pavord et al., 2012).  
1.7 IMPLEMENTATION OF STRATEGIES FOR MANAGING ANAEMIA AND 
IRON DEFICIENCY  
Combatting anaemia or iron deficiency requires a cohesive approach, as its 
occurrence is suggested to be multifactorial. Iron supplements have been widely 
used to correct iron deficiency in at-risk groups, whereas, in the general population, 
either dietary pattern modification or iron fortification in selected food vehicles may 
be implemented (WHO, 2008). Due to various factors affecting iron absorption, it is 
challenging to design an efficient strategy to tackle iron deficiency, especially at 
population level (Fairweather-Tait & Collings, 2010). Extensive literature is available 
from intervention studies investigating the effect of utilising dietary-based 
approaches; including dietary pattern modification, iron fortification and iron 
supplementation on the improvement of iron status. However, previous studies have 
reported inconsistent findings on the effectiveness of the utilised approach on iron 
status recovery. Dietary modification has been regarded as the strategy that 
requires long-term goal (Pasricha, Drakesmith, Black, Hipgrave, & Biggs, 2013) as 
altering the individual’s preference of food has been one of the barriers to improving 
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iron status through dietary modification (Lynch, 2011). Evidence from the most 
recent experimental trials has shown that iron fortification, which is considered as a 
medium-term strategy (Pasricha et al., 2013), will not completely improve general 
iron status, especially in countries where iron fortification is mandatory, including UK 
(SACN, 2010). The use of iron compounds in fortifying foods is one of the practical 
approaches to tackling iron deficiency (Ferreira da Silva, Dutra-de-Oliveira, & 
Marchini, 2004). Oral iron supplementation is widely used to improve iron status, 
especially ferrous sulphate, but efficacy is limited due to its adverse effects and low 
bioavailability, which have initiated studies using other iron compounds (Ferreira da 
Silva et al., 2004) such as iron polymaltose complex and iron protein succinylate 
(Santiago, 2012). The classic related adverse effects associated with iron 
supplementation include gastrointestinal discomfort (abdominal pains, constipation), 
black stools, nausea, vomitting and appetite loss, causing poor adherence which 
leads to inefficiency of intervention (Souza, Batista Filho, Bresani, Ferreira, & 
Figueiroa, 2009). 
Extensive literature is available from intervention studies investigating the effects of 
dietary-based approaches (dietary pattern modification or iron fortification) and a 
therapeutic approach (iron supplementation) on the improvement of iron status, 
reporting inconsistent findings. Scientific evidence from systematic reviews carried 
out to date that includes experimental, or/and observational studies also reveal 
discrepancies in the efficacies of these iron interventions in the recovery of iron 
status. For instance, a systematic review was carried out to assess the effect of 
added iron, in the form of supplements, fortified foods, and iron-rich dietary sources 
on iron status biomarkers in healthy adults by Casgrain, Collings, Harvey, Hooper, 
and Fairweather-Tait (2012). The main finding of the review was, that added iron 
from supplements, fortifiers or dietary source improved iron status, reflected by 
increased in principal iron biomarkers; haemoglobin (0.51 g/dl, CI: 0.37, 0.65 g/dl, 
p<0.00001) and serum ferritin concentrations (9.19 µg/l, CI: 6.63, 11.75 µg/l, 
p<0.00001) (Casgrain et al., 2012). Despite the increase in iron status biomarkers 
following intervention, high levels of heterogeneity were observed between studies, 
and of the 41 RCTs included in the review, 24 studies were evaluated as very much 
at risk of bias (Casgrain et al., 2012). Inclusion criteria of selected studies that were 
not specific to one type of iron intervention may have led to high level of 
heterogeneity, therefore, results presented should be interpreted prudently.  
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Gera, Sachdev, and Boy (2012) carried out another meta-analysis but focusing 
solely on the effect of iron-fortified foods on iron biomarkers replicated the findings 
by demonstrating the effectiveness of iron fortification intervention in improving iron 
status. It was reported that haemoglobin (0.42 g/dl, CI: 0.28, 0.56, p<0.001) and 
serum ferritin (1.36 µg/l, CI: 1.23, 1.52 µg/l, p<0.001) concentrations at post-
intervention increased after iron-fortified food consumption. Lower risk of anaemia 
and iron deficiency were also observed following the intervention (Gera et al., 2012). 
However, the observation revealed a high level of heterogeneity for both iron 
biomarkers and level of bias is not summarised as a whole but available in a 
separate supplemental data. The inclusion of only fortification studies makes the 
selection criteria tighter, but no control on age range and sex may have contributed 
to the high level of heterogeneity, thus, cautious interpretation is also necessary 
particularly on the impact on iron status following the iron intervention.  
A systematic review by Jackson, Williams, McEvoy, MacDonald-Wicks, and 
Patterson (2016) carried out recently to determine the effectiveness of animal meat 
consumption, as part of dietary modification strategy, on the improvement of iron 
status in adults reported different observation from the previous 2 meta-analyses. 
Contradictory findings were observed in the pool of experimental studies, reporting 
mixed findings on the effectiveness of consuming the different type of meats on 
haemoglobin or serum ferritin concentrations, irrespective of the duration of studies 
and amount of meat consumed (Jackson et al., 2016). Inconsistent findings were 
also demonstrated from the observational studies included in the review which 
investigated the impact of vegetarian and omnivore diets on iron status, however, 
70% of the studies showed increase in serum ferritin concentrations following 
omnivore diet as opposed to a vegetarian diet (Jackson et al., 2016). The review 
included 49 studies, including only 8 experimental studies, of which 3 was regarded 
as high quality out of only 7 studies. Due to the heterogeneity of the studies included 
in the review, no meta-analysis was carried out in this review. This shows that 
limited studies are available to date, especially from the RCTs, to reach a conclusive 
judgement on the effectiveness of incorporating the use of more meat in the diet (as 
part of a dietary modification strategy) in improving iron status.  
It is well established that a wide range of studies have been carried out addressing 
different strategies in managing anaemia, ID or IDA, and in support of the mentioned 
systematic reviews, appraisal of the most recently published individual experimental 
studies employing individual or/and integrated strategies to improve iron status, 
particularly in women also revealed disparities in findings (Table 1.7).  
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Table 1.7 Experimental studies investigating the effect of different types of interventions on the recovery of iron status 
Study Participant Intervention 
 
Main findings 
A) Dietary modification  
 
Blanton (2013) 
United States 
Women, n= 43 
18-30 years 
Beef or non-beef lunch  
16-week 
No significant difference between intervention and control 
groups in all iron status indices. 
 
Remark: Moderate amount of beef (85 g) supplied in the study did not sufficient to improve iron status indices. Participants were not 
deficient at baseline, which may have contributed to the non-significant increase as no physiological demands for iron. 
 
McArthur, Petocz, 
Caterson, and 
Samman (2012) 
Australia 
Women, n=76 
18-35 years 
A: Pork-diet + placebo 
B: Control diet + placebo 
C: Control diet +supplement 
12-week 
 
SF concentration significantly higher at post-intervention 
in C compared to A & B groups. 
Remark: Iron intake, which is high at baseline, was similar at post-intervention in A, indicates 100 g did not sufficient to increase iron 
status indices. The supplement used contained ascorbic acid, which may have contributed to enhanced iron absorption. 
 
SF: Serum ferritin 
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Table 1.7 Experimental studies investigating the effect of different types of interventions on the recovery of iron status 
Study Participant Intervention Main findings 
B) Iron fortification  
Karl et al. (2010) 
United States 
Women, n=142 
21 ± 4 years 
Iron-fortified food bars or 
placebo food bars 
9-week 
Hb concentration significantly higher at post-intervention 
in the intervention group compared to placebo.   
Remark: Despite the high iron content of the food bars (28 mg), other iron status did not improve, may be due to iron loss during the 
process of the fortified bars, and incorporation of iron enhancer may have aided in the iron absorption.  
 
Andersson et al. 
(2010) 
Switzerland 
Women, n=142, 
18-40 years 
A: Fortified margarine (FP) 
B: Fortified margarine (Na) 
C: Placebo margarine 
32-week 
SF concentration significantly higher at post-intervention 
in B compared to A and C groups.  
Remark: The study employed a random serial sampling to assess the iron status indices at 3 times throughout study duration (except 
baseline and post-intervention), not a fixed time point for all participants, which may have affected the interpretation of results in terms of 
the difference in participants’ response to the intervention.  
 
Blanco-Rojo et al. 
(2011) 
Spain 
Women, n=130, 
18-35 years 
Iron-fortified juice or placebo 
juice 
16-week 
SF concentration significantly higher at post-intervention 
in the intervention group compared to placebo. 
Remark: Highly bioavailable iron compound (microencapsulated iron pyrophosphate) used in the fortified juice, as well as the readily 
available ascorbic acid in juice, may have aided in the absorption, hence the improvement in SF concentration.  
 
Beck, Conlon, Kruger, 
Coad, and 
Stonehouse (2011) 
Australia 
Women, n=89, 
18-44 years 
A: Iron-fortified cereal + kiwi 
B: Iron-fortified cereal + banana 
16-week 
SF concentration significantly higher at post-intervention 
in A compared to B.  
Remark: The study included no control group that consumed only iron-fortified cereals and the ascorbic acid in kiwi fruits administered 
was higher than in banana, which may have contributed to the enhanced iron absorption.  
Hb: haemoglobin; FP: ferric pyrophosphate; Na: sodium iron edetate or NaFeEDTA 
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Table 1.7 Experimental studies investigating the effect of different types of interventions on the recovery of iron status 
Study Study population Intervention Main findings 
C) Iron supplementation   
Hoppe, Brün, 
Larsson, Moraeus, 
and Hulthén (2013) 
Switzerland  
Women, n= 77 
*24 years  
A: haem blood-based bread 
B: ferrous fumarate 35mg 
C: ferrous fumarate 60mg 
D: iron-free supplement 
12-week 
No significant difference between A and B, C, D groups 
in all iron status indices.  
Remark: Cautious interpretation of results necessary as two types of placebos used due to company shut down; no bread control to 
compare with the blood-based group. Adverse effects reported were gastrointestinal discomforts in supplement groups. 
 
Ortiz et al. (2011) 
Colombia/Argentina 
Pregnant women, 
n=80 
*>16 years 
A: iron poly maltose (IP) 
B: ferrous sulphate (FS) 
12-week / 100 mg  
SF concentration significantly higher at post-intervention 
in group A compared to group B.  
Remark: Group A reported fewer adverse effects indicating better safety and higher adherence, group B reported vomiting, nausea and 
constipation. IP was given in 2 different forms of single dose container or film tablet, FS in conventional tablet form, no placebo group.  
 
Vaucher, Druais, 
Waldvogel, and 
Favrat (2012) 
France 
 
Women, n=198 
18-50 years 
A: ferrous sulphate (FS) 
B: placebo 
12-week / 80 mg 
SF and haemoglobin concentrations significantly higher 
at post-intervention in group A compared to group B. 
Remark: The significant increase observed in SF, Hb, and other biomarkers may be due to the prolong-released type of FS used in the 
study. Classic adverse effects symptoms related to gastrointestinal discomforts reported in the intervention group.  
 
Berber et al. (2014) 
Turkey 
Women, n=104 
19-60 years 
A: iron succinylate flacon 
B: iron glycine sulphate 
12-week / 80 mg 
Haemoglobin concentration significantly higher at post-
intervention in iron ferrous group (B) compared to iron 
ferric group (A) 
Remark: A total of 104 randomised and partake in the study, but the study included only 64 in the analyses mostly due to absence at the 
control visit (after 12-week) (n=17) and hypermenorrhoea (n=15).  FS was not included as a control as a comparison of the efficacy.  
 
*SD and range for age not available  
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1.8 THE EFFECT OF DIETARY COMPONENTS ON NON-HAEM IRON 
ABSORPTION AND RECOVERY OF IRON STATUS  
The influence of dietary components on non-haem iron absorption have been 
established in numerous single meal studies using an iron isotope technique 
(SACN, 2010). Iron absorption and bioavailability may be reduced in the presence of 
calcium, polyphenols, phytates, or peptides derived from incomplete digested 
protein. However, iron uptake has been shown to increase in the presence of 
muscle tissues which is haem source of iron, or ascorbic acid which is capable of 
reducing ferric to ferrous iron to be absorbed in the duodenum (Hurrell & Egli, 2010). 
As previously demonstrated in various studies in different settings, ascorbic acid has 
been suggested to enhance iron absorption, dose dependently (Conrad & Umbreit, 
1993) by reducing iron into the absorbable ferrous (Fe2+) form as well as functioning 
as a chelating agent (Abbaspour et al., 2014). Earlier studies have shown the 
capability of ascorbic acid in counteracting the effect of dietary iron inhibitors, such 
as phytate, polyphenols, calcium and milk components, by increasing both native 
and supplemental iron, but not significantly affecting the inhibitory effect of 
polyphenols from plant-based foods (Abbaspour et al., 2014). However, the 
enhancing effect of ascorbic acid has been shown to be diminished due to its lack of 
stability with cooking, processing and storage (Teucher, Olivares, & Cori, 2004). A 
mechanism describing how meat or its elements, contribute to the enhanced effect 
on non-haem iron absorption has not been established, due to discrepancies in 
findings (SACN, 2010). Elements in phytic acid, known as myoinositol 
hexakisphosphate (Hurrell & Egli, 2010), and tannin (Disler et al., 1975b) or galloyl 
esters (Hurrell, Reddy, & Cook, 1999) in polyphenols have been postulated and 
demonstrated to be responsible for the reduction of non-haem iron absorption. The 
formation of insoluble complexes with iron, rendering iron to be unavailable for the 
uptake has been suggested to be the mechanism of action of these components 
(Khokhar & Apenten, 2003; Nielsen, Tetens, & Meyer, 2013). Calcium affects both 
haem and non-haem iron absorption (Hallberg, Rossander-Hulthèn, Brune, & 
Gleerup, 1993), however, there are limited and inconsistent findings on the impact of 
calcium, milk components or animal proteins on non-haem iron absorption 
(Abbaspour et al., 2014).  
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There are a number of methods that can be utilised to quantify iron absorption in 
human subjects, which include isotopes (radio or stable), whole body counting 
following administration of radio-labelled isotopes, plasma kinetic studies, or 
chemical balance studies (International Atomic Energy Agency, 2012). However, it 
has been demonstrated that the use of stable iron isotopes is the most effective 
approach to properly determine dietary iron absorption as well as iron utilisation 
(SACN, 2010).  
Iron bioavailability can be directly quantified using stable iron isotopes by measuring 
the estimation of isotope incorporation into the erythrocyte (Fairweather-Tait, 2001) 
or whole body counting (Benito & Miller, 1998). Stable or radioactive forms of 
isotopes are available and test meals used in the research can be either extrinsically 
(directly added to test meal) or intrinsically (added during the production of food) 
labelled. Generic radioactive isotopes (55Fe or 59Fe) have been used in the earliest 
isotope-nutrition research, however, these radioisotopes can only be used in 
research involving non-vulnerable groups such as non-pregnant women or healthy 
adults (International Atomic Energy Agency, 2012). For 59Fe, direct measures of iron 
absorption can be carried out using whole body counting methods, but not for 55Fe 
as this isotope does not emit gamma rays (ɣ). The ingested tracer can be measured 
as early as one hour after ingestion, and again after 14 days to allow incorporation. 
Using whole body counting methods, the amount of iron ingested and retained in the 
systems will indicate absolute value of iron absorption.  
In contrast, stable isotopes cannot be measured with whole body counting (Wienk, 
Marx, & Beynen, 1999).  However, stable isotopes can be applied in groups of 
children, infants or pregnant women as they carry no adverse effects with no 
radiation discharge (International Atomic Energy Agency, 2012). The incorporation 
of stable isotopes in the erythrocyte nevertheless, is the preferred method 
particularly in humans (Benito & Miller, 1998), in which iron absorption can be 
estimated based on the mass of the isotopes measured in blood via mass 
spectrometry (Wienk et al., 1999). Using the data collected from mass spectrometry 
analysis, the mass ratio (before and after test meal consumption) is used to 
calculate the amount of iron absorbed (International Atomic Energy Agency, 2012). 
Stable iron isotope technique measures the fraction of absorbed dietary iron, and its 
incorporation into the erythrocytes 14-days post-dosing as a measure of iron 
utilisation or bioavailability (International Atomic Energy Agency, 2012).  
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The whole blood samples collected before and after the isotope-dosing are typically 
measured using mass spectrometry to obtain an iron ratio that will be used in the 
estimation of fractional iron absorption (International Atomic Energy Agency, 2012). 
Different types of mass spectrometry have their own pros and cons, however, the 
key principle behind the measurement is the capability of these instruments to 
separate and quantify the different mass of the iron isotopes of interest (International 
Atomic Energy Agency, 2012). Using the ratio of iron gathered by the instrument, 
fractional iron absorption is estimated using a series of published equations 
(International Atomic Energy Agency, 2012). Figure 1.7 illustrates the process of 
determining iron absorption from a test meal.  
The principle behind the use of isotopes is that the absorbed iron in a labelled meal, 
be it with the stable or radioactive type will end up in a common non-haem iron pool. 
The absorption can then be measured in the assumed common pool by following 
what happens to the isotopes which function as a tracer (Benito & Miller, 1998). 
There are 5 important stages involved in human iron bioavailability studies: (i) 
recruitment of human participants; (ii) administration of labelled test meals with the 
selected isotopes after overnight fast; (iii) abstaining from food and drink a few hours 
after test meal administration; (iv) iron isotopic analysis from blood collected 14-days 
post meal administration and (v) estimation of fractional iron absorption (Benito & 
Miller, 1998). 
                                                                                                                  
 
 
 
Figure 1.7 Determination of fractional iron absorption - adapted from 
International Atomic Energy Agency (2012) and International 
Atomic Energy Agency (2014) 
Blood sample 
(Baseline) 
Test meal 
(Day 0) 
Absorption of the tracer and 
incorporation into erythrocyte  
(14-day interval) 
Blood sample 
(Post dosing) 
57Fe 
2.12% 
80% 
incorporated 
into RBC 
57Fe 
2.12% 
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Estimation of fractional iron absorption involves the use of published equations 
beginning with determination of blood volumes of research participants. Blood 
volume of the participants is needed to estimate the circulating body iron pool using 
a published equation (McKie et al., 2001), and can be obtained by experiments or 
using a fixed value (Wienk et al., 1999) of 65 per kg of body weight (International 
Atomic Energy Agency, 2012). Alternatively, a published equation by Shayeghi et al. 
(2005) can also been used to accurately calculate blood volume, which takes into 
account the height and weight of the female participants.  
With the initial information on blood volumes gathered, the circulating iron pool can 
be estimated. The estimated circulating iron can then be used to calculate the 
amount of tracer incorporated into the erythrocyte (Andrews, 2005; Latunde-Dada, 
Simpson, & McKie, 2006). At this stage, the outcome from isotopic analysis of whole 
blood collected at baseline and post-dosing (expressed as ratio), as well as the 
natural abundance, atomic mass and atomic weight of tracer are used as part of 
calculation.   
The percentages of isotopes absorbed and incorporated into erythrocyte has been 
suggested to depend on individual iron status, ranging from 80% for a healthy 
individual to 96% for those with iron deficiency anaemia (Wienk et al., 1999). 
Generally, the final fractional iron absorption (%) is estimated with the 80% 
assumption (International Atomic Energy Agency, 2012). However, differences in 
background iron status will contribute to the inter-variability between the subjects, 
and the use of a reference iron dose will correct the variation between subjects and 
enable comparison of the fractional iron absorption to be made between different 
iron bioavailability studies (Wienk et al., 1999).  
It was agreed by experts that the isotope-labelling method is the gold standard in 
measuring iron bioavailability in human studies, especially for micronutrients such as 
iron, zinc, folate as well as vitamin A (Casgrain, Collings, Harvey, Boza, & 
Fairweather-Tait, 2010). However, it was stated in a report on iron and health by 
SACN in 2010 that findings on non-haem iron absorption from single meal studies 
which have used isotope methods, are inconsistent. The inconsistencies were due 
to the presence of enhancers and inhibitors in the meal used, causing an increase 
or reduction in iron absorption.  
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1.8.1 Dietary inhibitory factors of iron absorption 
According to a review on iron by Abbaspour et al. (2014), phytates, polyphenols, 
calcium and some proteins are classified as the main inhibitors of iron absorption. 
Calcium has been demonstrated to affect both, non-haem and haem iron absorption 
(Hallberg et al., 1993). However, as phytates and polyphenols are mainly derived 
from plant-based diet and commonly lead to significantly reduced iron absorption 
(Abbaspour et al., 2014; Davidsson, 2003), the review focused on these two main 
inhibitors. Approximately 90% of phytate in the western-style diet is derived from 
cereals, such as bran or oat, and has been shown to inhibit iron absorption in a 
dose-dependent manner in a number of bioavailability studies since the late 80s 
(Zijp, Korver, & Tijburg, 2000).  
A study to investigate iron absorption using two different strains of isotope-labelled 
cowpea (red and white) with fortifiers (NaFeEDTA and ferrous sulphate) was carried 
out in 16 Dutch students aged 18-40 years. Cowpeas are known to have 
considerable amounts of non-haem iron compared to rice and maize, and a higher 
content of polyphenols and phytic acid (Abizari et al., 2012). A low range of 
fractional iron absorption was observed in both white cowpeas (1.2-1.7%) and red 
cowpeas (0.9-1.4%), irrespective of fortifiers used (NaFeEDTA or ferrous sulphate). 
Lower iron absorption in red cowpeas was observed in the study (non-significant) 
due to higher polyphenol content in red strain. Irrespective of strain, NaFeEDTA 
enhanced the iron absorption more than FeSO4 (p<0.05).  
It was deduced that the use of a single meal consisting of a combination of both 
polyphenol and phytic acid molar ratio to iron (PP and PA : iron) may have 
exaggerated the inhibition effect, as no significant difference was observed between 
strains even though the red strain had higher polyphenol content (Abizari et al., 
2012). The study, however, did not include any control test meal to allow 
comparison to be made.  
In India, several studies carried out among low socio-economic groups showed that 
dietary iron consumption is below the recommended amount. Iron absorption was 
expected to be low, as the diets were largely plant-derived (rice, pulses and 
vegetables) (Thankachan, Muthayya, Walczyk, Kurpad, & Hurrell, 2007) with large 
amounts of phytates. In a study carried out in 45 iron deficient (ID) and 15 iron 
replete (IR) women aged 18-35 years, it was reported that iron absorption from the 
rice-based meal in the ID subjects (8.3%) were significantly higher (>3-fold) 
compared to IR subjects (2.7%) (p<0.05) (Kalasuramath, Kurpad, & Thankachan, 
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2013). The women were assigned to 4 groups of 15, three groups for ID women 
(millet, rice or wheat-based meal) and 1 group for IR (rice-based meal) women for 
comparison. The study found a higher iron absorption from rice and wheat meals 
(8.3 and 11.2% respectively) compared to millet meal (4.6%) within the ID group 
(p<0.05). It was postulated that the addition of cooked tomato that is high in ascorbic 
acid in the wheat meal had to some degree aided absorption (Kalasuramath et al., 
2013), as wheat flour is normally rich in phytates (Hurrell, 2002a). Additionally, the 
combination of millet and green leafy vegetables known to be high in phytates and 
tannins may have possibly contributed to the increase in the inhibitory effect, 
resulting in the lowest iron absorption of 4.6%.  
Bæch et al. (2003) used a known phytate-rich test meal, administered with different 
amounts of pork in 45 healthy women to determine a dose-dependent effect of using 
meat as a dietary enhancer to promote higher iron absorption. The women were 
assigned to consume isotope-labelled meals of rice with tomato sauce with 0, 25, 50 
or 75 g of pork. It was shown that iron absorption was not significantly higher with 
pork when 25 g pork was given (7.1%) compared to the control meal (5.9%) but iron 
absorption was significantly higher with 50 g and 75 g (8.6% and 9.2%) compared to  
when no pork was added (p<0.001). Additionally, iron absorption was higher in the 
meal administered with 75 g pork compared to 25 g (p<0.05). It was suggested that 
a higher intake of meat, combined with a diet high in phytate, particularly in 
developing countries, may be useful in improving iron absorption (Bæch et al., 
2003).  
Instead of adding an enhancer into a phytate-rich meal, Petry, Ines, Christophe, 
Thomas, and Richard (2010) applied a dehulling and dephytinisation processes, to 
reduce the polyphenol and phytate content of test meals, resulting in higher iron 
absorption. The study was carried out in 49 women aged 18-45 years, grouped into 
3 separate studies using isotope-labelled whole bean porridge meal (control) or 
bean porridge meals which had been either dehulled, dephytinised or a combination 
of both. It was found that dehulling did not appear to increase iron absorption as 
predicted, but lowered it from 2.6% (control meal) to 1.6% (p<0.001). However, iron 
absorption increased 2.6-fold from 2.4% to 8.7% (p<0.001) following the removal of 
both phytates and polyphenols by both dephytinisation and dehulling (Petry et al., 
2010).  
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Petry, Egli, Campion, Nielsen, and Hurrell (2013) demonstrated that genetic 
modification of beans leads to a higher iron absorption in a study using iron isotope-
labelled bean meal with a reduced concentration of phytic acid by >90% (bean 
known as lpa) but not polyphenol content. A cohort of 20 healthy women aged 18-30 
years were administered two varieties of bean porridge (W and B) with modified 
polyphenol (PP) compared to parent-line with native phytic acid (PA): (a) lpa-B: high 
PP, low PA; (b) lpa-W: low PP, high PA; (c) wt-B: parent-line B and (d) wt-W: parent-
line W. Comparing modified PA beans with the parent line, it was demonstrated that 
there was a higher iron absorption from the lpa-B compared to wt-B (6.14 to 3.84%, 
p<0.001) and lpa-W compared to wt-W (3.99 to 2.68%, p<0.001). It was shown that, 
despite the large difference in polyphenol content, there was no difference in iron 
absorption (p=0.09) and total iron absorbed (p=0.26) between the 2 varieties. This 
finding is practical especially in the countries where beans are staple foods, 
however, careful interpretation is needed if extrapolating the finding with mixed diets 
as other nutrient interactions may be present resulting in different magnitude of iron 
absorption.  
Petry et al. (2016) carried out a further study comparing 3 types of beans including 
lpa beans (lpa), bio-fortified beans which has high iron content (bb) and control 
beans (cb), administered with either rice or potatoes in 29 women aged 18-30 years, 
with plasma ferritin concentrations < 25 µg/l. It was found that the same modified 
bean (lpa bean) caused side gastro-intestinal effects to the participants and that the 
iron absorption was not significantly different between lpa, bb and cb (8.6%, 7.3% 
and 8.0% respectively), consistent with the total iron absorbed of 421 µg, 431 µg 
and 278 µg. Four of the participants dropped out from the study, due to adverse 
events of vomitting, whilst seven complained about symptoms associated with 
gastro-intestinal discomfort such as diarrhoea and nausea. The events occurred 
following consumption of lpa beans, not with bb or cb beans, leading to the 
discovery of the presence of PHA-L (proteins of lectin) which affected the digestive 
tract of women. This effect was due to the fact that the lpa bean utilised in the study 
was not properly cooked, which results in a complex formation of pectinic acid  and 
cations (Petry et al., 2016).   
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Phytate (inositol hexaphosphate or pentaphosphate), mainly found in cereals and 
polyphenols, and also derived from plant-based diets caused inhibition of iron 
absorption by chelating the non-haem iron, rendering it unavailable for the uptake at 
luminal level (Beck, Conlon, Kruger, & Coad, 2014). However, polyphenol is not only 
found in vegetables, but also in beverages such as tea that contains phenolic 
compounds (iron-binding properties) that bind to either catechol or galloyl groups 
(Zijp et al., 2000). 
1.8.1.1 Inhibitory effects of tea-containing polyphenol 
With the exception of water, tea, which originates from a plant scientifically known 
as Camellia sinensis and is considered to be one of the most frequently consumed 
drinks in the world (Vuong, 2014). Tea leaves are manufactured to either produce 
green, black or oolong teas (Łuczaj & Skrzydlewska, 2005). Unfermented green tea 
is made by either pan frying or steaming the leaves to ensure the inactivation of the 
enzyme polyphenol oxidase. This process results in catechin concentrations of 30-
42% (dry weight) which is responsible for the sharpness and bitterness of the tea 
(Dufresne & Farnworth, 2001). Contrary to green tea, black tea is made by crushing 
the tea leaves to promote activation of polyphenol oxidase which leads to lower 
concentrations of catechins (10-12% dry weight). The oxidation products which 
include theaflavins (3-6% dry weight) and thearubigins (10-20% dry weight) give the 
tea its distinctive black colour (Haslam, 2003). Tea leaves, which are made into 
dried form, consist of chlorophyll, enzymes, caffeine, carbohydrates, protein, 
theanine, and the richest component of flavonoids, which consist of mainly catechins 
(Vuong, 2014).  
In a review on tea and health by Vuong (2014), tea was found to be capable of 
exhibiting health benefits such as reduction in risk of cancer, diabetes, 
cardiovascular disease or obesity, however, there were discrepancies in the 
reported literature which was mostly derived from observational epidemiological 
studies. Despite its health benefits, it was also suggested that phenolic components 
in black tea may disrupt iron uptake, resulting in poor iron status, especially in at-risk 
groups such as pregnant women, children, or the elderly (Gardner, Ruxton, & 
Leeds, 2006). In addition, tea has been identified as the most popular beverage, 
predominantly in the countries where iron deficiency is prevalent (Disler et al., 
1975a).  
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1.8.1.2 Intervention studies: effect of tea consumption on iron status 
Intervention studies demonstrating that consumption of tea can lead to poor iron 
status are scarce. However, Prystai, Kies, and Driskell (1999) carried out a study in 
a group of 9 adults (5 females, 4 males) aged 22-43 years who were given a 
controlled diet with either black tea, decaffeinated black tea, green or no tea 
(control) for 14 days. Faecal analysis revealed that there was no significant 
difference between male and female subjects for each type of tea, including control, 
but urinary analysis showed a lower value of iron in females compared to males for 
control diet (no tea) (p<0.05). Iron balance [intake - (faecal + urinary)] was found to 
be more negative when green tea was administered compared to other teas 
(p<0.001). Iron balance was lower with tea consumption, regardless of type, 
compared to control, however, no difference was observed between genders. A 
metabolic study, especially which involves collection of urine and faeces may yield 
accurate findings, however, this study was limited by its low number of participants 
which limit interpretation to a general population.  
Breet, Kruger, Jerling, and Oosthuizen (2005) demonstrated that black tea did not 
have an impact on iron status in 150 children aged 6-15 years, grouped into black or 
rooibos tea (control) groups, administered with 400 ml tea and brown bread at 
school, daily for 16 weeks. Unexpectedly, mean (± 95% CI) haemoglobin 
concentrations were found to be higher at the end of study (13.2 g/dl, CI: 13.0, 13.4) 
compared to 12.8 g/dl (CI: 12.5, 13.2) at baseline in the black tea group (p=0.002). 
In the black tea group, it was also observed that there were significant changes 
between baseline and 16-weeks in MCV, MCH, S-Tfn, and TIBC (p<0.0001), but not 
for transferrin saturation, serum iron and serum ferritin. The mean (± 95% CI) MCV, 
S-Tfn and TIBC were significantly higher at 16-weeks (77.2 fl, CI: 76.2, 78.2; 2.71 
g/l, CI: 2.54, 2.99; 60.6 µmol/l, CI: 56.8, 67.0) but lower for MCH (24.7 pg, CI: 24.8, 
24.7). However, no significant difference was observed between groups in all iron 
status biomarkers measured.  
No effect on iron status following tea consumption was reported by Schlesier et al. 
(2012) in shorter study of 4-weeks in 34 healthy adults (25 females, 9 males) aged 
19-32 years. It was a cross-over study, and all participants were required to 
consume 1 litre of green or black tea at home, with meal but without milk for 4 
weeks. Iron status biomarkers including haemoglobin, haematocrit, serum ferritin, 
serum iron, and TIBC were not affected in male subjects with black or green tea 
consumption.  
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However, in women, serum ferritin concentration was significantly lower after 4 
weeks of black tea consumption (mean ±S.D not provided) (p<0.05), but not green 
tea. Other iron status biomarkers were found to be unaffected by consumption of 
black or green tea in both gender (Schlesier et al., 2012).   
1.8.1.3 Cross-sectional studies: association between tea consumption and 
iron status 
Table 1.8 summarises cross-sectional studies carried out to date, investigating the 
association between tea consumption and iron status. Tea consumption did not lead 
to poor iron status, resulting in either anaemia, iron deficiency or iron deficiency 
anaemia, based on the findings reported. Consumption of tea as part of normal diet 
will not influence the iron status, especially for a generally healthy population 
(Mennen et al., 2007). A dietary pattern which may promote iron absorption, such as  
a diet high in ascorbic acid as observed in the study by Mehta, Pritchard, and 
Stegman (1992), or high in meat (Milman, Pedersen, Ovesen, & Schroll, 2004) may 
counteract the inhibition effect of tea, as no association between tea consumption 
and iron status was established in these studies. It was suggested that the 
association observed in the experimental studies may not represent actual dietary 
habits as they are carried out under controlled environments, not in free-living 
population (Hogenkamp, Jerling, Hoekstra, Melse-Boonstra, & MacIntyre, 2008). 
These studies, which are mainly part of larger scale studies e.g. national surveys, 
however, do not use specific measures to quantify the consumption of tea, despite 
the use of blood biomarkers to determine iron status. Validated food frequency 
questionnaires (FFQ), or tea questionnaires may not be a true representation of 
subjects’ tea intake, as recording food in an FFQ may result in underestimation due 
to focusing on current intake compared to previous intake (Palacios, Trak, 
Betancourt, Joshipura, & Tucker, 2015). 
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Table 1.8 Cross-sectional studies: association between tea consumption and poor iron status 
Study Study population Tea consumption Prevalence of  
anaemia/ ID/ IDA 
Association (tea and poor iron status) 
     
Mehta et al., 1992 
USA 
Adults, n= 11684 
19-74 years 
3.1 cups/day Hb : 5.3%  No association  
     
Galan et al., 1998 
France 
Adults, n= 9931 
35-60 years 
Not available Hb : 10.4%  
SF : 29.8%  
Hb & SF : 5.1%  
No association with either Hb (p=0.74) or SF 
(p=0.31) 
     
Milman et al., 2004 
Denmark 
Men, n= 2612 
40-70 years 
6 cups/day  
including coffee  
SF : 0.4-0.5% 
Hb & SF : 0.08-0.16%  
 
Negative association with serum ferritin 
(p<0.0001) 
     
Keskin et al., 2005 
Turkey 
Children, n=1014 
12-13 years 
4.8-8.5 cups/week  SF : 19.1% 
Hb & SF : 3.9% 
No statistical test performed but ID 
prevalence high in group that consumed 
more tea 
     
Mennen et al., 2007 
France 
Adults, n=2593 
42-68 years 
256-351ml/day (B) 
150-185 ml/day (G) 
104-140 ml/day (H) 
SF : 38-165 µg/l 
SF : 42-501 µg/l 
SF : 45 – 168 µg/l 
(Prevalence N/A) 
No association with SF across type of tea 
(black, green, herbal) (p>0.05) 
     
Hogenkamp et al., 2008 
South Africa 
 
Adults, n=1360 
15-65 years 
56.6-85.1 ml SF : 6.8-21.6% 
Hb & SF : 3.2-14.6% 
No association with either Hb (men p=0.33, 
women p=0.49) or SF (men p=0.059, women 
p=0.49) 
     
Hb – Haemoglobin (g/dl) indicates anaemia; SF-Serum ferritin (µg/l) indicates iron deficiency (ID); Combined Hb and SF indicates - iron deficiency anaemia (IDA); NA: not 
available 
Mehta et al. (1992); Galan et al. (1998); Milman et al. (2004);Keskin et al. (2005); Mennen et al. (2007); Hogenkamp et al. (2008)  
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1.8.1.4 Iron isotope-labelled studies: effect of tea consumption on iron status 
Disler et al. (1975a) showed that 200 ml of tea consumed with a simple iron salt 
solution (FeCl3), labelled with iron isotope, reduced iron absorption to 6.2% 
compared to 21.7% when the FeCl3 was administered with water (p<0.05). Iron 
absorption of another simple salt solution (FeSO4), reduced to 11.2% when 
administered with tea, with added ascorbic acid, as opposed to 30.9% when 
administered with water (p<0.01). Disler et al. (1975a) also used a simple test meal 
of intrinsically labelled bread and demonstrated a 3-fold reduction from 10.4% to 
3.3% (p<0.001) when the tea was administered with the labelled bread, compared to 
when it was administered with water. The galloyl component of polyphenol in tea 
may have caused the reduced iron uptake (Brune, Rossander, & Hallberg, 1989). 
A simple bread test meal was also used in a study carried out by Hurrell et al. (1999) 
investigating the effect of various polyphenol-containing beverages, including 
different types of tea on non-haem iron absorption in the US which included 77 
adults aged 19-40 years. In addition to observing reductions in iron absorption when 
tea was administered with bread, compared to water, the study also demonstrated a 
dose-dependent effect of tea concentration on iron absorption. It was shown that 
iron absorption decreased to 0.59%, compared to 6.58% with water as control 
(p<0.001). Diluting the same tea to 50% and 25% also significantly increased iron 
absorption to 1.05% and 1.18% respectively (p<0.001) (Hurrell et al., 1999). 
However, these studies were carried out using a simple test meal that did not 
contain a mixture of potential enhancers or inhibitors, which may potentially affect 
iron absorption. A simple iron salt solution without the use of test meal also may 
have affected the iron absorption in different ways, compared to when an actual 
labelled test meal was used.  
1.8.2 Dietary enhancing factors of iron absorption 
One of the current approaches used to improve iron nutrition in the UK includes 
compulsory fortification of flour and breast milk substitutes which target at-risk 
groups e.g. infants, young children, and pregnant women, as well as the overall 
population. Other than consuming iron rich food sources, the advice given includes 
to consume food sources that are high in ascorbic acid to maximise iron absorption 
as ascorbic acid, as well as meat, are the most researched potential enhancers of 
iron absorption (SACN, 2010). Extensive scientific evidence on the role of ascorbic 
acid in amplifying iron absorption, using different test meals has been reported since 
the 1950s (Cook & Reddy, 2001), and studies since the 2000s have focused more 
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on alternatives to ascorbic acid. One recent bioavailability study demonstrated the 
potential role of ascorbic acid in enhancing iron absorption in 47 healthy children 
aged 6-7 years (Davidsson, Walczyk, Zavaleta, & Hurrell, 2001). The test meal used 
was an isotope-labelled powdered-based breakfast drink with white bread, 
administered with either ascorbic acid solution or Na2EDTA to investigate the effect 
of these two compounds on iron absorption from the same standardised test meal. It 
was demonstrated that iron absorption was significantly increased (8.2%) when a 
higher ascorbic acid:iron ratio used (1.6:1) compared to 5.1% when a 0.6:1 ratio was 
used (p<0.01). When Na2EDTA was used, there was a significantly higher iron 
absorption of 3.8%, 3.5% and 3.7% (p<0.01) compared to 2.9%, 2.2% and 2.4%, 
respectively, when no enhancer was added to the test meal. On the contrary, Cook 
and Reddy (2001) demonstrated that with a complete diet, the effect of ascorbic acid 
on iron absorption was less evident compared to when a single test meal is used. 
Twelve generally healthy adult subjects aged between 20-38 years were recruited 
and participated in 4 different absorption studies. A hamburger meal was used as a 
control, where a further 3 types of diet; self-selected (SS), high in vitamin D diet 
(HC), and low vitamin C diets (LC) were consumed at home as and self-recorded for 
the duration of 5 days each. Instructions were given on how to choose a high or low 
vitamin C diet. It was reported that no significant difference was observed in 
fractional iron absorption between the three diets despite the difference in total 
ascorbic acid intake between the 3 diets. Iron absorption was generally higher in the 
HC diet (7.69%) as opposed to SS diet (4.57%) and LC diet (5.69%), as expected. 
This may be due to the fact that several meals eaten as part of the diet in a day may 
have an impact on the how ascorbic acid or any other dietary factors in the meal 
(polyphenol, animal tissue etc) interact, causing a lesser effect on iron absorption, 
compared to when overnight-fasted subjects were given a single meal in a 
controlled environment. A randomised crossover study was carried out in 
Switzerland by Fidler, Davidsson, Zeder, and Hurrell (2004) in 10 women aged 20-
26 years to assess the dose effect of erythorbic acid, an alternative to ascorbic acid 
on iron absorption. Erythorbic acid is a stereoisomer of ascorbic acid but dissimilar 
to ascorbic acid merely in the aspect of relative position of hydrogen and hydroxyl 
groups on the fifth carbon atom in the molecule. The subjects were administered 4 
isotope-labelled wheat-based cereals: (a) without any enhancer as a control; (b) with 
erythrobic acid (31.5 & 63 mg) and (c) ascorbic acid (63 mg). It was observed that 
iron absorption was higher (p<0.0001) in meals with erythrobic acid, irrespective of 
concentration (10.8% and 18.8%), compared to the control meal, without any 
enhancer (4.1%). A similar observation on iron absorption was reported with 
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ascorbic acid (11.7%) when compared to the control meal (p=0.0004). However, 
when ascorbic acid is compared against erythrobic acid, there was a higher 
absorption only when higher concentration of erythrobic is used (63 mg) (p=0.0002). 
Ascorbyl palmitate (AP), another substitute for ascorbic acid has shown to be 
effective in enhancing iron absorption. Pizarro et al. (2006) carried out a study in 14 
women aged 35-45 years, and used intrinsically labelled bread with different AP 
content (0, 222, 445, 890 mg) administered at different occasions. The iron 
absorption did not increase from 10.5% (control bread) with 222 mg AP (9.3%), but 
significantly increased to 14.6 % with 445 mg AP and 20.2% with 890 mg AP 
(p<0.001). The thermostable characteristics of AP have been demonstrated to be 
useful in promoting iron absorption in bread with high content of phytate (Pizarro et 
al., 2006) and also, the kinetics of erythrobic acid that prolongs its presence in 
duodenum have also proved to be beneficial in promoting higher iron absorption 
(Fidler et al., 2004).  
A study carried out in Chile in 13 women (32-50 years) which also aimed to focus on 
the effect of ascorbic acid on iron absorption used a sweetened lemonade drink, 
administered with different isotope-labelled noodle-based test meals (Olivares, 
Pizarro, Hertrampf, Fuenmayor, & Estévez, 2007). Iron absorption was reported to 
be not significantly different between bread (9.9%), noodles (8.5%) and noodle soup 
(8.1%). However, there was a significant increase from 8.1 to 14.7% (p=0.02) when 
lemonade was consumed with the noodle soup, as compared to when no lemonade 
was consumed, as anticipated. Ascorbic acid in the lemonade, consumed as part of 
the meal may have promoted the iron absorption (Olivares et al., 2007).  
A study by Cercamondi, Egli, Zeder, and Hurrell (2014) recently added to the 
available evidence demonstrating the efficiency of ascorbic acid in promoting higher 
iron absorption, and counteracting the inhibition effect of polyphenols in cereal 
porridge. The study was carried out in 18 healthy women aged 18-40 years and the 
test meal used was isotope-labelled sorghum-based porridge, administered with 
either: (a) no enhancer (control); (b) 40 mg ascorbic acid or (c) reduced-polyphenol 
porridge (treated with laccase). It was demonstrated that iron absorption from the 
porridge with ascorbic acid was 3-fold higher (13.6%), compared to the control meal 
(4.6%) (p<0.001), but not with the laccase-treated porridge (4.6%, p=0.4). This 
further demonstrates that ascorbic acid can be useful as an enhancer, especially in 
a meal high in polyphenols and phytic acid (Cercamondi et al., 2014).    
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It has been long established that ascorbic acid has the capability of reducing ferric 
iron to the ferrous form, enabling iron to form soluble complexes to be absorbed 
(Hurrell & Egli, 2010). Additionally, ascorbic acid is capable of counteracting the 
effect of iron absorption inhibitors such as polyphenols or calcium in milk products 
(Abbaspour et al., 2014), however, as it is thermolabile (Pizarro et al., 2006), and 
can be degraded with processing, storage or cooking may limit its capability to 
enhance iron absorption (Teucher et al., 2004).  
Vitamin D has recently been suggested to be a potential iron absorption enhancer 
by its role in the erythropoiesis process, but there is limited evidence available, 
especially linking haemoglobin and 25-hydroxyvitamin D (25(OH)D) concentrations 
in human studies (Sim et al., 2010). In addition, an in vitro study carried out in 
human cell lines demonstrated that administration of 25(OH)D and 1,25-
dihydroxyvitamin D (1,25(OH)D) for 6 hours reduced hepcidin expression (Bacchetta 
et al., 2013), which may have facilitated iron status regulation. Observational 
studies, however, report inconsistent findings in relation to the connection between 
vitamin D deficiency and iron deficiency. For instance, vitamin D deficiency was 
shown to result in higher risk of anaemia in participants aged >17 years (Sim et al., 
2010) but iron deficiency and anaemia not found to be associated with vitamin D 
deficiency in a study carried out in children (McGillivray et al., 2007).   
1.8.2.1 Enhancement effects of vitamin D  
Vitamin D has been shown to play role in calcium (Christakos et al., 2013), and 
phosphate homeostasis (Bikle, 2014) and bone health (Brouwer-Brolsma et al., 
2013). Recent observational and experimental studies have suggested that vitamin 
D has a role in other human physiological systems including cardiovascular, brain, 
pancreas, muscle and immune system, but the findings were inconsistent (Brouwer-
Brolsma et al., 2013). There are two main sources of vitamin D; consumption from 
the daily diet, or skin synthesis (Christakos et al., 2013). The dietary sources of 
vitamin D are relatively limited, mostly found in low amounts in an animal-based 
sources such as meat but abundant in fatty fish (Bikle, 2014), fish liver oils (DeLuca, 
2004) or fortified foods (Christakos et al., 2013). Vitamin D, which is a secosteroid 
hormone, exists in two major forms; D3 or cholecalciferol and D2 or ergocalciferol 
(SACN, 2016), which are both utilised in vitamin D-fortified foods and supplements 
(Holick et al., 2011). The additional methyl group and a double bond in the 
secosteroid skeleton cause the D2 to have higher molecular mass than the D3 
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(SACN, 2016). Figure 1.8 shows the structure of vitamin D in D2 and D3 forms 
(Norman, 2008). 
 
 
 
Figure 1.8 Structure of vitamin D2 and D3  
Vitamin D3 is endogenously produced in humans or animal skin via non-enzymatic 
reactions, facilitated by ultraviolet-B (UVB) radiation from the sun ranging between 
280-315 nm (SACN, 2016) that converts 7-dehydrocholesterol (7-DHC) found in the 
epidermis to form pre-vitamin D3 (pre-D3). As this pre-D3 is thermodynamically 
volatile, it undergoes a further thermal isomerisation reaction that produces vitamin 
D3 (Adams & Hewison, 2010). The degree of formation of pre-D3 in the skin is 
subject to the intensity of UVB and individual’s skin pigmentation (Holick, 2008). 
Dietary-based sources of vitamin D become pivotal when the synthesis via skin is 
insufficient, which may due to limited exposure to sunlight (SACN, 2016). Vitamin 
D2 is regarded as the primary analogue of vitamin D (Bikle, 2014), and is produced 
predominantly in plants and fungi from irradiation process of yeast sterol ergosterol 
(DeLuca, 2004; Holick et al., 2011).  
Skin-synthesised vitamin D3 diffuses into circulation after it enters the extracellular 
fluid (Holick et al., 2011). Conversion of vitamin D3 to the active and stable 
metabolite of vitamin D known as 25-hydroxyvitamin D3 (25OH-D) or calcidiol, takes 
place in the liver (Adams & Hewison, 2010) by 25-hydroxylases or high-capacity 
cytochrome P450 oxidases (CYPs) that originate from either mitochondria or 
endoplasmic reticulum (Bikle, 2014). 25(OH)D subsequently binds to vitamin D 
binding protein (VDBP) (SACN, 2016), and is transported to the kidney or other 
tissues, hydroxylated into the active metabolite, 1,25-dihydroxyvitamin D 
(1,25(OH)2D3 or calcitriol) by 1α-hydroxylase (Bikle, 2014). 1,25(OH)D binds to 
vitamin D receptor (VDR) and functions as a steroid, after being mobilised to the 
VITAMIN D3 VITAMIN D2 
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targeted tissues (Christakos et al., 2013). Dietary-based sources of vitamin D are 
transferred by the lymphatic system into the circulation, after being integrated into 
chylomicrons, and undergo the same processes of metabolism as from cutaneous 
synthesis (Holick, 2008). Homeostasis regulation functions to control the conversion 
rate to the active metabolite in kidney and depends on the parathyroid hormone 
(PTH) and fibroblast growth factor 23 (FGF23) concentrations (Henry, 2011). Figure 
1.9 summarises the overall overview of vitamin D synthesis and metabolic pathway.  
 
Key: 
7-DHC: 7-dehydrocholesterol; pre-D3: pre vitamin D3; 25(OH)D: 25-hydroxyvitamin D; Pi: phosphate 
ions; Ca: calcium; FGF23: fibroblast growth factor 23; 1,25(OH)2D: 1,25-dihydroxyvitamin D; RANKL: 
receptor activator of nuclear factor-kappaB ligand; ECaC: epithelial calcium channel; CABP: calbindin; 
Ca2+HPO42-: calcium hydrogen phosphate 
 
Figure 1.9 Vitamin D: acquisition, metabolism and biological functions - 
adapted from Holick et al. (2011) 
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25(OH)D which has a longer half-life (Norman, 2008) is the main circulatory form of 
vitamin D (Christakos et al., 2013), hence is extensively used as a vitamin D status 
biomarker, expressed in nmol/l or ng/ml (SACN, 2016). Assays that quantify the 
serum/plasma concentration of 25(OH)D have been extensively utilised in research 
to assess vitamin D status (Hilger et al., 2014). There is no internationally 
established threshold to define vitamin D adequacy (Thacher & Clarke, 2011), 
however, serum/plasma concentration 25(OH)D of < 25 nmol/l is regarded as a 
clinical vitamin D deficiency, associated with an indication of bone-related disorders 
such as bone pain and muscle weakness (van Schoor & Lips, 2011). There are 
several thresholds used worldwide to define vitamin D status for different age 
groups (Table 1.9), which supports by the significant variations in vitamin D 
deficiency prevalence observed across different countries, ranging between 2-90% 
(Hilger et al., 2014).  
Table 1.9 Vitamin D status based on different thresholds of serum/plasma 
25(OH)D concentration (nmol/l) 
Organisation/Reference Deficiency Insufficiency Sufficiency 
UK SACN (SACN, 2016) < 25  - > 25  
    
IOM (Ross, Taylor, Yaktine, & Del Valle, 
2011) 
<30  30-50  >50  
    
The Endocrine Society (Holick et al., 
2011) 
<50  52.5-72.5  75-250  
    
Vitamin D Council  0-75  77.5-97.5  100-200  
    
Vieth (2005) 0-25  25-40  40-100  
To convert to ng/ml: divide nmol/l by 2.5 
Vieth (2005): Desirable (75-160 nmol/l), Toxicity (>220 nmol/l); Vitamin D Council: Toxicity (375 nmol/l)  
 
A recently published SACN report for UK population has recommended <25 nmol/l 
of serum 25(OH)D as the threshold to define vitamin D deficiency for individual aged 
>4 years old (SACN, 2016). Table 1.10 summarises the NDNS population data for 
vitamin D status of women and men aged 19-64 years between 2008 and 2014 
based on serum 25(OH)D concentration (Bates et al., 2014; Henderson et al., 2003; 
Public Health England, 2016).  
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The table shows mean (±S.D) serum 25(OH)D concentrations, with the percentage 
of women and men who had mean (±S.D) serum 25(OH)D concentrations below < 
25 nmol/l, which is classified as vitamin D deficiency by the UK SACN. Based on the 
newly proposed threshold by the SACN, UK adults were not deficient across all 3 
NDNS population data, however, if the IOM threshold is applied, the reported mean 
(±S.D) serum 25(OH)D concentrations were classified as insufficient. Approximately 
1/5 of adults (between 15-24%) in the UK were vitamin D deficient based on the 
proposed SACN 25(OH)D threshold of <25 nmol/l.  
Not taking into account sex and seasonal variations, mean (±S.D) serum 25(OH)D 
concentration of adults was 45.4 ± 24.8 nmol/l (Bates et al., 2014). The NDNS 
population data for mean (±S.D) serum 25(OH)D concentrations of adults aged 19-
64 years were at the lowest in January-March (34.8 ± 22.9 nmol/l), followed by April-
June (44.2 ± 24.4 nmol/l), October-December (45.6 ± 22.7 nmol/l) and at the highest 
were in July-September (57.5 ± 23.4 nmol/l) (Bates et al., 2014).  
Table 1.10 NDNS population data for vitamin D status of adults aged 19-64 
years 
NDNS  Mean (±S.D) serum 
25(OH)D concentrations 
(nmol/l) 
Proportion of adults 
with mean (±S.D) 
serum 25(OH)D 
concentrations < 25 
nmol/l (%) 
2008/09-2010/11  
(Year 1-3) 
Men  45.6 ± 22.7 17.1 
Women  49.6 ± 25.6 18.6 
    
2008/09-2010/12  
(Year 1-4) 
Men  43.5 ± 23.9 24.0 
Women  47.3 ± 25.6 21.7 
    
2012/13-2013/14  
(Year 5-6) 
Men  42.4 ± 21.0 22.0 
Women  45.3 ± 21.1 15.0 
    
2008/09-2010/11 (Year 1-3) (Henderson et al., 2003); 2008/09-2010/12 (Year 1-4) (Bates et al., 2014); 
2012/13-2013/14 (Year 5-6) (Public Health England, 2016) 
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Even though food-based sources of vitamin D are available, they are predominantly 
limited to animal origin foods such as oily fish (Brouwer-Brolsma et al., 2013), 
causing difficulty in sustaining sufficient vitamin D status (Adams & Hewison, 2010). 
The vitamin D recommended intake in different populations worldwide is currently 
set to between 100-800 IU (Adams & Hewison, 2010), and 400 IU specific to UK 
population (SACN, 2016). The range between 100-800 IU is regarded as 
underestimated, contributes to the difficulty in maintaining sufficient vitamin D status, 
hence, the need for additional vitamin D from supplement form (Adams & Hewison, 
2010).  
There is no international consensus on the optimal dietary intake of vitamin D 
(Brouwer-Brolsma et al., 2013), however, a recent RNI of 400 IU/day (10 µg) was 
proposed for general UK population aged >4 years, including pregnant and lactating 
women (SACN, 2016). The RNI proposed includes the daily intake from either 
naturally-contained vitamin D food sources, vitamin D-fortified foods or supplements. 
Table 1.11 summarises the recommended dietary and supplement intakes from 
various sources worldwide. 
Table 1.11 Overview of vitamin D dietary and supplement 
recommendations for adults  
Reference Dietary  Supplements (D2 or D3) 
 
UK SACN  
(SACN, 2016) 
400 IU/day (10 µg) 400 IU/day (10 µg) 
   
IOM  
(Ross et al., 2011) 
600 IU/day (15 µg) 600 IU/day (15 µg) 
   
The Endocrine 
Society  
(Holick et al., 2011) 
600 IU/day (15 µg) 6000 IU/day (150 µg) or 
50000 IU/week (1250 µg) 
(8 weeks) 
   
Vitamin D Council 5000 IU/day (125 µg) 5000 IU/day (125 µg) 
   
Vieth (2005) 200 IU/day (5 µg) 4000 IU/day (100 µg) 
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The mean (±S.D) daily dietary intake of vitamin D for adults aged 19-64 years was 
2.8 ± 2.1 µg and was higher in men (3.1 ± 2.3 µg) compared to women (2.6 ± 1.9 
µg) (Bates et al., 2014). Recently compiled and published NDNS population data 
showed that the daily dietary intake of vitamin D in adults has not changed as 
compared to the earlier NDNS data by Bates et al. (2014), with overall mean (±S.D) 
daily dietary intake of vitamin D for adults of 2.8 ± 2.1 µg, 3.1 ± 2.3 µg (men), and 
slightly lower in women (2.5 ± 1.9 µg) (Public Health England, 2016). The food 
group contributing to vitamin D dietary intake the most in adults was meat and meat 
products (29%), followed by egg and egg dishes (19%), fish and fish dishes (15%) 
and fat spread (13%) (Public Health England, 2016).  
1.8.2.2 Association between iron and vitamin D deficiencies: human 
observational studies 
An association between vitamin D deficiency and a higher risk of anaemia was 
reported in a cross-sectional study carried out in adolescents and adults of both 
sexes aged 17+ years who attended 11 medical centres in the California, USA as 
part of routine health care examinations (Sim et al., 2010). Participants were 
classified as anaemic based on Hb concentration of <11 g/dl and vitamin D deficient 
based on serum 25(OH)D concentration of <75 nmol/l. Of the 554 participants who 
were included in the study, more than half (57%) were found to be not deficient in 
vitamin D. Anaemia prevalence in the vitamin D deficient group (48.8%) was found 
to be significantly higher in the non-deficient group (35.7%, p<0.01). However, the 
mean (SD not provided) haemoglobin concentration was not significantly lower in 
vitamin D deficient group (11.0 g/dl) compared to non-deficient group (11.7 g/dl, 
p=0.12). As opposed to only 1/5 of the participants in the non-deficient group, half of 
the participants in the vitamin D deficient group were administered with 
erythropoietin stimulating agents (ESA), suggesting anaemia is commonly 
associated with the incidence of ACKD, and possibly vitamin D deficiency. The 
study, however, used a threshold of 75 nmol/l to define vitamin D deficiency, which 
may have also included participants that are classified as sufficient based on the 
IOM recommendation (Ross et al., 2011). It is demonstrated by the fact that only 2% 
of the total of 43% vitamin D deficient participants were severely deficient, based on 
the threshold of <25 nmol/l by IOM. In addition, the iron stores, indicated by the 
mean (SD not provided) plasma ferritin concentration of > 15 µg/l in both groups 
were in the normal range, and were in fact, significantly higher in the vitamin D 
deficient group (364 µg/l) compared to non-deficient group (189 µg/l, p=0.01). The 
study included a wide range of ages and both sexes, which may have confounded 
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the findings related to incidence of anaemia and vitamin D deficiency, reported in 
the study. Despite the nature of observational studies that do not provide a causal 
effect, the study demonstrated appropriate evidence to instigate further investigation 
on the link between these two deficiencies.  
A weak but significant linear association between haemoglobin and serum 25(OH)D 
concentrations (r=0.221, p=0.026) was observed in another cross-sectional study 
carried out in 102 Korean children aged 3-24 months who attended a medical centre 
in Korea (Jin, Lee, & Kim, 2013). Participants were classified into 3 groups: ID (Hb 
>11 g/dl, plasma ferritin ≤ 12 µg/l), IDA (Hb ≤ 11 g/dl, plasma ferritin ≤ 12 µg/l) and 
normal. Vitamin D status was defined by using serum 25(OH)D threshold of ≤ 50 
nmol/l (deficiency), 50-75 nmol/l (insufficiency) and >75 nmol/l (normal). It was 
observed that vitamin D deficiency was more predominant in IDA (67%) compared 
to ID (53%) and normal (29%) groups. It was shown in the mean (±S.D) serum 
25(OH)D concentration, as it was the lowest in the IDA (45.3 ± 28.5 nmol/l), as 
opposed to the ID (57.5 ± 55.8 nmol/l) and normal groups (81.8 ± 60.8 nmol/l) (Jin et 
al., 2013). The study is limited by the unequal number of participants in each group 
and may be subject to selection bias due to the nature of the study. The study 
included only children who attended the medical centre, who have a complete 
specific set of biochemical data (Hb, MCV, red cell width, platelets, serum ferritin, 
serum iron, TIBC, serum transferrin saturation, calcium, alkaline phosphatase and 
serum 25(OH)D concentrations), which may prone to selection bias. However, 
serum iron concentration was found to be one of the factors that affected serum 
25(OH)D concentration by regression analyses, which may require further 
investigation on the long-term consequences linking iron and vitamin D deficiencies.  
In a larger scale of cross-sectional study, Lee et al. (2015) reported that the 
incidence of vitamin D deficiency was higher in anaemic female participants (65%), 
compared to only 40% anaemic male participants with mean (SE) of 34.3(1.3) and 
41(2.8) nmol/l, respectively. The study included a Korean nationally representative 
data derived from 2526 participants aged 10-20 years, and used different thresholds 
of Hb (female: <12 g/dl, male:<13 g/dl); serum ferritin (<12 µg/l) and serum 
transferrin saturation (<16%) to define iron status. A serum 25(OH)D threshold of 
<37.5 nmol/l was used to classify participants as deficient, or insufficient (37.5-72.5 
nmol/l) and sufficient (≥75 nmol/l) (Lee et al., 2015). It can be concluded that vitamin 
D deficiency observed in the participants lead to increased risk of anaemia, and was 
more prevalent in female participants (Lee et al., 2015). The study was limited to the 
nature of cross-sectional study that is unable to determine a causal effect, and also 
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the inclusion of both sexes may have also have impacted up on the findings as 
menstrual losses in females may cause iron deficiency that leads to anaemia. 
However, the study included a large sample size and the findings in the study are 
consistent with the observation in previous studies that reported concurrent 
incidence of iron and vitamin D deficiencies in similar individuals. 
A cross-sectional study which included data obtained from 263 children aged 3 
months-12 years who attended an outpatient department of a hospital in New Delhi, 
India reported a higher anaemia incidence in vitamin D deficient participants (66%) 
compared to vitamin D sufficient participants (35%) (Sharma, Jain, & Dabla, 2015). 
Participants were stratified into 3 groups based on serum 25(OH)D threshold of ≤ 30 
nmol/l (deficiency), 30-75 nmol/l (insufficiency) and >75 nmol/l (sufficiency). 
Anaemia was considered present with Hb <11 g/dl, MCV < 70 fl and red cell width 
(RDW) >15%, and IDA was present with serum ferritin < 12 µg/l, TIBC > 450 µg/dl, 
or transferrin saturation < 15%. Mean (±S.D) haemoglobin concentration was 
reported to be significantly lower in the vitamin D deficient group (9.86 ± 2.6 g/dl) 
compared to sufficient group (11.25 ± 1.9 g/dl, p<0.01) but no significant difference 
was observed between groups in serum ferritin concentration. A moderate, but 
significant linear association (r=0.317, p=0.013) between serum 25(OH)D and 
haemoglobin concentrations was observed. A multiple regression test carried out 
discovered that there was an increased risk of vitamin D deficiency in participants 
who were anaemic (p<0.001) (Sharma et al., 2015), also consistent with findings 
from the previous studies. The study showed that concurrent incidence of anaemia 
and vitamin D deficiency are prevalent in infants and young children, which should 
be addressed, as physiological requirements of iron and vitamin D are crucial at this 
age group for normal body functions.  
Based on evidence gathered from these recent cross-sectional studies, it can be 
established that there is a link between anaemia and vitamin D deficiency, 
demonstrated across different populations. However, it should be noted that 
different observational studies have employed various thresholds, especially in 
defining vitamin D status as there is no established international threshold. The 
different thresholds used in each study may have an effect on the reported figures of 
prevalence, causing difficulty in the comparison and interpretation.  
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1.8.2.3 Effect of vitamin D on iron status: human intervention studies 
A single-blinded randomised controlled trial was carried out in 30 IDA patients 
recruited from an outpatient department in a medical institute in India, aged 15-60 
years who had IDA (Hb < 12 g/dl, serum ferritin < 15 µg/l) and serum 25(OH)D of < 
50 nmol/l, to investigate the effect of intramuscular vitamin D3 therapy on iron status 
(Sooragonda et al., 2014). All participants were administered with iron intravenously 
in separate doses for 12 weeks but were randomised into a vitamin D therapy (600, 
000 IU) and placebo group. No significant effect of intervention on haemoglobin or 
serum ferritin concentrations was observed between the vitamin D and placebo 
groups. In addition, no association between serum 25(OH)D and haemoglobin 
concentration was observed, contrasting from the findings of observational studies. 
It was established that a 12-week intramuscular bolus dosage of vitamin D3 did not 
improve the iron status of patients diagnosed with IDA (Sooragonda et al., 2014). It 
should be noted that the study was a single-blinded RCT, did not report baseline 
concentrations of serum ferritin despite the change reported within both groups, and 
the small sample size may have limited the study to observe a significant change in 
iron status indices.  
An 8-week randomised controlled trial in 200 hypertensive patients who attended an 
outpatient department of a hospital in Austria, aged >18 years with a low serum 
25(OH)D concentration of < 75 nmol/l was carried out to determine the effect of 
vitamin D supplementation on haemoglobin concentrations (Ernst et al., 2016). 
Participants were randomised into 2 groups to consume either 7 drops/day of 
vitamin D3 oily drops (2800 IU) or matching placebo. The following thresholds were 
used as participants’ inclusion criteria: anaemia (Hb < 12.5 g/dl); vitamin D deficient 
(< 30 nmol/l); vitamin D insufficient (30-49.9 nmol/l) and borderline vitamin D (50-
74.9 nmol/l). It was observed that vitamin D supplementation did not have a 
significant effect on the haemoglobin concentration, or any other full blood count 
indices. Participants were generally non-anaemic at baseline in both groups and 
remained non-anaemic at post-intervention (Ernst et al., 2016). It was shown in the 
study that supplementation of vitamin D3 (2800 IU) did not improve hypertensive 
patients’ iron status as hypothesised. Despite the strong study design and large 
sample size, the baseline concentration of haemoglobin (>14 g/dl) and serum 
25(OH)D (>50 nmol/l) were clearly in the normal ranges, which may have influenced 
the participants’ response to the intervention. It should also be noted that 
hypertensive patients may have other underlying problems that may have 
contributed to the non-significant improvement in iron status.  
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No significant improvement in iron status biomarkers including haemoglobin 
concentration were observed in a randomised controlled trial carried out in Norway 
following a longer duration of 16-weeks vitamin D3 supplementation (Madar et al., 
2016). The study was carried out in 251 healthy adults of both sexes aged 18-50 
years, randomised into 3 groups, consuming 1 tablet/day of vitamin D3 (1000 IU), 
vitamin D3 (400 IU) and placebo. It was observed that supplementation of vitamin 
D3 of both doses, analysed pooled or separately, had no significant effect on all iron 
status biomarkers of participants, including serum ferritin and haemoglobin 
concentrations between the vitamin D and placebo groups (Madar et al., 2016). The 
study included no clear definition of serum 25(OH)D concentration as participants’ 
inclusion criteria, but overall mean (±S.D) serum 25(OH)D concentration at baseline 
for all participants was reported to be 29 ± 17.6 nmol/l, with over half proportion of 
participants (53%) with serum 25(OH)D concentration <25 nmol/l. In addition, it was 
shown that baseline serum 25(OH)D concentration did not associate with any of the 
iron status biomarkers (Madar et al., 2016). The non-significant improvement in the 
iron status following the vitamin D supplementation may be due to the fact that the 
participants included in the study were not iron depleted or anaemic at baseline, as 
it has been shown that physiological demand of iron dictates the rate of iron 
absorbed. A different approach was employed by Hennigar et al. (2016) using a 
calcium/vitamin D-fortified snack bar with the aim to improve iron status in 152 
healthy adult soldiers of both sexes aged 18-42 years who had undergone military 
training for 9 weeks. The participants were randomised to receive the fortified (1032 
mg/13.7µg Ca/vitamin D3 per snack bar) or placebo snack bars and instructed to 
consume 2 bars daily. The main finding yielded a similar observation from the 
previous studies that used vitamin D supplements, with no significant effect reported 
on any of the iron biomarkers, including plasma ferritin and haemoglobin 
concentrations following fortified food consumption between the fortified and non-
fortified placebo groups. However, high compliance of the fortified foods was 
supported with the significantly higher mean (±S.D) vitamin D dietary intake in the 
intervention group at post-intervention (27.8 ± 5.13 µg) as opposed to the placebo 
group (5.3 ± 3.45 µg, p<0.05) (Hennigar et al., 2016). The study was limited to the 
fact that there was no pre-defined iron or vitamin D status in recruiting the 
participants and the short duration of the study, but the double-blinded study design 
was one of the strengths. The non-significant improvement observed in the iron 
status biomarkers may be due to the normal baseline concentration of both 
haemoglobin (> 12 g/dl) and serum ferritin concentrations (> 50 µg/l), which is 
associated with low homeostatic iron demands.   
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A randomised controlled trial investigating the effect of iron-fortified fruit juice 
consumption on both iron and vitamin D status was carried out in 41 women aged 
18-35 years, with low iron stores (serum ferritin < 40 µg/l) (Blanco-Rojo et al., 2013). 
The participants were randomised to receive 500 ml/day of iron-fortified fruit juice 
containing 18 mg of iron, or placebo fruit juice for a period of 16 weeks. There were 
significantly higher mean (±S.D) haemoglobin and serum ferritin concentrations at 
post-intervention, relative to baseline, in the iron-fortified group (13.7 ± 0.7 g/dl, 33.5 
± 16.9 µg/l) , as compared to placebo group (13.1 ± 0.7 g/dl, 20.2 ± 14.6 µg/l) at 
p<0.01 and p<0.05, respectively. No significant difference was observed between 
the groups on the serum 25(OH)D concentration. The study showed that more than 
half of the participants (53.6%) were vitamin D deficient based on serum 25(OH)D 
threshold of < 50 nmol/l at baseline, with an overall mean (±S.D) of 50.2 ± 14.0 
nmol/l. Despite a non-significant improvement in serum 25(OH)D concentration, the 
study demonstrated a positive and significant association between serum 25(OH)D 
concentration and transferrin saturation (p=0.007, r value not provided), but not with 
serum ferritin or haemoglobin concentrations (Blanco-Rojo et al., 2013). The high 
baseline concentration of serum 25(OH)D concentration with no additional vitamin D 
in the iron-fortified juice may have contributed to the non-significant change of 
serum 25(OH)D concentration at post-intervention. The inclusion of iron deficient 
participants lead to a significant improvement in most iron status biomarkers, 
however, it should also be noted that the fortified juice used in the study contained 
added ascorbic acid in the form of liquid that is highly bioavailable, hence, this may 
have contributed to the improvement in principal iron status biomarkers.  
Toxqui et al. (2013) carried out a randomised controlled trial by incorporating both 
iron and vitamin D in skimmed milk, to investigate the effect of fortified skimmed milk 
consumption on iron status in 129 iron deficient Spanish women aged 18-35 years 
with serum ferritin < 30 µg/l. The participants were randomised to receive 
iron/vitamin D fortified skimmed milk (Fe/D group) or iron-fortified skimmed milk (Fe 
group) and were required to consume the 500 ml skimmed milk containing 15 mg 
iron and/or 5 µg vitamin D according to the assigned group for 16 weeks. No 
significant difference was observed in serum ferritin and haemoglobin 
concentrations between the groups, but significantly higher erythrocyte counts, 
haematocrit % and haemoglobin concentration were observed at 8 weeks (interim) 
in the Fe/D group. At 8 weeks, mean (±S.D) haemoglobin concentration was 
significantly higher in the Fe/D group (13.3 ± 0.8 g/dl) compared to Fe group (13.0 ± 
0.7 g/dl) (p<0.05), but not significantly higher at post-intervention (Toxqui et al., 
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2013). Negligible effect of the added vitamin D on the improvement of iron stores 
may be due to milk components (whey, casein, calcium) in the skimmed milk used 
as the fortification vehicle in the study, which may have reduced the iron absorption. 
The serum ferritin concentration at baseline was > 20 µg/l in both groups and 
remained below 30 µg/l at all time points and at post-intervention, despite the high 
content of iron added to the fortified skimmed milk. It should also be noted that the 
serum ferritin threshold used in the study was higher (<30 µg/l) as opposed to a 
lower threshold proposed by WHO of < 12 µg/l to define ID (WHO/UNICEF/UNU, 
2001).  
Based on the evidence gathered from the recent intervention studies, it can be 
established that not all iron status biomarkers were improved in vitamin D 
interventions. Most improvements were observed when iron deficient participants 
were included in the studies, compared to generally healthy participants who had 
low systemic iron requirements, indicating that initial participants’ iron status 
background at the start of interventions may dictate the response to vitamin D 
interventions. Additionally, factors such as (i) amount of iron and vitamin D (low, 
high or none); (ii) forms of iron and vitamin D (fortified foods or supplements); and 
(iii) duration of interventions, contributes to inconsistencies in the reported findings. 
1.8.2.4 Effect of vitamin D on iron status: in vivo and in vitro studies 
Based on the evidence that anaemia is linked to both incidence of vitamin D 
deficiency and increased hepcidin concentration in kidney patients (ACKD), 
Bacchetta et al. (2013) carried out an in vitro study investigating the role of vitamin D 
in regulation of hepcidin expression, as hepcidin is known for its role as iron 
regulator. It was shown that treating different cell  lines (human PBMC and THP1 
monocytes, and HepG2 hepatocytes) with 100 nM of 25(OH)D and 5 nM of 
1,25(OH)D for a duration of 6 hours reduced the expression of HAMP, the gene 
responsible for hepcidin production. It was observed that hepcidin expression was 
significantly reduced by at least 0.4-fold when treated with 25(OH)D and 1,25(OH)D 
(p<0.001) compared to control vehicle treatment. It was suggested that treating the 
cell lines with 25(OH)D and 1,25(OH)D caused direct inhibition on transcription of 
the HAMP gene (Bacchetta et al., 2013), which may have ultimately lead to 
increased iron absorption.  
 
 82 
 
Based on findings in the in vitro study that demonstrated the effect of vitamin D on 
the regulation of hepcidin, Bacchetta et al. (2013) carried out a pilot human study 
using 7 healthy participants, orally supplemented with vitamin D2 bolus dose of 100, 
000 IU once. Evidence from this human study supported the in vitro findings, that 
serum hepcidin concentration was significantly reduced to 34% (mean ±S.D not 
provided) following 24 hours of supplementation (p<0.05). Analysis of serum for the 
next 72 hours of after vitamin D supplementation showed that the serum hepcidin 
concentration was further decreased to 33% (p<0.01) (mean ±S.D not provided). 
However, instead of increasing, mean (±S.D) serum ferritin concentration was found 
to have significantly decreased to 138.8 ± 25.0 µg/l (24 hours) to 124.5 ± 21.7 µg/l 
(72 hours) (p=0.04) (Bacchetta et al., 2013). It should be noted that participants 
included in the study were not iron depleted, but generally healthy, which may have 
explained the observation. It was reported in the study that the baseline serum 
ferritin concentration of participants was described as between 18-160 µg/l for 
female, and 18-2710 µg/l  for male (Bacchetta et al., 2013), which is considered iron 
replete based on the WHO serum ferritin threshold of >12 µg/l (WHO/UNICEF/UNU, 
2001). In addition to iron status biomarkers, the study also included the 
measurement of serum PTH concentration (n=6) and it was reported that mean 
(±S.D) serum PTH concentration was significantly lower at 72 hours (51.3 ± 7.5 
pg/ml) compared to 58.9 ± 6.4 pg/ml at 24 hours (p=0.06) (Bacchetta et al., 2013). A 
small sample size was a limitation of this pilot study, but the significant decline 
observed in serum hepcidin concentration despite the small sample size, in addition 
to the evidence from the in vitro study is sufficient to initiate larger scale 
investigations especially RCTs.  
A recent experimental study that included both in vitro study and in vivo pilot human 
trial was carried out by Zughaier, Alvarez, Sloan, Konrad, and Tangpricha (2014), 
based on the evidence available on the connection between anaemia and vitamin D 
deficiency by measuring hepcidin expression following vitamin D 
treatment/intervention. The in vitro study used a monocyte cell line (THP-1), treated 
with 1,25(OH)D with doses between 5-40 nM. The cell line was induced with 
lipopolysaccharide (LPS) to cause inflammation, and the HAMP gene expression 
was quantified with polymerase chain reaction (PCR) (Zughaier et al., 2014). After 6 
hours, hepcidin expression was found to be significantly suppressed to 15-fold 
(LPS/20 nM 1,25-OHD) and 20-fold (LPS/40 nM 1,25-OHD) compared to control 
(p<0.05). Ferroportin, which is an iron exporter, was found to be increased, as a 
result of the reduced hepcidin, but only significantly increased with a 40 nM dose of 
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1,25(OH)D (p<0.05) (Zughaier et al., 2014). This indicates that with the presence of 
inflammation, vitamin D suppresses the transcription of the HAMP gene, and 
increases ferroportin concentration, to ultimately transport iron for utilisation. In 
addition, the treatment of 1,25(OH)D at both doses resulted in a significantly higher 
concentration of NRAMP1, the endosomal iron transporter (p<0.05). Pro-hepcidin 
cytokines (IL6 and IL1β) were found to be significantly reduced by at least 2-fold 
with a 20 nM dose of 1,25(OH)D (p<0.05) and further reduced with 40 nM dose 
(p<0.05), supporting the proposed theory that vitamin D regulates hepcidin by 
reducing the release of these cytokines (Zughaier et al., 2014). Zughaier et al. 
(2014) included 38 kidney patients, who were at stage 2 and 3 of ACKD in the in 
vivo part of the study. The patients were randomised to receive oral administration 
of vitamin D3 (50 000 IU/week), and every other week for 40 weeks or placebo for 
12 weeks. There was no data provided on the change of biomarkers measured 
following the supplementation, but a moderate, significant, negative association was 
found between the serum hepcidin and serum 25(OH)D concentrations (r=-0.38, 
p=0.02) (n=38). However, it should be taken into consideration that mean (±S.D) 
baseline concentration of serum 25(OH)D concentration was significantly higher in 
the placebo group (82.3 ± 21.3 nmol/l) compared to the intervention group (68.8 ± 
15.8 nmol/l) (p=0.03). The study demonstrated that bolus administration of vitamin 
D3 affected the serum hepcidin concentration which may lead to increase in iron 
status biomarkers. However, the study was carried out in kidney patients, who are 
commonly associated with anaemia due to chronic disease, and results may not be 
able to be generalised to the general population, healthy or iron deficient.  
To the best of our knowledge, these were the only experimental trials that combined 
both in vitro and in vivo studies investigating the potential mechanism of the role of 
vitamin D in iron homeostasis, by regulation of transcription of the HAMP gene that 
is responsible for hepcidin production, which is known to function as an iron 
regulator. However, the in vivo part of the studies used a bolus concentration of 
vitamin D2 or D3 and were carried out in a small sample of healthy participants 
(Bacchetta et al., 2013) and ACKD patients (Zughaier et al., 2014). There is a 
scarcity of randomised controlled trials, investigating the effect of the vitamin D 
supplementation administered routinely, as an iron absorption enhancer on iron 
status especially in a population who are at risk of iron deficiency. 
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1.8.2.5 Proposed mechanism of the effect of vitamin D on iron homeostasis 
The underlying mechanism behind the effect of vitamin D on iron regulation is poorly 
understood (Madar et al., 2016), and the proposed theory was based on 
observations reported in studies carried out in patients with  disease complication-
derived anaemia, such as haemodialysis patients (Miskulin et al., 2016; Naini, 
Hedaiati, Gholami, Pezeshki, & Moinzadeh, 2015) or critically ill patients (Smith et 
al., 2016b). Vitamin D has recently been suggested to play role in erythropoiesis, but 
there is limited evidence available, especially linking haemoglobin and serum 
25(OH) concentrations in humans (Sim et al., 2010).  
A double-blind randomised controlled trial was carried out in 64 renal patients 
undergoing haemodialysis treatment aged 18-80 years who had a concurrent 
incidence of vitamin D deficiency, anaemia, and were administered with 
erythropoietin stimulating agent (ESA) to manage anaemia at the time of recruitment 
(Naini et al., 2015). Patients were included using the following thresholds; Hb 
concentration <11 g/dl, serum 25(OH)D concentration < 75 nmol/l, and randomised 
to receive placebo or vitamin D 50 000 IU/week) for 12 weeks and subsequently 
every 3 weeks, for a total of 16 weeks. No significant difference was observed in 
haemoglobin concentration between the two groups, however, the dose of ESA was 
found to be significantly lower at post-intervention in the intervention group 
(p<0.001) (data not provided) (Naini et al., 2015). Mean (±S.D) haemoglobin 
concentrations were similar at baseline (9.8 ± 1.6, 10.1 ± 1.7 g/dl) and post-
intervention (10.6 ± 1.1, 11.2 ± 1.2 g/dl) for male and female participants, 
respectively. The reduced ESA dose in the intervention group as opposed to the 
placebo group indicates that vitamin D may play role in increasing erythropoiesis 
and that anaemia is effectively managed. However, the study was carried out in set 
of renal patients and cannot be generalised to the general population, despite the 
strong double-blind RCT study design.  
Another randomised controlled trial carried out in haemodialysis patients diagnosed 
with vitamin D deficiency, however, observed no significant effect of vitamin D2 
supplementation on ESA utilisation (Miskulin et al., 2016). The 6-month study was 
carried out in 276 patients with serum 25(OH)D concentration of < 75 nmol/l at 
baseline, who were prescribed with vitamin D receptor agonist (VDRA) treatment 
and ESA. The participants were randomised to receive either vitamin D2 (50 000 
IU/week) or placebo. As expected, mean (±S.D) serum 25(OH)D concentration was 
significantly higher at post-intervention in the intervention group (98.0 ± 37.3 nmol/l) 
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compared to placebo group (43.8 ± 18.5 nmol/l). No significant difference in the ESA 
weekly dose between groups was observed which may indicate the ineffectiveness 
of vitamin D supplementation in reducing anaemia, as demonstrated in the study by 
Naini et al. (2015). However, the participants included in the trial were generally 
elderly with a mean (±S.D) age of 61.1 ± 13.6, with a high incidence of diabetes 
(46%) and hypertension (30%), with comorbidities such as ischaemic heart disease 
and heart failure (both 29%) (Miskulin et al., 2016), which may have indirectly 
affected the findings in the study.  
A pilot randomised controlled study carried out in 28 healthy adults aged 18-65 
years in the USA by Smith et al. (2016a) also hypothesised that  vitamin D therapy 
would lead to a reduction in the release of pro-hepcidin cytokines which cause 
suppression of hepcidin expression and ultimately increase in iron uptake. 
Participants were randomised to receive either an oral dose of vitamin D3 (250 000 
IU) or matching placebo and measurement of blood biomarkers was carried out at 
baseline and 1-week post-intervention (Smith et al., 2016a). It was observed that 
plasma hepcidin concentration (geometric mean, 95% CI) significantly decreased by 
73% at post-intervention in the vitamin D group (2.4, 0.8-7.4 ng/ml) compared to the 
placebo group (9.0, 4.8-16.7 ng/ml) (p=0.04). However, no significant increase in 
plasma ferritin concentration was observed between the groups (Smith et al., 
2016a). Vitamin D supplementation may have affected the hepcidin expression 
directly, without affecting the release of cytokines as previously demonstrated in the 
in vivo studies and patients, who were likely to have existing inflammation (Smith et 
al., 2016a). The non-significant increase observed in the plasma ferritin 
concentrations, despite the significant effect of vitamin D on hepcidin expression, 
may be due to the short study duration and small sample size, which are the 
limitation of the study.  
Based on existing evidence from observational, human interventions and in vitro 
studies, anaemia was clearly associated with the incidence of vitamin D deficiency, 
though there is no clear mechanism (Sim et al., 2010). The proposed theory, 
however, revolves around the mechanism of action of vitamin D that affects hepcidin 
expression, pro-inflammatory cytokine production, and rate of erythropoiesis. 
Erythroid precursor cells are responsible to express 1,25(OH)D receptors, which 
then stimulates the production and development of progenitor cell, that are required 
in erythropoiesis. The compromised concentration of the vitamin D active 
metabolite, 1,25(OH)D will then change the rate of erythropoiesis (Santoro et al., 
2015; Sim et al., 2010). This active metabolite has also been suggested to improve 
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the responsiveness of patients that were administered with ESA in managing 
anaemia, by improving erythropoiesis, thus decreasing the use of ESA when 
supplementing with vitamin D (Ernst et al., 2016). The involvement of inflammatory 
cytokines in the proposed mechanism is particularly related to anaemia due to 
inflammation mostly in chronic disease patients. The release of inflammatory 
cytokines leads to increased hepcidin concentration, known as its role as an iron 
regulator (Smith et al., 2016a). The use of vitamin D has been shown to decrease 
hepcidin expression and increase ferroportin to export more iron and ultimately 
decrease the incidence of anaemia (Madar et al., 2016).  
On the basis of the aspects covered in this general introduction, it can be 
summarised that iron, as an element, is vital as it is required in most human 
metabolic processes. It also shows that individual’s iron status, measured by various 
iron biomarkers, is affected by the mechanism of action of various molecules or 
enzymes that play roles in iron homeostasis. In the context of UK population, in 
particular, dietary intake of iron does not achieve the recommended RNI and there is 
the mild prevalence of anaemia and iron deficiency, especially in premenopausal 
women, which is the focus of this present research. Despite the established 
strategies proposed in the management of poor iron status, the sole approach to 
either dietary modification, iron fortification or iron supplementation will not lead to 
the recovery of iron status. Therefore, it is important to carry out well-designed 
intervention studies that are focus on the utilisation of more than sole strategy in the 
management of anaemia and ID.  
Despite extensive literature available emphasising the influence of different dietary 
factors (ascorbic acid or polyphenols) on iron absorption, it is apparent that few iron 
absorption intervention studies have been carried out in the UK population 
investigating the effect of tea consumption on iron uptake. According to the NDNS, 
UK adults consume approximately 1114 grams/day of tea, coffee, and tea (Bates et 
al., 2014), therefore understanding the link between tea consumption and iron 
uptake will be potentially useful.  
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Previous studies addressing this area have been carried out outside of the UK using 
different types of test meals, however, there is limited evidence available to date, 
particularly using a typical meal relative to UK dietary patterns. In addition, to the 
best of our knowledge, no human studies addressing the impact of the time interval 
of tea consumption, relative to an iron-containing test meal, on iron absorption have 
been carried out in the UK. Apart from an animal study carried out by Disler et al. 
(1975b) using 10 male Sprague rats and a human study investigating the time 
interval effect of tea and coffee consumption, respectively on iron absorption (Morck, 
Lynch, & Cook, 1983), there is no available evidence to date, that a 1-hour time 
interval will attenuate the inhibitory effect of tea on iron absorption.  
As discussed earlier, a peptide hormone hepcidin plays a key role in the regulation 
of iron homeostasis, however, there is little mechanistic research in this area 
especially in humans (Roe, Collings, Dainty, Swinkels, & Fairweather-Tait, 2009). In 
addition, there is recently emerging evidence of the utilisation of vitamin D, as a 
novel iron absorption enhancer that acts through the suppression of hepcidin, the 
main iron regulator. However, there is a paucity of intervention studies, especially 
randomised controlled trials that investigate the effect of vitamin D supplement 
consumption as a routine therapy, on the recovery of iron status in individuals with 
low iron stores. Previous studies were mostly cross-sectional studies which cannot 
establish a causal-effect relationship, utilising bolus concentrations of vitamin D or 
fortified in a food vehicle, carried out in patients, and cannot be generalised to the 
general population, or in vitro studies which cannot be directly extrapolated to 
humans.  
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1.9 AIMS AND OBJECTIVES 
The aims and objectives of the present research was to manipulate the effect of 
potential inhibitors and enhancers of iron absorption to improve the overall iron 
status in premenopausal women. The research was divided into two clinical trials 
that were aimed to increase the iron bioavailability and iron status by (a) modulating 
the time interval of tea consumption, that is known to be an iron inhibitor, to increase 
iron absorption from a porridge meal in a cohort of healthy UK women, and (b) 
incorporating vitamin D supplementation, as a potential novel iron enhancer, in 
combination with the consumption of an iron-fortified breakfast cereal to improve 
iron status of the UK women with marginal and low iron stores.  
The first clinical trial was aimed to assess the effect of time interval of tea 
consumption relative to an iron-containing test meal on non-haem iron absorption 
from a typical western breakfast specific to UK population, using a stable iron 
isotope (57Fe) in non-pregnant women as well as investigating the potential role of 
hepcidin in iron metabolism.  
The second clinical trial was designed to investigate the effect of 8-weeks vitamin 
D3 supplementation consumed with an iron-fortified breakfast cereal on 
haematological indicators and hepcidin response in marginally and iron deficient UK 
women. The study integrated 2 strategies proposed to tackle incidence of iron 
deficiency, by using vitamin D3 supplements that may potentially act as a novel iron 
absorption enhancer, in combination with the consumption of iron-fortified foods, in 
order to improve iron status in the UK premenopausal women with low iron stores. 
In addition to investigating the efficacy, this study is also designed to assess the 
effect of a high dose of vitamin D3 (1500 IU) on iron metabolism, by measuring 
plasma hepcidin concentrations, in addition to plasma PTH and VDBP 
concentrations to investigate a possible mechanism that links vitamin D and iron 
deficiency, as postulated from the existing literature.  
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CHAPTER 2 
Materials and Methods 
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2.1 MATERIALS  
2.1.1 INSTRUMENTS 
Instruments used for each measurement in the study are summarised in Table 2.1.  
Table 2.1 Instruments used for anthropometric, blood biomarkers and iron 
isotopic measurements 
Measurement Instruments Supplier  
Anthropometric  Digital stadiometer  SECA, Hamburg, Germany 
 Electronic weighing scale  
Blood biomarkers Coulter counter Beckman Coulter Inc, 
California, USA 
 Automated immuno-analyser Biomerieux, Marcy-I’Etoile, 
France 
 Microplate washer Thermo Fisher Scientific, 
Massachusetts, USA 
 Microplate reader Biochrom Ltd, Massachusetts, 
USA 
Iron isotope ratio Mass spectrometry Agilent Technologies Ltd, 
Tokyo, Japan 
 
2.1.2 CHEMICALS/REAGENTS 
Table 2.2 outlines the chemicals and reagents used in the study.  
Table 2.2 Chemicals and reagents used for acid-washing procedure, iron 
isotopic analysis and full blood counts measurements 
Procedure Chemicals/reagents Supplier  
Acid washing   Deionised water (through deioniser) Purite Ltd, Thame, UK 
 Nitric acid Fisher Chemical, 
Loughborough, UK 
Iron isotopic 
analysis 
Ultrapure water  Sigma Aldrich Inc, 
Missouri, USA 
 Tetramethylphenylammonium 
hydroxide (TMAH) 
Sigma Aldrich Inc, 
Missouri, USA 
Full blood 
counts 
Coulter reagents and coulter rinse 
shutdown diluent 
Beckman Coulter Inc, 
California, USA 
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2.1.3 ELISA ASSAY KITS 
The ready-to-use reagents, built in strip form used for plasma ferritin determination 
and plasma 25(OH)D total were obtained from Biomerieux (Marcy-I’Etoile, France). 
Commercial Human ELISA kits for C-reactive protein (CRP), soluble transferrin 
receptor (sTfR), with quality control sets (low, medium, high) were purchased from 
R&D Systems Inc (Minneapolis, USA). The commercial ELISA kits for human 
hepcidin were purchased from Sincere Biotech Co. Ltd (Beijing, China) and R&D 
Systems Inc (Minneapolis, USA) for experimental study 1 and 2, respectively. 
Human Intact parathyroid hormone (PTH) ELISA kit and 25(OH)D were purchased 
from Calbiotech Inc (California, USA) complete with 2 sets of quality controls for 
each kit. The human Fe (ferritin) ELISA kit was purchased from Elabscience 
Biotechnology Co Ltd (Bethesda, USA). ELISA kit for plasma 25(OH)D and ferritin 
concentrations were used to re-analyse the blood samples which were below the 
detection limit of the mini VIDAS automated immuno-analyser.  
Quality controls (low, medium and high) including expected range were obtained for 
each kit from the similar company supplying the specified ELISA kits. For iron 
isotopic analysis, an iron (Fe) pure single element standard was purchased from 
Perkin Elmer, Massachusetts, USA. 
2.1.4 FOODSTUFFS 
Instant porridge (Sainsbury’s Express Porridge Original), tea bag (Yorkshire 
Everyday Black Tea), and white granulated sugar (Fairtrade International, Bonn, 
Germany) were purchased from Sainsbury’s UK Ltd, and semi skimmed milk 
portions were obtained from Lakeland Dairies Co-op Society UK Ltd. Ultrapure 
water to prepare the test meal and tea were obtained from Sigma Aldrich, Inc, UK. 
Ascorbic acid powder used in the preparation of the reference iron dose was 
purchased from Sports Supplements Ltd (Essex, UK).   
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2.2 METHODS 
2.2.1 PARTICIPANTS 
2.2.1.1 Experimental Study 1 (Chapter 3) 
Twelve premenopausal women aged between 19 to 40 years old were included in 
the study based on criteria described in Table 2.3. Participants were recruited using 
convenience sampling within the University of Chester, UK only. Posters (Appendix 
A) and emails (Appendix B) were used as a medium to recruit the potential 
participants amongst staff and students. All participants were given a participant 
information sheet (PIS, Appendix C) and briefed on the study protocol before the 
beginning of the study. The eligible participants also provided written informed 
consent (Appendix D) prior to the start of the study.   
Table 2.3 Inclusion and exclusion criteria of participants 
Inclusion criteria Exclusion criteria 
Women aged 19-40 years History of gastrointestinal and metabolic disorders 
Healthy Have donated blood in the past 6 months 
Non-pregnant nor lactating Regular consumption of nutritional supplements 
 
2.2.1.2 Experimental Study 2 (Chapter 4) 
The inclusion criteria were premenopausal women, healthy, aged 19-49 years, and 
non-pregnant nor lactating. The women were included after screening session 
based on plasma ferritin concentration of < 20 µg/l and plasma 25(OH)D 
concentration of < 250 nmol/l. The women were excluded if they had a history of 
gastrointestinal and metabolic disorders, had donated blood since the past 6 
months, and regularly consumed nutritional supplements.  
2.2.2 SAMPLE SIZE 
2.2.2.1 Experimental Study 1 (Chapter 3) 
Sample size was estimated using iron absorption data from a study by Derman et al. 
(1977) carried out in adult women aged between 21-71 years in India. The study 
aimed to investigate the inhibition effect of tea or coffee on iron absorption from 
maize meal, labelled with radioisotopes 55Fe or 59Fe.  
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It was reported in the study that mean (±S.D) iron absorption was 6.7 ± 6.2% when 
the test meals were administered with tea and 34.0 ± 23.0% when the test meals 
were administered without tea. With an effect size of 1.3, the total sample size 
required in the proposed study was 10. Allowing for a 20% drop out rate, the total 
sample size required to demonstrate a significant difference in iron absorption 
between consumption of meal with and without tea was estimated to be 12 
(power=0.95, α err prob=0.05). Sample size was estimated using of G Power 
Software Version 3.1.7 (Faul, Erdfelder, Lang, & Buchner, 2007).  
2.2.2.2 Experimental Study 2 (Chapter 4) 
Sample size was estimated using serum ferritin concentrations (µg/l) from a double-
blind placebo-controlled study carried out by Scholz-Ahrens et al. (2004) in women 
aged 20-40 years with serum ferritin concentrations of < 22 µg/l. The study was 
designed to determine the effect of 8 weeks iron-fortified milk supplementation on 
iron stores. At the beginning of study, mean (±S.D) serum ferritin concentrations 
were not significantly different between the iron-fortified group (13.3 ± 6.90 µg/l) and 
control group (12.6 ± 6.78 µg/l) (p=0.69). At the end of study, it was observed that 
mean (±S.D) ferritin concentrations were 17.65 ± 11.85 µg/l in the iron-fortified 
group, compared to 10.60 ± 8.13 µg/l in the control group (p=0.01). With an effect 
size of 0.7, the total sample size required in the present study was 26/group 
(Power=0.80, α err prob=0.05). Allowing for a 20% drop-out rate, the total sample 
size required to demonstrate a significant difference in iron stores between vitamin 
D group and placebo was estimated to be 62 (31 participants/group). The sample 
size was estimated using of G-Power Software (Version 3.1.7).  
2.2.3 STUDY DESIGN 
2.2.3.1 Experimental Study 1 (Chapter 3) 
A non-randomised controlled trial to investigate the effect of tea on non-haem iron 
absorption using a porridge meal labelled with a stable iron isotope (57Fe) was 
carried out in 12 participants over a period of 56 days at University of Chester, UK. 
The data collection started in November, 2014 and the final clinic was completed in 
March, 2015. All participants were administered three standardised test meals and a 
reference iron dose at 4 separate clinics (Table 2.4).  
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Table 2.4 Administration of test meals according to clinic 
Clinic  Day Test meal (Instant porridge) 
1 0 Test meal I administered with water (control) 
2 14 Test meal II with tea administered simultaneously with a meal 
3 28 Test meal III with tea administered 1 hour post-meal 
4 42 Reference iron dose administered without a test meal 
 
2.2.3.1.1 Trial registration/Ethical approval 
The study was registered at clinicaltrials.gov (Protocol ID: 14/NW/0310 S-
LS17042014, ClinicalTrials.gov ID: NCT02365103). The study protocol was 
approved by the National Research Ethics Service Committee North West-Greater 
Manchester East, Manchester, UK (REC reference: 14/NW/0310, IRAS Project ID 
154775) (Appendix E). 
2.2.3.1.2 Study protocol 
All the eligible participants were invited to partake in the study and provided 
informed consent at the beginning of the study. The participants were required to 
fast for approximately 10 hours prior to their scheduled clinic and expected to attend 
5 clinics in total at the clinical laboratory within the Department of Clinical Sciences 
& Nutrition at the University of Chester over a period of 56 days between 8-10 am. 
The schematic study protocol is illustrated in the flow chart (Figure 2.1).  
All participants were asked to attend a total of 5 clinic sessions (day 0, 14, 28, 42 
and 56) with a 14-day interval between clinics to allow the incorporation of the 
isotope into the erythrocyte. A standardised test meal of porridge extrinsically 
labelled with 57FeSO4 solution was given to the participants with water or tea 
depending on the clinics, under supervision of researcher. The participants were not 
permitted to consume food or drink for 3-4 hours after the administration of the 
labelled test meal. All the containers used to administer the test meals were washed 
with ultrapure water to ensure complete consumption of both test meals and isotope.  
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Figure 2.1 Study protocol (administration of test meals) 
2.2.3.1.2.1 Clinic 1 (Day 0) 
The participants’ height and weight were measured and a 30 ml fasted blood sample 
was collected in trace element-free EDTA blood collection tubes for isotopic analysis 
and iron status measurements. The whole blood sample collected at every clinic 
was used for iron isotopic analysis and FBC measurement and plasma sample was 
used for iron status measurements.  
12 eligible participants included and given informed consent 
Clinic 1 (Day 0) 
Measurement of height & weight 
24 hour food recall and be given 3-day food 
diary 
30 ml fasted baseline blood sample 
Test meal I with water 
Clinic 2 (Day 14) 
Measurement of weight 
24 hour recall  
30 ml fasted blood sample 
Test meal II with (tea given simultaneously) 
Clinic 3 (Day 28) 
Measurement of weight 
24 hour recall  
30 ml fasted blood sample 
Test meal III with (tea given 1 hour after) 
Clinic 4 (Day 42) 
Measurement of weight 
24 hour food recall and be given 3-day food 
diary 
30 ml fasted blood sample 
Reference iron dose (without test meal) 
Clinic 5 (Day 56) 
Measurement of weight 
24 hour food recall  
30 ml fasted blood sample 
 
Fractional iron absorption (%) 
Pre-isotope test meal I 
Fractional iron absorption (%) 
Post-isotope test meal I 
Pre-isotope test meal II 
 
Fractional iron absorption (%) 
Post-isotope test meal II 
Pre-isotope test meal III 
 
Fractional iron absorption (%) 
Post-isotope test meal III 
Pre-isotope reference iron 
dose 
 
Fractional iron absorption (%) 
Post-isotope reference iron 
dose 
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The researcher conducted a 24-hour food recall interview and participants were 
given a 3-day food diary to record their dietary intakes at home. Participants were 
then administered test meal I, with water to serve as a control.  
2.2.3.1.2.2 Clinic 2 (Day 14) 
The participant’s weight was measured and a 30 ml fasted blood sample was 
collected in trace element-free EDTA blood collection tubes. The researcher 
conducted a 24-hour food recall interview and participants were then administered 
test meal II, simultaneously with tea.  
2.2.3.1.2.3 Clinic 3 (Day 28) 
The same processes in Clinic 2 were repeated, with participants were then given 
test meal III, and tea was administered 1 hour post-meal.  
2.2.3.1.2.4 Clinic 4 (Day 42) 
The same processes in Clinic 2 were repeated, with participants were then 
administered a reference iron dose and were given another 3-day food diary to 
record their dietary intakes. 
2.2.3.1.2.5 Clinic 5 (Day 56) 
The same processes in Clinic 2 were repeated, with the collection of final whole 
blood sample without administration of any test meal.  
2.2.3.1.3 Stable iron isotopes  
A single isotope technique was employed in the study using a stable iron isotope 
57Fe. The stable iron isotope 57Fe was purchased from Trace Sciences (Ontario, 
Canada) in metal form (300 mg), converted to sterile form of ferrous sulphate 
solution (57FeSO4) and tested for endotoxin by Anazao Health Corporation (Florida, 
USA) (Appendix F). The enriched stable iron isotopes were transferred and kept in 
individual vials, flushed with nitrogen before being sealed and stored at -20oC until 
test meal administration by the researcher. The specified dose for test meals and 
reference iron dose used in the study were 4 mg and 3 mg respectively.  
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2.2.3.1.3.1 Preparation of labelled isotope 57Fe 
The dissolution process to produce a clear 57FeSO4 solution safe for human 
consumption was carried out by the Anazao Health Corporation. Following complete 
dissolution of the substance, which resulted in a clear and colourless solution, the 
solution was filtered over 0.5 µm membrane. The prepared 57FeSO4 solution was 
shipped to the Department in 1 vial containing 75 ml (300 mg). The solution was 
then transferred into individual sterile borosilicate glass clear sample vial with fitted 
caps (Fisher Scientific UK Ltd), labelled with dose and concentration/ml. The 
labelled vials were flushed with nitrogen, sealed and stored at -20oC to be used 
either with test meals (4 mg) or reference iron doses (3 mg).  
2.2.3.1.4 Test meals 
The test meal used in the study was Express Oat Porridge Original (Sainsbury’s UK 
Ltd). Test meals were freshly prepared on the day of each clinic by adding 200 ml of 
boiling TraceSELECT Ultra, Fluka Analytical ultrapure water (Sigma-Aldrich UK Ltd) 
to 55 g of porridge. This test meal was used at all clinics using the same 
standardised method of preparation.  
The nutritional content of the porridge is summarised in Table 2.5. To each test 
meal, 4 mg dose of 57FeSO4 was extrinsically added before the consumption. The 
reference iron dose was extrinsically labelled with 3 mg dose of the 57FeSO4 with 35 
mg of ascorbic acid and administered in ultrapure water without any test meals.  
Table 2.5 Nutrition information of test meal 
Nutrient Per 100 g Per serving (1 pot = 55 g) 
Energy (kJ/kcal) 1569/372 863/205 
Fat (g) 6.2 3.4 
   Saturated (g) 1.1 0.6 
   MUFA (g) 2.4 1.3 
   PUFA (g) 2.3 1.3 
Carbohydrate (g) 59.6 32.8 
   Sugars (g) 15.9 8.7 
   Starch (g) 43.7 24.0 
Fibre (g) 7.2 3.9 
Protein (g) 15.8 8.7 
Salt (g) 0.25 0.14 
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2.2.3.1.5 Tea 
Black tea (Yorkshire Tea, Bettys and Taylors Group Ltd, UK) was prepared using a 
standardised method at each clinic, by adding 200 ml of boiling TraceSELECT Ultra, 
Fluka Analytical ultrapure water (Sigma-Aldrich UK Ltd) to one tea bag (3 g) and the 
mixture was steeped and infused for 3 minutes before straining for consumption. In 
each cup of tea, 12 ml of homogenised semi skimmed milk UHT (Lakeland Dairies 
Co-op Society UK Ltd) was added and participants were offered white granulated 
sugar (Fairtrade International, Bonn, Germany) with the tea to their preference. The 
tea was prepared on the day of the clinic and kept warm in a flask before 
consumption. The tea was administered at specific times either simultaneously with 
test meal, or 1 hour post-meal.  
2.2.3.2 Experimental Study 2 (Chapter 4) 
The study was a placebo controlled, double-blind randomised controlled trial, 
designed to investigate the effect of vitamin D3 supplementation, consumed with 
iron-fortified breakfast cereal on iron absorption and hepcidin response in a cohort of 
iron deficient UK women. The study was registered at clinicaltrials.gov 
(ClinicalTrials.gov. ID: NCT 02714361). The study protocol was approved by the 
Faculty of Life Sciences Research Ethics Committee (FREC reference: 
1078/15/SF/CSN) (Appendix G). The study was carried out for the period of 8 weeks 
in Chester, UK. The data was collected between September 2015 and April 2016.  
2.2.3.2.1 Recruitment & screening 
The prevalence of iron deficiency based on plasma ferritin concentration in women 
aged 19-64 years in the UK was reported to be approximately 16% (Bates et al., 
2014). To achieve the required sample size, approximately 325 women would have 
to be screened. Participants were first recruited and screened from staff and 
students at the University of Chester, UK only using posters and flyers (Appendix 
H), emails sent to various departments within faculties (Appendix I), staff and 
student discussion boards, the university intranet, and university web page. 
However, due to the low number of women eligible for the study after the initial 
screening, recruitment was carried out on a larger scale, in the wider city of Chester. 
A press release was used as a medium of recruitment, in November 2015 and 
January 2016 to obtain the estimated sample size. The press release was placed in 
the local newspapers, The Chester Chronicle and The Standard (Appendix J). A 
total of 186 women attended the initial screening clinics and 62 were eligible based 
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on the plasma ferritin concentration threshold of < 20 µg/l to define iron deficiency 
and plasma 25(OH)D concentration of < 250 nmol/l. However, 12 of the eligible 
participants withdraw from participating in the study. The reasons were; fell sick 
(n=1), didn’t respond to the invitation email (n=6), and refused to participate 
following the screening session (n=5). After screening, 50 participants were included 
and randomised. Figure 2.2 outlines the study design which included 2 main 
phases. Phase 1 was the recruitment and screening phase when potential 
participants were screened for iron deficiency and identified. Phase 2 was the 
intervention phase where all participants consumed iron-fortified breakfast cereal, 
together with either vitamin D3 supplements containing 1500 IU (38 µg) (vitamin D 
group) or placebo (placebo group) daily for the duration of 8 weeks. 
2.2.3.2.2 Phase 1: Screening 
All participants were given a participant information sheet (PIS, Appendix K) and a 
date was arranged for the blood collection to ascertain the plasma ferritin 
concentration, which was used to indicate iron stores levels in the present study. 
The potential participants provided written informed consent (Appendix L) and were 
asked to complete a screening questionnaire to ensure eligibility criteria were met 
(Appendix M). During the screening clinic, 4 ml of blood was collected in a lithium 
heparin blood collection tube at the clinical laboratory within the Department of 
Clinical Sciences & Nutrition at the University of Chester by the researcher who is a 
trained phlebotomist. The plasma sample collected was used to determine the 
concentration of ferritin and 25(OH)D. Based on the blood analysis, participants 
were notified of their results via email. The eligible participants were then invited to 
continue to Phase 2 of the study. Participants who had abnormally high plasma 
ferritin concentrations from the screening (n=2) were advised to arrange a check-up 
with their registered general practitioner.  
2.2.3.2.3 Phase 2: Intervention 
A total of 50 participants who were eligible to continue with the study were 
randomised to receive either 1500 IU (38 µg) of vitamin D3 or placebo. Both groups 
were instructed to consume an iron-fortified breakfast cereals with either vitamin D3 
or a placebo daily according to the group assigned for the duration of 8 weeks. The 
participants were also provided with semi-skimmed milk and were required to 
consume 60 grams of iron-fortified cereals in pre-weighed tubs with 200 ml of milk in 
the morning every day for the duration of the study. The participants were instructed 
to consume the vitamin D3 capsules or placebo capsules with 200 ml of water in the 
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evening, also daily, for the 8-week duration of the study. All the participants were 
reminded to not alter their dietary habits and physical activity, in addition, to 
abstaining from donating blood during the course of the study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Study protocol 
Study population:  
Women aged 19-49 years  
Screening clinic (n=186): 
Iron deficiency based on plasma ferritin threshold of < 20 µg/l 
and 25(OH)D of < 250 nmol/l 
Eligible (n=62) 
Agreed to partake (n=50)  
Randomisation (n=50)  
Excluded (n=12) 
  Refused to participate (n=5) 
  Sick (n=1) 
  No response (n=6) 
 
Iron-fortified breakfast cereal 
(9mg iron) with Vitamin D3 
(1500 IU) (n=25) 
8 weeks 
Iron-fortified breakfast cereal 
(9mg iron) with placebo  
(n=25)  
8 weeks 
Clinic 1 (Week 0) 
Baseline measurements:  
Anthropometric measurements (height & weight)  
3-day food diary administered  
30 ml fasted venous blood sample 
                                       Clinic 2 (Week 4) 
Interim measurements:  
Anthropometric measurements (weight)  
Collected baseline 3-day food diary and administered post-intervention 3-day food diary 
30 ml fasted venous blood sample 
 
Clinic 3 (Week 8) 
Post-intervention measurements:  
Anthropometric measurements (weight)  
Collected final 3-day food diary 
30 ml fasted venous blood sample 
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2.2.3.2.4 Study clinics 
Participants were all required to attend clinics after overnight fasts of approximately 
8 hours and were expected to attend 3 clinics in total. Participants were asked to 
consume only water during the overnight fast. Each clinic lasted approximately 30 
minutes and took place between 8-10 am. Details of each clinic are as follows. 
Clinic 1 (Week 0, baseline): Height (cm) was measured using digital stadiometer 
and weight (kg) using weighing scales, followed by collection of a 30 ml fasted 
venous blood sample collection. Participants were given a 3-day food diary to be 
completed before the next clinic. A 4-week supply of both iron-fortified breakfast 
cereals in individually packed containers and semi-skimmed milk were provided to 
the participants, together with a supplement pot, containing 8 weeks of supplements 
with assigned participant ID. The protocol was explained to participants and an 
email was sent as a reminder to the participants one day before the following clinic.  
Clinic 2 (Week 4, interim): The same procedure was repeated except for 
measurement of height. Participants were given a further 3-day food diary to be 
completed before the next clinic and the previous diary was collected. A further 4-
week supply of iron-fortified breakfast cereals and semi-skimmed milk were provided 
to the participants.  
Clinic 3 (Week 8, post-intervention): Weight was measured and a 30ml fasted 
venous blood was taken. The final 3-day food diary and supplement pot (with any) of 
the remaining capsules to calculate the compliance was collected.   
2.2.3.2.5 Randomisation and blinding of participants 
The randomisation process was carried out using computer-generated software 
(www.randomization.com) by a third party, independent to the study. Participants 
(n=50) were randomised to 2 groups: vitamin D3 (vitamin D group) or placebo 
(placebo group). The third party allocated 62 capsules of vitamin D3 and placebo 
into each supplement pot according to the generated plan. An excess of 6 capsules 
in each pot enabled the researcher to estimate compliance once the study was 
completed. Each supplement pot was then sealed in a tamper proof supplement pot 
and numbered ready to be provided to participants. The participants and researcher 
were double-blinded as to which groups participants were assigned. The researcher 
administered the numbered supplement pot (i.e; 001) to the participants based on 
the sequence that participants attended their baseline clinic (Week 0).  
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The blinding was maintained throughout the study period of 8 weeks and allocation 
was not unlocked until the end of the data analysis.  
2.2.3.2.6 Iron-fortified break cereals  
The iron-fortified breakfast cereal used in the study was a commercially available 
whole grain rice and wheat flakes cereal (Weight Watchers UK Ltd). The supplies of 
both breakfast cereals and milk were provided to the participants at the first visit 
(Clinic 1). Participants were instructed to consume one pre-weighed tub of cereal 
(60g) containing approximately 9 mg of iron with 200 ml of semi-skimmed milk 
(Tesco PLC,UK), daily. Each participant was also given a measuring cup to 
measure approximately 200 ml of semi-skimmed milk to consume with the cereal, to 
ensure the standardisation of meal consumed by each participant. It was stressed 
during the first clinic that the participants need to consume the cereal daily. 
However, in the event of missing a meal, it was advised that they consumed the 
cereal immediately. If the cereal was consumed the following day, the specified 
cereal which was supposed to be consumed that day will have to be consumed as 
usual. Participants were asked about any problems regarding consumption of the 
provided cereal during the interim clinic (Week 4) and were requested to notify 
researcher if any problem surfaced e.g. adverse effects during the 8-week course of 
study. This cereal was selected as it is fortified with iron, and previous iron-fortified 
cereal studies have reported the use of between 7-18 mg of total iron. A total of 9 
mg iron in the current study provides approximately 60% of the RNI/day for women 
aged 19-50 years (Department of Health, 1991). The nutritional content of the 
breakfast cereal is shown in Table 2.6. 
Table 2.6 Nutritional information of iron-fortified breakfast cereal  
Nutrient Per 100 g Per recommended serving (60 g) 
Energy (kJ/kcal)  1566/370 940/222 
Fat (g) 2.1 1.2 
     Saturated  0.4 0.2 
Carbohydrates (g) 70 42 
     Sugars 16 9.6 
Fibre (g) 7.5 4.6 
Protein (g) 14 8.4 
Salt (g) 0.6 0.4 
Iron (mg) 15.0 9 
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2.2.3.2.7 Vitamin D supplement and placebo 
The supplement used was vitamin D3 cholecalciferol (1500 IU, 38 µg, Pharma Nord 
ApS, Vejle, Denmark), liquefied in cold-pressed olive oil and encapsulated in a clear 
soft gel 7 mm capsule. Each capsule supplied was made of a combination of olive 
oil, gelatine, glycerol, and purified water at Pharma Nord ApS, Vejle, Denmark. The 
supplements were packaged in blister packs, and manufactured specific to the 
research requirement and according to pharmaceutical standards (EC and 
Scandinavia). Batch numbers and expiry dates were printed on each blister pack. 
The matching placebo was also custom-produced to the requirement of the study by 
Pharma Nord ApS, Vejle, Denmark. Placebo was produced in the same manner, 
without the active ingredients. The placebo was matched with vitamin D3 in terms of 
appearance, size, colour and taste to achieve the double-blind design.    
2.2.3.2.7.1 Assessment of compliance 
Compliance to the supplementation (%) was calculated on the basis of (62 – 
remaining capsules in the pot)/56 x100. For the total duration of 8 weeks, 
participants were required to consume 56 capsules of vitamin D3 or placebo.  
2.2.4 ANTHROPOMETRIC MEASUREMENTS 
Instruments used were calibrated before every measurement.  
2.2.4.1 Height 
Height was measured to the nearest 0.1 cm with a wall mounted digital stadiometer 
(Model 264 SECA, Hamburg, Germany). Before the start of measurement, 
participants were checked to ensure they were wearing minimal clothing and 
barefoot to allow accurate positioning. With the head positioned at Frankfurt 
horizontal plane, participants were instructed to stand with the legs straight, heels 
closed together, shoulders relaxed, and arms at the side. The 4 points, which 
included back of the head, buttocks, heels and scapulae, were checked to make 
sure they were in line with the vertical surface of the stadiometer.  
The reading was taken when the headboard was lowered to the highest point of 
participants’ head. The measurement was performed in duplicate to ensure the 
accuracy (Lee & Nieman, 2010). 
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2.2.4.2 Body weight 
Body weight was measured to the nearest 0.1 kg using an electronic scale (Model 
875 SECA, Hamburg, Germany). The scale was set on a flat and hard surface to 
ensure stability when the measurement was made. Before the measurement, 
participants were asked to be barefoot, empty out the pockets and wear minimal 
clothing. To ensure even distribution of body weight on both feet, participants were 
instructed to stand still in the middle of the platform scale without touching anything. 
The measurement was performed in duplicate to ensure the accuracy (Lee & 
Nieman, 2010).  
2.2.4.3 Body mass index (BMI) 
The BMI was calculated using height and weight obtained from the anthropometric 
measurement of the participants. The equation used to obtain the BMI was: BMI = 
weight (kg)/height (m2) and the cut off values to define BMI are summarised in 
Table 2.7.  
Table 2.7 Classification of BMI (WHO, 1998)  
Classification of BMI BMI (kg/m2) Obesity class 
Underweight < 18.5  
Normal 18.5 – 24.9  
Overweight 25.0 – 29.9  
Obesity 30.0 – 34.9 I 
 35.0 – 39.9 II 
Extreme obesity ≥ 40.0 III 
 
2.2.5 VENEPUNCTURE PROCEDURE  
2.2.5.1 Venepuncture protocol 
Venepuncture was performed by the researcher, a trained phlebotomist, to obtain 30 
ml blood samples from participants during each clinic. The participant was 
positioned with the arm stretched straight from shoulder to wrist on the cushion of 
phlebotomy chair. After the suitable vein was identified and selected, tourniquet was 
applied approximately 3-4 inches above the selected puncture area. Using a 70% 
ethanol swab, the puncture site was cleaned by performing circular motion and the 
area was left to dry. The needle was then inserted to hub; cap removed and held 
with the bevel up. 
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With a thumb placed just below the puncture area, the needle was inserted smoothly 
into the vein by trained researcher. Holding the one-use holder firmly, the vacutainer 
tube was inserted and tourniquet was released once the blood started to flow. Once 
the blood flow stopped, the tube was removed from the needle and inverted several 
times to mix. A gauze pad was placed on the puncture site, and the needle was 
slowly removed and slight pressure was applied for at least 2 minutes. The needle 
was appropriately disposed in sharp bin container and a clean bandage or 
micropore tape was applied on puncture area.  
2.2.5.2 Blood handling 
Both whole blood and plasma obtained from the venepuncture were used in the 
study for analysis. Whole blood samples for iron absorption analysis were collected 
in trace element-free collection tubes with EDTA (BD Company, New Jersey, USA) 
for the first experimental study (Chapter 3) or lithium heparin and EDTA collection 
tubes for the second experimental study (Chapter 4). All the collected blood samples 
were aliquoted into micro centrifuge tubes, and stored at -80oC prior to analysis. 
Whole blood samples were used immediately after each clinic to measure full blood 
counts (FBC). To obtain plasma samples, the blood tubes were centrifuged for 10 
minutes at 1600 × g at 4oC. The plasma was then aliquoted into micro centrifuge 
tubes and stored before being used for analysis. Whole blood and plasma samples 
were used for the analysis of iron status biomarkers, including full blood counts (red 
blood cell counts, haemoglobin concentration, haematocrit level, MCV, MCH, MCHC 
and white blood counts), plasma ferritin, plasma CRP and plasma hepcidin 
concentrations for the first experimental study (Chapter 3). Plasma samples were 
used to analyse iron status biomarkers (CRP, ferritin, soluble transferrin receptor, 
and hepcidin) and vitamin D metabolism biomarkers (25-OH D, PTH, and VDBP) 
concentrations for the second experimental study (Chapter 4). 
2.2.6 ANALYSIS OF BLOOD SAMPLES 
2.2.6.1 Determination of full blood counts (FBC)  
The measurement of FBC was carried out using an automated Beckman Coulter 
Ac.T diff Haematology Analyser (Beckman Coulter Inc, California, USA). The 
analyser operated based on the coulter principle which involved counting and sizing, 
triplicate counting, extended platelet counting and cyanmethaemoglobin method. 
The analyser provided 18 parameters of full blood counts which include white cell 
differential. Once the sample mode was selected and ID number entered on the 
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interface screen, approximately 12 µl of whole blood was aspirated and the results 
were displayed. The normal values/ranges for the FBC used in the study are 
summarised in the following Table 2.8. The intra-assay CV for this measurement 
was 1.9%. 
Table 2.8 Normal range of full blood count concentration for adult women 
Full blood counts (FBC) indicators Unit Normal values 
  RBC count ×1012/L 3.8 – 5.2 
  Haemoglobin concentration g/dL 11.5 – 15.5 
  Haematocrit/packed cell volume (PCV) L/L 0.37 – 0.47 
  Mean corpuscular volume (MCV) fl 80 - 96 
  Mean corpuscular haemoglobin (MCH) pg 27 – 32 
  Mean corpuscular haemoglobin concentration (MCHC) g/dL 32 – 36 
  White blood count (WBC) ×109/L 4 - 11 
  Platelet  ×109/L 150-400 
(Data extracted from “Williams Haematology” (Kaushansky et al., 2015) 
2.2.6.2 Determination of plasma ferritin concentrations  
Plasma ferritin concentrations were measured using mini VIDAS Biomerieux 
automated immunoanalyser using enzyme linked fluorescent assay (ELFA) 
technique (Biomerieux, Marcy-I’Etoile, France). The procedure for measuring 
plasma ferritin involved ready-to-use and pre-dispensed sealed reagent strips and a 
solid phase receptacle (SPR). The SPR was coated with monoclonal anti-mouse 
ferritin immunoglobulins that act as the solid phase and pipetting device for the 
assay. During the assays, the SPR functioned as a pipetting device that aspirates 
the reagents in and out, and 4-Methyl-umbelliferyl phosphate the final substrate 
aspirated at the final stage of the assays. This substrate was then hydrolysed by a 
conjugate enzyme into 4-methyl-umbelliferone, a fluorescent product that can be 
detected at 450 nm wavelengths.  
The necessary reagents required for the assay were removed from the refrigerator 
and allowed to reach room temperature for at least 30 minutes. The plasma sample 
was mixed using a vortex mixer and 100 µl of plasma sample was added to the first 
well of the ferritin strip and for each plasma sample, one ferritin strip and SPR was 
used. Both the ferritin strip and SPR were simultaneously inserted into the selected 
section of the instrument and assay was automatically initiated.  
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The assay procedure was completed in approximately 30 minutes. Once the result 
concentration was displayed, the ferritin strip and SPR were unloaded and 
appropriately disposed in a clinical waste container. The threshold concentration of 
>15 µg/l was used to define adequacy of plasma ferritin concentration for non-
pregnant women aged above 15 years, as recommended by WHO/UNICEF/UNU 
(2001). The similar threshold was also used in assessing iron status of UK 
population in the NDNS, in combination with haemoglobin concentrations (SACN, 
2010). The intra-assay CV for this assay was 4.69%.  
However, some of the samples (n=3) in the experimental study 2 (Chapter 4) were 
analysed using a commercial human ferritin ELISA kit (Elabscience Biotechnology 
Co. Ltd), due to undetectable concentrations of below 1.5 µg/l when using mini 
VIDAS. The assay procedure is as follows.  
The reagents were brought to room temperature before use. Concentrated wash 
buffer, a specific antibody, and conjugate were diluted to the required concentrations 
and cooled to room temperature prior to analysis. Using the serial dilution method, 8 
tubes of standards were prepared 15 minutes prior to the procedure. The assay was 
started by adding 100 µl of standard, blank, and samples to a pre-coated 96 well 
plate, sealed and incubated for 90 minutes in an incubator at 37oC. After 1.5 hours, 
wells were emptied and without washing, 100 µl of biotinylated detection antibody 
working solution was added to each well. The plate was sealed and incubated for a 
further 1 hour at 37oC. Each well was then washed and aspirated with 350 µl of 
wash buffer three times. Following the washing step, 100 µl of HRP conjugate was 
added, the plate was sealed and incubated at 37oC for 30 minutes. The washing 
step was repeated 5 times after the incubation period time. A total of 90 µl of 
substrate solution was then added to each well, plate was covered with a plate 
sealer, and incubated for a minimum of 15 minutes at 37oC protected from light 
using aluminium foil. Once apparent gradient started to show in standard wells, 50 
µl of stop solution was added to each well. The absorbance was read at a 450 nm 
wavelength using microplate reader. 
2.2.6.3 Determination of plasma CRP concentrations 
A commercial Quantikine Human CRP Immunoassay ELISA kit (R&D Systems Inc, 
Minneapolis, USA) was used to determine the plasma CRP concentrations of 
participants in the present study.  
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The reagents and plasma samples required for the assay were allowed to reach 
room temperature before the start of analysis. All the reagents were prepared: wash 
buffer and calibrator diluent RD5P (1X) was diluted, both colour reagents were 
mixed equally to form substrate solution, and 7 tubes of CRP standards were 
prepared by serial dilution process. A total of 100 µl of assay diluent RD1F was 
added to the wells followed by a 50 µl of each standard, control and sample added 
to the wells. An adhesive strip was used to cover the microplate which was allowed 
to incubate for 2 hours at room temperature. After the incubation period, each well 
was aspirated and washed 4 times using 400 µl of wash buffer. A total of 200 µl 
CRP conjugate was then added to the wells and microplate was covered with an 
adhesive strip for a further 2 hours incubation period time. Each well was then 
aspirated and washed again for 4 times using 400 µl of wash buffer. A total of 200 µl 
substrate solution was added to the wells and allowed to incubate for 30 minutes at 
room temperature. The microplate was protected from the light using aluminium foil. 
After the incubation period, 50 µl of stop solution was added to the wells. The assay 
was completed by determining the optical density of each well using a microplate 
reader that was set at 450 nm with a 570 nm secondary wavelength, within 30 
minutes of adding the stop solution. A threshold of < 3-10 mg/l was used to define 
normal ranges of CRP concentrations (WHO/CDC, 2004). The intra-assay and inter-
assay CV for this assay were 11.5% and 3.3%, respectively.  
2.2.6.4 Determination of plasma hepcidin concentrations 
Hepcidin concentrations were measured in plasma samples using a Human 
Hepcidin (Hepc) ELISA kit (Sincere Biotech Co Ltd, Beijing, China) for the first 
experimental study (Chapter 3) and using a human hepcidin immunoassay 
quantikine ELISA kit (R&D Systems Inc, Minneapolis, USA) for the second 
experimental study (Chapter 4).  
2.2.6.4.1 Experimental Study 1 (Chapter 3) 
The reagents and plasma samples required for the assay were brought to room 
temperature 30 minutes prior to the start of analysis. All the reagents were prepared: 
standards were reconstituted with deionised water in 1:2 serial dilutions. The wash 
buffer working solution was prepared by diluting wash buffer concentrate in 
deionised water at a ratio of 1:25. The three other reagents were prepared less than 
30 minutes before the analysis. A total of 100 µl of standard, controls, and 
participants’ diluted plasma samples were added to the wells and then allowed to 
incubate for 1.5 hours at 37oC.  
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After the incubation period, the microplate was washed with 350 µl of wash buffer 
twice with 1 minute interval between each wash. A total of 100 µl biotinylated anti-
human hepcidin working solution was then added to the wells and microplate was 
incubated for 1 hour at 37oC. The microplate was then washed with 350 µl of wash 
buffer for 3 times with 1 minute interval between each wash. A total of 100 µl avidin-
biotin-peroxidase complex (ABC) working solution was added to each well, except 
the control wells and microplate was incubated for 0.5 hours at 37oC. After 30 
minutes, the microplate was washed with 350 µl of wash buffer 5 times with 1 
minute interval between each wash. A total of 100 µl substrate working solution was 
added to each well, except the control wells and microplate was incubated for ≤ 30 
minutes at 37oC away from light. A total of 100 µl stop solution was then added to 
the wells. The optical density was determined using a microplate reader set at 450 
nm within 10 minutes of the stop solution added into each well. The normal 
threshold level of plasma hepcidin in healthy women used in the study was between 
17 – 286 ng/ml (Ganz et al., 2008). The intra-assay and inter-assay CV for this 
assay were 5.7% and 10.8% respectively.  
2.2.6.4.2 Experimental Study 2 (Chapter 4) 
Hepcidin concentrations were measured in plasma samples using a human hepcidin 
immunoassay quantikine ELISA kit (R&D Systems Inc, Minneapolis, USA). Plasma 
samples to be analysed were first prepared with a 5-fold dilution using the calibrator 
diluent RD5-26 which was primarily diluted (1:4). All the reagents used in the assay 
were brought to room temperature prior to analysis. Wash buffer concentrate was 
diluted to the required volume. The human hepcidin standard was first reconstituted 
and used to make 8 standards of serial dilutions (0-1000 ng/ml). The assay was 
started by adding 50 µl of assay diluent RD1-21 into each well followed by 50 µl of 
standard, control, and samples into each well. The microplate was then sealed and 
incubated at room temperature for 2 hours. After the incubation period, the 
microplate was washed and aspirated 4 times. Following the wash steps, 200 µl of 
human hepcidin conjugate was added into each well, sealed and incubated for a 
further 2 hours at room temperature. Following this, the same wash step was 
repeated, followed by addition of substrate solution which was prepared 15 minutes 
before and the microplate was incubated protected from light using aluminium foil, 
for 30 minutes at room temperature. 50 µl of stop solution was then added and 
absorbance was measured at 450 nm (with a secondary wavelength of 570 nm) 
using a microplate reader within 30 minutes.  
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2.2.6.5 Determination of plasma soluble transferrin receptor (sTfR) 
concentration 
Soluble transferrin receptor (sTfR) concentrations were measured in plasma 
samples using a human sTfR immunoassay Quantikine IVD ELISA kit (R&D 
Systems Inc, Minneapolis, USA). All reagents were allowed to reach room 
temperature before use. Wash buffer concentrate was then diluted to the required 
concentration, followed by reconstituting the vial of standards and allowing to sit for 
30 minutes prior to analysis. The assay was started by adding 100 µl of sTfR assay 
diluent into each well, followed by 20 µl of standard, samples, and control. The 
microplate was then sealed and incubated at room temperature for 1 hour. After the 
incubation period, the microplate was washed and aspirated 4 times with 400 µl of 
wash buffer, followed the addition of 100 µl of the sTfR conjugate, microplate was 
sealed and incubated for a further 1 hour at room temperature. The wash step was 
repeated and 100 µl of the substrate was added to each well. The microplate then 
was incubated at room temperature for 30 minutes away from sources of light using 
aluminium foil. After 30 minutes, stop solution was added to the wells and the optical 
density was determined using microplate reader set at 450 nm, with a 570 nm of 
secondary wavelength.  
2.2.6.6 Determination of plasma 25(OH)D concentration  
Plasma 25(OH)D concentrations were measured using a mini VIDAS Biomerieux 
automated immunoanalyser using an enzyme-linked fluorescent assay (ELFA) 
technique (Biomerieux, Marcy-I’Etoile, France). The procedure for measuring 
25(OH)D involved ready-to-use and pre-dispensed sealed reagent strips and a solid 
phase receptacle (SPR). The SPR was coated with vitamin D antigen that acts as 
the solid phase and pipetting device for the assay. During the assays, the SPR acts 
as a pipetting device that aspirates the reagents in and out, and 4-Methyl-
umbelliferyl phosphate the final substrate aspirated at the final stage of the assays. 
This substrate was then hydrolysed by a conjugate enzyme into 4-methyl-
umbelliferone, a fluorescent product that can be detected at a wavelength of 450 
nm. The reagents required for the assay were allowed to reach room temperature 
for at least 30 minutes. The plasma sample was mixed using a vortex mixer and 100 
µl of plasma sample was added to the first well of the vitamin D strip. For each 
plasma sample, one vitamin D strip and SPR was used. Both the vitamin D strip and 
SPR were simultaneously inserted into the instrument and the assay was 
automatically initiated.  
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The assay procedure was completed in approximately 40 minutes. Once the 
resulting concentration was displayed, the vitamin D strip and SPR were unloaded 
and appropriately disposed of into a clinical waste container.  
Some samples in the second experimental study (Chapter 4) were re-analysed 
using 25(OH)D ELISA kit (Calbiotech Inc, California, USA) as the concentrations 
were <20.3 nmol/l which is below the detectable range of the mini VIDAS bio 
analyser. The assay procedure is as follows. All the reagents were allowed to reach 
room temperature before use. The wash buffer and biotinylated conjugate 
concentrates were diluted to the required concentrations before starting the assay. 
Standards, controls and samples (10 µl) were added to the wells of 96-well pre 
coated microplate. This was followed by the addition of 200 µl of biotinylated 25(OH) 
vitamin D reagent working solutions to the wells and the microplate was mixed using 
a microplate shaker at 400 rpm. After mixing, the microplate was sealed and 
incubated at room temperature for 1.5 hours. The microplate was then aspirated and 
washed 3 times using 300 µl of wash buffer, followed by the addition of 200 µl of 
streptavidin-HRP conjugate and the microplate was incubated at room temperature 
for 30 minutes. The same wash step was repeated, and 200 µl of the substrate was 
added to the wells. The microplate was then incubated for a further 30 minutes at 
room temperature, protected from the light using aluminium foil. After 30 minutes, 50 
µl of stop solution was dispensed to each well and mixed using microplate shaker 
for a minimum 20 seconds. Following this, the absorbance was determined using 
microplate reader set at 450 nm.  
2.2.6.7 Determination of plasma parathyroid hormone (PTH) concentration  
Parathyroid hormone (PTH) concentrations in plasma samples were measured 
using an intact PTH ELISA kit (Calbiotech Inc, California, USA). Reagents were 
allowed to reach room temperature prior to analysis, and were ready to use except 
for wash buffer which was diluted using deionised water (1:25). Samples, standards, 
and controls (25 µl) were added to each well. This was followed by addition of 50 µl 
of anti-PTH-biotin reagents and 50 µl of the anti-PTH-HRP conjugate to each well. 
The microplate was then sealed, and incubated on a microplate shaker set at 500 
rpm for 1.5 hours at room temperature. After the incubation period, the microplate 
was aspirated and washed 4 times using 300 µl of wash buffer. Substrate (100 µl) 
was added to each well and the microplate was incubated for 15 minutes at room 
temperature. After the incubation period, 50 µl of stop solution was added to each 
well, and the microplate was gently mixed.  
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Following this, the absorbance was determined using microplate reader set at 450 
nm, with 620 nm as a secondary wavelength.  
2.2.6.8 Determination of plasma vitamin D binding protein (VDBP) 
concentration 
Vitamin D binding protein (VDBP) concentrations in the plasma samples were 
measured using a human vitamin D binding protein immunoassay Quantikine ELISA 
kit (R&D Systems Inc, Minneapolis, USA). The plasma samples were first diluted 
2000-fold using calibrator diluent RD6-11. All reagents were brought to room 
temperature before use. Wash buffer was diluted into the desired concentration 
(1:20). Standard was first reconstituted with 1ml deionised water, followed by serial 
dilutions to produce 6 standards (0-250 ng/ml). Assay diluent RD1-19 (100 µl) was 
added to each well, followed by addition of samples, standards, and controls (50 µl) 
into the designated well. The microplate was then sealed and incubated at room 
temperature for 1 hour on a microplate shaker set at 500 rpm. After the incubation 
period, the microplate was aspirated and washed using 400 µl of wash buffer 4 
times. VDBP conjugate (200 µl) was added into each well, sealed and incubated at 
room temperature for a further 2 hours on the microplate shaker at the same speed. 
The wash step was repeated with the same amount of wash buffer and wash times. 
After the wash step was completed, 200 µl of substrate solution was added to each 
well and the microplate was allowed to incubate for 30 minutes at room temperature 
protected from sources of light using aluminium foil. After 30 minutes, 50 µl of stop 
solution was added and when colour changes appeared uniform, the absorbance 
was determined at 450 nm, with 570 nm secondary wavelength.  
2.2.6.9 Normal thresholds used for blood biomarkers using plasma samples 
Table 2.9 shows the normal thresholds used to define normal ranges of blood 
biomarkers determined in Section 2.2.6.2 – 2.2.6.8.  
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Table 2.9 Normal thresholds of iron and vitamin D status biomarkers 
Biomarkers Normal thresholds Reference 
Ferritin  > 15 µg/l WHO/UNICEF/UNU (2001) 
CRP  <3-10 mg/l WHO/CDC (2004) 
Hepcidin  17-286 ng/ml Ganz et al. (2008) 
sTfR <6 mg/l *Manufacturer of kit (R&D Systems Inc, 
Minneapolis, United States) 
25(OH)D  >50 nmol/l IOM (Ross et al., 2011) 
PTH  1.59-6.89 pmol/l Blanco-Rojo et al. (2013) 
VDBP  300-600 µg/ml Gomme and Bertolini (2004) 
* WHO (2014) suggested using manufacturer threshold as no internationally accepted threshold has 
been established 
 
 2.2.6.10 Coefficients of variations (CV): Inter and Intra-Assay 
Table 2.10 shows both inter and intra-assay CV for each assay determined in 
Section 2.2.6.2 – 2.2.6.8. Samples of a standard calibration curves generated for 
each assay are shown in Appendix N. The automated immunoanalyser used was 
accredited by periodic quality control by the Vitamin D External Quality Assessment 
Scheme (DEQAS).  
Table 2.10 Coefficients of variations (CV): inter and intra-assay  
Assays Inter-assay CV (%) Intra-assay CV (%) 
Ferritin (Mini VIDAS) - 4.69 
CRP 1.94 2.74 
Hepcidin  1.92 11.45 
sTfR  1.82 5.01 
25(OH)D    
     Mini VIDAS - 1.99 
     ELISA kit 3.62 11.31 
PTH 0.69 6.99 
VDBP 2.70 11.29 
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2.2.7 IRON ABSORPTION DETERMINATION  
2.2.7.1 Iron isotope ratio analysis  
Whole blood samples were transported in dry ice to the MRC-Human Nutrition 
Research Unit, Cambridge, United Kingdom for the iron isotope ratio analysis. 
Analysis was carried out using triple quadrupole ICP-MS/MS 8800 (Agilent 
Technologies, Japan). Prior to analysis, the frozen samples were defrosted to room 
temperature and mixed by vortex mixer. A total of 100 µl whole blood sample was 
then mixed with 9.9 ml of 0.005% TMAH (v/v) (BioXtra grade, Sigma Aldrich Inc, 
Missouri, USA) ready for the isotopic analysis. 
The ICP-MS used (Agilent 8800) has an octopole-based collision/reaction cell, 
positioned in the middle of two quadrupole analysers. The prepared samples, 
together with standards were then introduced into the ICP-MS with a MicroMist 
nebuliser and a Peltier-cooled (2oC) Scott-type spray chamber.  
Table 2.11 summarises the interferences that might occur during the ICP-MS 
analysis, which can be eliminated by the use of a mixture of 10% ammonia in helium 
as a reaction gas. This mixture which is introduced into the octopole cell also 
functioned to applicably reduce the signal at certain level in order to ensure a 
precise isotope ratio analysis. The isotopes were measured as a Fe ammonia 
cluster, mFe (NH3)2 at masses 88, 90, 91 and 92. An external standard correction for 
mass bias correction was performed using Iron (Fe) Pure Single Element Standard, 
1,000 µg/mL, 2% HNO3 (Perkin Elmer, Massachusetts, USA) as a baseline 
reference.  
Table 2.11 Interferences affecting iron isotopes in ICP-MS analysis 
Isotope Natural 
abundance 
Polyatomic and doubly charged 
interference 
Isobaric 
interference 
54Fe 5.845 40Ar14N, 53Cr1H, 108Cd++, 108Pd++ 54Cr 
56Fe 91.754 40Ar16O, 40Ca16O, 55Mn1H, 112Cd++, 
112Sn++ 
 
57Fe 2.119 40Ar16O1H, 40Ca16O1H, 56Fe1H, 114Cd++, 
114Sn++ 
 
58Fe 0.282 40Ar18O, 40Ca18O, 42Ca16O, 57Fe1H, 
116Cd++, 116Sn++ 
58Ni 
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2.2.7.2 Erythrocyte iron incorporation calculations 
Fractional iron absorption (%) was estimated by the erythrocyte iron incorporation 
method, 14-days post-dosing of the isotope, which involved the use of published 
equations to establish the final % of iron absorption of each participant. The 
equations were used to determine the (a) circulating iron body pool (mg); (b) iron 
incorporation into red blood cells (RBCs), and subsequently estimate the (c) 
fractional iron absorption (%). The estimated % of iron absorption was then 
normalised to a fixed reference value of 40% to take into account inter-participant 
variability (International Atomic Energy Agency, 2012). All the equations used are 
described as follows and summarised in the Table 2.12. 
Table 2.12 Equations to estimate fractional iron absorption (%) 
Indication Equations 
1Blood volume 
(ml/kg) 
(16.52 x height) + (38.46 x weight) – 1369 
 
2Circulating body 
iron pool (mg) 
Hb (g/l) x BV (ml) × 3.47 (mg iron)/ Hb (g) × 0.001 (ml) 
 
3Iron incorporation 
into RBCs (mg) 
Rt – Ro/Ro   × circulating iron (mg)/Wnatural fe  ×  NA57Fe/100  
× m57Fe 
 
Rt  = 57Fe: 58Fe ratio at time t after dosing; 
Ro  = 57Fe: 58Fe ratio at baseline; 
Wnatural Fe  = average atomic weight of Fe (55.845mg/mmol); 
NA57Fe  = natural abundance of 57Fe (2.1191%); 
m57Fe  = atomic mass of 57Fe (56.935)  
 
4Absorption of 57Fe 
(%) 
57Fe incorporation/57Fe dose × 1.25 x 100 
 
5Normalised 
absorption (%) 
Absorption observed × 40/Absorption from reference iron 
dose 
1Shayeghi et al. (2005), 2McKie et al. (2001), 3(Andrews, 2005), 4Latunde-Dada et al. (2006), 5Bjorn-
Rasmussen, Hallberg, and Rossander (1977) 
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2.2.7.2.1 Blood volume 
Blood volume value is required to calculate the circulating iron body pool, which can 
be estimated using published equations specific for women or men (Shayeghi et al., 
2005). The current study used this published equation that is based on height and 
weight of participants. The estimation equation was developed based on women 
with 144-179 cm in height, weighing between 45-73 kg which fit the range of 
participants in the present study. However, for many of the previous bioavailability 
studies, a fixed 65 ml/kg body weight was typically used for healthy, non-pregnant 
women (Brown et al., 1962; Wennesland et al., 1959).  
2.2.7.2.2 Circulating body iron pool 
The published equation by McKie et al. (2001) was used to estimate each of 
participants’ circulating body iron pool. The values of haemoglobin concentrations 
(Hb) and body weight used in the calculation were from Clinic 1. The value of 3.47 
represents the approximate average amount of iron in 1 g of haemoglobin 
(International Atomic Energy Agency, 2012).  
2.2.7.2.3 Iron incorporation into red blood cells 
Based on the estimation of blood volume and circulating body iron pool for each 
participant, iron incorporation into RBCs was calculated using the equation in Table 
2.12 (Andrews, 2005). 
2.2.7.2.4 Percentage absorption of 57Fe 
Based on the previous bioavailability studies, a fixed 80% assumption of absorbed 
isotope into RBCs was used to estimate the percentage absorption from the 
equation in Table 2.12 (Latunde-Dada et al., 2006). 
2.2.7.2.5 Normalisation to reference dose 
To take into consideration inter-variability of iron status between participants, a 
reference iron dose containing 3 mg of 57FeSO4 with 35 mg of ascorbic acid (Lynch 
et al., 2007) was used in Clinic 4, administered without any test meal. The dose 
given was to signify optimum conditions for iron absorption, which was fixed to a 
reference value of 40% (Bjorn-Rasmussen et al., 1977). The use of reference iron 
dose will correct the inter-variability between participants’ iron status and enables 
comparison to be made with previous iron bioavailability studies.  
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2.2.8 ASSESSMENT OF DIETARY INTAKE 
2.2.8.1 Experimental Study 1 (Chapter 3) 
Two dietary assessment methods were utilised in the present study: (a) 3-day food 
diary and (b) 24-hour dietary recalls. Participants were required to complete a 3-day 
food diary at baseline and post-intervention (to include 2 weekdays and 1 weekend 
day) to estimate their habitual dietary intake. A 24-hour recall interview was 
completed at each clinic to assess dietary intake, a day prior to the test meal 
administration during which they were asked to recall food consumption, including 
drinks for the past 24 hours in detail to the researcher. All the dietary records were 
analysed for nutritional content by using computerised dietary analysis software 
(Microdiet for Windows software, Version 2.8.8, Downlee Systems UK Ltd). The 
food items used for the analysis were derived from McCance and Widdowson’s The 
Composition of Foods 6th Summary Edition 2002 (Food Standards Agency, 2002). If 
there were food items not available in the specified database, McCance latest 
version of each food was used, or new food items added to database based on the 
available nutritional information. Dietary reference values from the Committee on the 
Medical Aspects of Food Policy (COMA) 1991 were used for comparison with the 
intake of energy, macronutrients and micronutrients of the participants (Table 2.13). 
Details on each dietary assessment method are as follows.  
Table 2.13 RNI/day for females aged 19-50 years (COMA, 1999) 
Nutrient/day COMA RNI (1991) Unit 
Energy* 1940 kcal 
Protein 45 gram 
Carbohydrate** 33 gram 
Fat** 47 gram 
Iron  14.8 mg 
Vitamin C 40 mg 
Calcium 700 mg 
*Estimated Average Requirements (EARs) for energy; **% of Energy;  
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2.2.8.1.1 3-day food diary 
The dietary intake of the participants was first assessed using a 3-day food diary 
(Appendix O). The diary comprised of instructions on how to appropriately record 
participants’ dietary intakes, including a guide to portion sizes, how to describe the 
foods/drinks in detail, together with a sample diary. In each section of diary, there 
were columns for the time, locations, description of food/drink consumed, brand and 
amount/quantity for the participants to complete. There was also a section for the 
participants to specify any physical activity performed for that particular day. If the 
foods/drinks consumed were homemade, there were also recipe sections provided 
for the participants to specifically note in the diary.  
2.2.8.1.2 24-hour recall interview 
This method was used at each clinic to assess participants’ habitual food 
consumption, including drinks for the previous 24 hours. The researcher recorded 
intakes on a specific form (Appendix P), and the participants were asked to provide 
the description of the foods and drinks in as much detail as possible including brand, 
preparation methods/recipe or serving size. The participants were facilitated to 
estimate the portion size by demonstrating common household measurements such 
as table spoon, tea spoon, or cup. The participants were also asked about any 
physical activities performed on the previous day. Once the recall was completed, all 
the records were checked again with the participants to ensure there were no 
omission of foods and drinks.  
2.2.8.2 Experimental Study 2 (Chapter 4) 
Participants were required to complete a 3-day food diary (Appendix Q) at baseline 
and post intervention (to include 2 weekdays and 1 weekend day) to estimate their 
habitual dietary intake. The diary comprised of instructions on how to appropriately 
record participants’ dietary intakes, including a guide to portion sizes, how to 
describe the foods/drinks in detail, together with a sample diary. In each section of 
the diary, there were columns for time of consumption, location, description of 
food/drink consumed, brand and amount/quantity for the participants to complete. 
There was also a section for the participants to specify any physical activity 
performed during that particular day. If the foods/drinks consumed were homemade, 
there were also recipe sections provided for the participants to specifically note in 
the diary. 
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Dietary records were analysed for nutritional content by using Nutritics Professional 
Nutrition Analysis Software (Nutritics Ltd, Dublin, Ireland). The food items used for 
the analysis were derived from McCance and Widdowson’s The Composition of 
Foods (Food Standards Agency, 2002). The DRVs from the Committee on Medical 
Aspects of Food Policy (COMA) 1991 in combination with the Scientific Advisory 
Committee on Nutrition (2015) were used as a reference to compare the intake of 
energy, macro, and micronutrients of the participants. Table 2.14 shows the RNI 
values used in the study to compare to the dietary intake of participants.  
Table 2.14 RNI/day for females aged 19-50 years (SACN/COMA, 2015) 
Nutrient/day SACN/COMA RNI 2015 
Energy 2175 kcal/ 9.1MJ (19-34 years)                                
 2103 kcal/ 8.8MJ (35-54 years)                               
Protein  0.75 gram/kg body weight 
Total carbohydrate 50% daily food energy (g) 
Total fat < 35% daily food energy (g) 
Iron 14.8 mg 
Vitamin D 10 µg 
Calcium  700 mg 
*Estimated Average Requirements (EARs) for energy; **% of Energy;  
 
2.2.9 STATISTICAL ANALYSIS 
2.2.9.1 Experimental Study 1 (Chapter 3) 
All statistical analyses were performed with IBM SPSS Statistic Data Editor Software 
(Version 21). The Shapiro-Wilks test was used to ascertain the normal/non-normal 
distribution for each parameter. The non-normally distributed data, including the 
fractional iron absorption (%) and total iron absorbed (mg) were log transformed for 
the purpose of performing statistical analyses, and results were re-transformed to be 
reported as mean and standard deviation. One way repeated measures Analysis of 
Variance (ANOVA) statistical tests were performed to compare the iron absorption 
from each pair of meals in comparison to control test meal (water). Pearson’s 
correlation coefficient tests were performed to investigate the association between 
different iron status biomarkers and iron absorption (fractional absorption and total 
absorbed in mg). Differences were considered significant with a p-value ≤ 0.05.   
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2.2.9.1 Experimental Study 2 (Chapter 4) 
All statistical analyses were performed using IBM SPSS Statistic Data Editor 
Software (Version 21). Shapiro-Wilks or Kolmogorov-Smirnov tests were used to 
determine the normal distribution of data as appropriate. Descriptive statistics were 
used to describe frequencies, means and standard deviations. Baseline 
characteristics comparisons between the groups (vitamin D and placebo groups) 
were carried out using independent t-test for normally distributed or Mann-Whitney 
test for non-normally distributed data. Mixed model repeated measures analysis of 
variance (ANOVA) was performed to determine the effect of intervention and the 
interaction with time points for all iron status and vitamin D status blood biomarkers. 
Post-hoc analyses were carried out when there were intervention x time point 
interactions observed to identify the differences within or between the groups. The 
changes in all iron status and vitamin D status blood biomarkers from baseline to 
post-intervention (week 8) between the two groups were compared and analysed 
using independent t-test for normally distributed or Mann-Whitney test for non-
normally distributed data. Pearson’s or Spearman’s correlation coefficient tests were 
performed as appropriate, to investigate the relationship between different iron 
status biomarkers and vitamin D biomarkers. Differences were considered 
significant with a p-value ≤ 0.05.    
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CHAPTER 3 
A one-hour time interval between a meal containing iron and 
tea consumption, attenuates the inhibitory effects on iron 
absorption. A controlled trial in a cohort of healthy UK 
women using a stable iron isotope (57Fe). 
 
 
 
 
 
 
 
 
 
 
 
 
 Findings from this chapter have been disseminated at the following conference: 
International Conference on Advance in Human Nutrition, Food Science & Technology 
2016, 26-27th June, 2016, Toronto, Canada (Appendix R) 
 An article based on this chapter has been submitted for peer review to the following 
journal: American Journal of Nutrition (AJCN) with a title “A one-hour time interval 
between meal containing iron and tea consumption, attenuates the inhibitory effect on 
iron absorption. A controlled trial in a cohort of healthy UK women using a stable iron 
isotope (57Fe). 
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3.1 OBJECTIVES 
3.1.1 General objective 
To determine the inhibition effect of tea consumption on non-haem iron absorption 
from a porridge meal in a cohort of healthy UK women using of a single iron stable-
isotope technique (57Fe). 
 
3.1.2 Specific Objectives 
 To determine fractional non-haem iron absorption from an iron-containing 
isotope-labelled porridge meal (57Fe) administered with tea and water 
(control). 
 To assess the effect of variation in the time interval of tea consumption 
relative to a meal on non-haem iron absorption, following consumption of 
iron-containing isotope-labelled porridge meal (57Fe). 
 To investigate the potential role of hepcidin in regulating iron absorption by 
measuring plasma hepcidin concentrations following consumption of an iron-
containing isotope-labelled test meal (57Fe). 
  
3.2 HYPOTHESES 
H1: There will be a significantly lower fractional iron absorption when a porridge 
meal is consumed with tea compared to water.   
H0: There will be no significantly lower fractional iron absorption when a porridge 
meal is consumed with tea compared to water.   
 
H1: Fractional iron absorption will be significantly lower when the tea is consumed 
simultaneously with a meal compared to when it is consumed 1-hour after the meal. 
H0: Fractional iron absorption will not be significantly lower when the tea is 
consumed simultaneously with a meal compared to when it is consumed 1-hour 
after the meal. 
 
H1: There will be a significant inverse association between fractional iron absorption 
and plasma hepcidin concentration. 
H0: There will be no significant inverse association between fractional iron 
absorption and plasma hepcidin concentration. 
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3.3 RESULTS 
3.3.1 BASELINE PHYSICAL CHARACTERISTICS OF PARTICIPANTS 
The participants were healthy women aged between 19-37 years, recruited from 
University of Chester with a mean (±S.D) age of 24.8 ± 6.9 years. The majority of 
the participants (67%) were in 19-29 years age group. The majority of participants 
were white (83.3%), with 1 Asian and 1 black participant (8.3%). Before the start of 
the study, the participants were required to complete a set of screening 
questionnaires to assess eligibility and one participant reported to be a vegetarian 
(8.3%). The BMI of participants ranged from 17.6-25.9 kg/m2 with 67% in the normal 
category (<25 kg/m2). There was no significant change in the participants’ BMI from 
baseline to post-intervention (p=0.078). The baseline physical characteristics of 
participants are summarised in Table 3.1. 
 
Table 3.1 Baseline characteristics of participants (n=12) 
Variables Mean (±S.D) Range 
Age  24.8 ± 6.9 19-37 
Height (cm) 166.6 ± 6.5 154.7 – 176.2 
Weight (kg) 63.0 ± 10.8 42.2 – 79.2 
Body Mass Index (BMI) (kg/m2) 22.6 ± 2.7 17.6 – 25.9 
 
3.3.2 IRON STATUS 
Table 3.2 shows the mean (±S.D) concentrations of all iron status biomarkers 
measured in the present study. The concentrations of participants’ iron status 
biomarkers remained within the normal range at each points during the 56 days of 
trial. All participants had full blood count indices, plasma CRP, plasma ferritin, and 
plasma hepcidin concentrations within the normal ranges. There were no changes 
observed in participants’ plasma CRP and plasma hepcidin concentrations between 
baseline (Day 0) and post-intervention (Day 56). The majority of the participants had 
plasma ferritin concentration within the normal range for healthy women, with no 
elevated plasma ferritin concentration due to acute phase reactions indicated by the 
plasma CRP measurement. Seven of the 12 participants (60%) were not iron 
deficient based on plasma ferritin concentration of < 15 µg/l, and only 2 participants 
were found to be anaemic (haemoglobin concentration < 12 g/dl) at baseline. 
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However, there was a significantly lower plasma ferritin concentration at post-
intervention compared to baseline (p=0.026). 
The mean (±S.D) concentrations of all parameters that comprise of FBC indices 
were within the normal range, apart from MCHC that were significantly lower 
(p=0.050) at Day 56, and MCV that was significantly higher (p=0.013) at post-
intervention (Day 56) compared to baseline (Day 0). Mean (±S.D) plasma hepcidin 
concentration was similarly within the normal range (96.04 ± 119.58 ng/ml), apart 
from 3 participants who had plasma hepcidin concentrations of > 150 ng/ml, with the 
highest being 386 ng/ml at baseline, which explains the high standard deviation. In 
addition, one participant had a plasma hepcidin concentration below the detectable 
range of assay kit of <0.06 ng/ml at Day 56. A reference value of between 17-286 
ng/ml from a study which reported 5-95% normal range for healthy women, sampled 
in the USA and Italy (Ganz et al., 2008) was used to compare the concentrations 
found in the current study, as there are no agreed universal normal threshold values 
for hepcidin to date.  
Table 3.2 Mean (±S.D) concentration of iron status biomarkers (n=12)  
Iron status biomarkers Day 0 Day 56 p-value 
Plasma ferritin (ug/l) 38.81 ± 42.71 29.39 ± 33.38 *0.026 
Plasma CRP (mg/l) 0.62 ± 0.77 0.40 ± 0.46 0.084 
Full blood counts     
    - White blood cells (x109/l)  4.97 ± 1.12 5.08 ± 1.33 0.789 
    - Haemoglobin (g/dl)  12.33 ± 1.52 12.48 ± 1.12 0.683 
    - Haematocrit (%) 35.97 ± 4.49 38.46 ± 4.53 0.107 
    - Red blood cells (x1012/l)  3.93 ± 0.55 4.10 ± 0.65 0.347 
    - Mean corpuscular volume (fl)  91.84 ± 6.93 94.23 ± 5.92 *0.013 
    - Mean corpuscular hb (MCH) (pg)  31.82 ± 4.81 31.03 ± 4.71 0.126 
    - MCH concentration (g/dl) 34.60 ± 4.63 32.91 ± 4.64 *0.050 
    - Platelet (x109/l)  260.67 ± 4.53 247.83 ± 55.03 0.132 
Plasma hepcidin (ng/ml) 96.04 ± 119.58 75.90 ± 96.43 0.099 
  *Significant between time point (p<0.05) 
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3.3.3 DIETARY INTAKE 
Dietary intake of the participants was measured using; (a) a 24-hour recall to 
ascertain participants didn’t consume any food items containing high concentrations 
of iron, prior the clinics to attempt and eliminate confounding factors that may affect 
the proportion of iron absorption in participants; and (b) a 3-day food diary to monitor 
that participants maintained their usual dietary pattern and to establish their habitual 
food intake. 
 
Table 3.3 shows the dietary intake of the participants measured using a 3-day food 
diary, with comparisons to population data reported in the 2008-2012 UK NDNS. 
There was no difference observed at baseline and post-intervention in the mean 
daily intake (±S.D) of energy, protein, fat, carbohydrate, vitamin C and calcium. 
Mean (±S.D) iron intake, however, was found to be significantly higher (8.4 ± 1.8 
mg) at post-intervention, compared to baseline (6.7 ± 1.5 mg) (p=0.035). Analysis 
from the 24-hour recall showed that most of the foods consumed by the participants 
that contributed to the dietary iron intake of participants were from a haem source, 
(e.g. pork, beef, lamb and chicken) and the non-haem sources came generally from 
fortified food items (e.g. bread and breakfast cereals). This is consistent with figures 
reported in NDNS which showed that 38% of dietary iron intake of adults was from 
cereal/cereal products, followed by 19% from meat & meat products and 17% from 
vegetables and potatoes. Mean (±S.D) daily energy intake and macronutrient intake 
of participants were also comparable to the population data reported in the NDNS, 
despite the slightly lower intakes of iron, vitamin C, and calcium, which may be due 
to the low number of participants recruited in the present study compared to larger 
number in the national survey. The dietary analysis from the 24-hour recall from 
each clinic revealed no unusually high intake of iron, calcium or vitamin C, which 
may have confounded participants’ iron absorption. 
 
The participants’ estimated dietary intakes were compared to Dietary Reference 
Values (DRV) recommended by the SACN, UK (Table 3.4). Participant’s energy 
intake was approximately 70% of the RNI, and 50% of the RNI for iron. No 
participant met the requirement of 14.8 mg of iron/day, indicating a poor dietary iron 
intake despite generally not being iron deficient or anaemic. Vitamin C, an enhancer 
of iron absorption, intake was 5-fold higher than the RNI. It was reported in the 
NDNS that women aged between 19-64 years consumed 204% (vitamin C) and 
78% (iron) of the RNI.  
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Table 3.3 Estimated dietary intake of participants (n=12) at baseline and 
post-intervention 
Nutrient Day 0 Day 56 p-value a2008-12 NDNS  
 Mean ± S.D Mean ± S.D  Mean (±S.D) 
Energy (MJ) 6.746 ± 1.914 6.984 ± 1.670 0.523 6.78 ± 1.91 
Energy (kcal) 1612 ± 458 1669 ± 399 0.523 1613 ± 455 
Protein (g) 66.1 ± 22.9 67.0 ± 17.0 0.903 65.4 ± 18.3 
Fat (g) 66.8 ± 32.1 62.4 ± 14.7 0.641 60.1 ± 22.7 
Carbohydrate (g) 190.8 ± 47.1 220.5 ± 92.2 0.347 197 ± 61 
Iron (mg) 6.7 ± 1.5 8.4 ± 1.8 *0.035 9.6 ± 3.0 
Vitamin C (mg) 76.7 ± 68.3 77.5 ± 43.3 0.875 81.6 ± 59.8 
Calcium (mg) 581.0 ± 186.2 610.7 ± 243.6 0.701 728 ± 260 
aBates et al. (2014) 
Table 3.4 Comparison of participants’ dietary intake to UK DRV 
Nutrient  RNI (SACN 2015) Day 0 Day 56 
  aPercentage < RNI 
Energy (MJ/kcal) 9.1/2175 (19-34 years) 
8.8/2103 (35-54 years) 
92 92 
Protein (g) 0.75 per kg  17 0 
Fat (g) <35% 42 58 
Carbohydrate (g) 50% 50 50 
Iron (mg) 14.8 100 100 
Vitamin C (mg) 40 50 17 
Calcium (mg) 700 75 67 
aPercentage < RNI = Proportion of participants with mean daily intakes below the RNI 
Figure 3.1 shows participants’ dietary intakes of this study participant’ compared to 
the RNI. Only protein and vitamin C exceeds the RNIs of women aged 19-50 years.  
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Figure 3.1 Participants’ percentage mean daily intake of energy, protein, fat, carbohydrate, iron, vitamin C and calcium compared 
to UK DRVs 
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3.3.4 IRON ABSORPTION 
Iron absorption in the current study was estimated using a standardised test meal, 
which was administered successively at 14-day intervals with either water (TM I), 
simultaneously with tea (TM II) and tea administered 1 hour post-test meal (TM III). 
Each test meal was extrinsically labelled with 4 mg 57FeSO4, except for the 
reference iron dose which was labelled with 3 mg 57FeSO4 and 35 mg of ascorbic 
acid. TM I (water) served as a reference meal and was used as the basis for 
comparison, to calculate the iron absorption ratio and inhibition effect of tea (%). 
Table 3.5 shows (a) the fractional iron absorption percentage, normalised to the 
reference iron dose to correct inter-variability between iron status backgrounds of 
participants and (b) total iron absorbed in mg, without normalisation to the reference 
iron dose.  
 
Table 3.5 Mean (±S.D) of iron absorption from test meals with specified 
beverages 
 Test meals 
 Test meal I 
(with water) 
Test meal II 
(with tea 
simultaneously) 
Test meal III 
(with tea 1 hour 
post-meal) 
Fractional iron absorption (%) 5.69 ± 8.5 3.57 ± 4.2 *5.73 ± 5.4 
Iron absorption ratio  0.65 ± 0.67 1.18 ± 1.19 
Total iron absorbed (mg) 0.226 ± 0.51 0.142 ± 0.26 *0.185 ± 0.28 
*significantly higher than TM II (p<0.05) 
3.3.4.1 Iron absorption from test meals 
It was observed that mean (±S.D) iron absorption, both in terms of fractional 
absorption (%) or total absorbed (mg) was higher in TM I (meal + water) and TM III 
(meal + tea + 1 hour) compared to TM II (meal + tea), as anticipated. A marked 
reduction of 2.1% was observed in mean iron absorption when the test meal was 
administered simultaneously with tea (TM II), compared to the control test meal 
administered with water (TM I). However, the reduction was not statistically 
significant (p=0.398). Iron absorption was approximately 2.2% higher when tea was 
administered 1 hour (TM III) after the participants were administered their test meal 
(p=0.046), compared to when test meal was administered simultaneously with tea 
(TM II). Consistent with the percentage iron absorbed, the mean total iron absorbed 
(mg) was also significantly higher (0.043 mg) in TM III (meal + tea + 1 hour) 
 129 
 
*Significantly higher than TM II (p=0.046) 
*Significantly higher than TM II (p=0.049) 
compared to TM II (meal + tea) (p=0.049). There was no significant difference 
between TM I (meal + water) and TM II (meal + tea) with regards to the total iron 
absorbed (p=0.530). No differences were observed between TM I (meal + water) 
and TM III (meal + tea + 1 hour) for both fractional iron absorption (p=0.335) and 
total iron absorbed (p=0.304). Figure 3.2 (A) shows the fractional iron absorption 
(%) and (B) shows the total amount of iron absorbed from all test meals including 
reference iron dose.  
 
 
 
 
 
Figure 3.2 Iron absorption from test meals (A) fractional iron absorption 
(%) (B) total iron absorbed (mg)  
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Table 3.6 shows the participants’ iron absorption, demonstrating individual 
variations. Due to variation in iron status of participants, which affects the iron 
absorption, the reported fractional iron absorption in this study has been normalised 
using a reference iron dose. The use of this reference dose is to account for inter-
variability between participants, and enable the findings to be compared against the 
findings in previous studies. There was a wide range of percentage absorption, 
varying from undetectable (0%) to 31.1%, accounting for the large standard 
deviation.  
 
Table 3.6 Individual iron absorption and absorption ratio compared to 
reference meal (water) 
Participant TM I TM II TM III Reference iron 
dose 
 % % *Ratio % *Ratio % 
1 31.1 15.5 0.5 17.0 0.6 58.8 
2 5.0 2.9 0.6 2.2 0.4 41.2 
3 0 3.0 0 0 0 6.5 
4 0 0 0 0 0 10.4 
5 2.4 4.6 1.9 5.9 2.4 23.0 
6 8.7 2.1 0.2 7.6 0.9 12.6 
7 4.5 2.6 0.6 6.7 1.5 9.9 
8 3.6 5.5 1.6 4.9 1.4 55.1 
9 1.5 1.5 1.0 3.3 2.3 36.9 
10 7.9 0 0 6.5 0.8 16.6 
11 0 0 0 0.5 0 10.8 
12 3.7 5.2 1.4 14.3 3.9 22.4 
*Absorption ratio of less than 1 implied inhibition effect of tea, computed in relative to TM I (water) as 
reference test meal 
 
A number of participants (n=4) were found to have not absorbed any iron for all the 
test meals except the reference iron dose. It was noted that their iron absorption 
from the reference iron dose were lower compared to others, indicating that they 
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were not iron deficient and had low iron demand physiologically. It was also 
observed that five participants had reduced iron absorption when the test meal was 
administered with tea, compared to when it was administered with water, however, 
the reduction was not significant. Eight participants had an increase in iron 
absorption when the tea was administered 1 hour after the test meal, as compared 
to when it was administered simultaneously with the meal. Based on the ratio data, 
an inhibition effect of tea when administered TM II (meal + tea) was observed in 8 
participants, compared to smaller number (n=7) when administered TM III (meal + 
tea + 1 hour). This shows that the inhibition effect is reduced with a 1-hour time 
interval between administration of test meal and tea consumption. 
 
3.3.4.2 Time interval effect of tea consumption on iron absorption 
Inhibition effects (%) were calculated based on the mean total iron absorbed from 
the test meals administered with tea (TM II and TM III), in comparison to the test 
meal with water as a reference meal (TM I). This is to illustrate the inhibition effect 
related to the time intervals used, between administering the tea simultaneously with 
the meal, or a 1-hour time interval between the meal and the tea. A 2-fold reduction 
in inhibition effect was observed, from 37.2% in TM II (meal + tea) to 18.1% in TM III 
(meal + tea + 1 hour), indicating that allowing at least a 1-hour time interval between 
a meal and tea consumption will lead to increased iron absorption. Figure 3.3 
shows the impact of a 1-hour time interval on the inhibition effects of tea on iron 
absorption.  
 
 
 
Figure 3.3 Inhibition effects of TM II and TM III compared to reference meal 
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3.3.5 ASSOCIATION BETWEEN IRON ABSORPTION AND IRON STATUS 
BIOMARKERS (PLASMA FERRITIN AND HEPCIDIN CONCENTRATIONS) 
Plasma ferritin concentration is the amount of total iron storage in body and it has 
been shown to be well correlated with iron absorption in previous studies. It was 
observed in the present study that there were inverse association between plasma 
ferritin concentration with both fractional iron absorption and total iron absorbed 
(mg) in the study (Figure 3.4). It was found that there were low and modest, but 
significant inverse associations between plasma ferritin concentrations and iron 
absorption (r=-0.330, p=0.043) and total iron absorbed (r=-0.486, p=0.005), 
respectively.  
Plasma hepcidin concentrations were measured to investigate the role of this 
peptide hormone in regulating iron absorption. Similar to the observation in plasma 
ferritin concentration, plasma hepcidin concentration was found to be moderate and 
significantly associated with both, fractional iron absorption (r=-0.475, p=0.007) and 
with total iron absorbed (r=-0.560, p=0.004) (Figure 3.5).  
A significant linear association between plasma ferritin and plasma hepcidin 
concentration (p=0.885, p=0.0001) was observed which indicates a very high 
association between these two key iron biomarkers that have a substantial role in 
the regulation of iron absorption (Figure 3.6). 
 
Figure 3.4 Association between plasma ferritin concentration & iron 
absorption 
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Figure 3.5 Association between plasma hepcidin concentration & iron 
absorption  
 
Figure 3.6 Association between plasma ferritin concentration (µg/l) and 
plasma hepcidin concentration (ng/ml)  
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A steeper slope is observed with TM II (meal + tea) (B) compared to TM I (water) (A) 
when comparing log iron absorption (%) against log ferritin concentrations. The 
steepest slope remained in TM II (B) when it was compared against TM III (meal + 
tea) (C), suggesting that higher inhibition effect is shown is B, when tea is consumed 
with test meal (Figure 3.7). 
 
 
Figure 3.7 Linear association comparing log10 (fractional iron absorption) 
and log10 (plasma ferritin concentrations) in different test meals 
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CHAPTER 4 
A double-blind randomised controlled trial investigating the 
effect of vitamin D3 supplementation on iron absorption and 
hepcidin response following the consumption of an iron-
fortified breakfast cereal, in iron deficient women. 
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4.1 OBJECTIVES 
4.1.1 General objective 
To investigate the effect of an 8-week daily dose of vitamin D3 (1500 IU) consumed 
with 60 g of commercially available iron-fortified breakfast cereal containing 9 mg of 
iron, on haematological indicators in a cohort of marginally and iron deficient 
childbearing-aged UK women. 
4.1.2 Specific objectives 
 To examine the effect of vitamin D3 supplementation, consumed with the 
iron-fortified breakfast cereals on the recovery of iron status in women with 
marginal and low iron stores 
 To assess the effectiveness of iron-fortified breakfast cereals consumption, 
as part of regular diet on the recovery of iron status in women with marginal 
and low iron stores 
 To investigate the effect of vitamin D3 on plasma hepcidin concentration, to 
have better understanding of the potential role of vitamin D as an iron 
absorption enhancer  
4.2 HYPOTHESES 
H1: There will be a significant improvement in haematological indicators following 8 
weeks vitamin D3 supplementation consumed with iron-fortified breakfast cereals in 
the vitamin D group compared to placebo group. 
H0: There will be no significant improvement in haematological indicators following 8 
weeks vitamin D3 supplementation consumed with iron-fortified breakfast cereals in 
the vitamin D group compared to placebo group. 
 
H1: There will be a significant improvement in haematological indicators following 8 
weeks consumption of iron-fortified breakfast cereals in both groups.  
H0: There will be no significant improvement in haematological indicators following 8 
weeks consumption of iron-fortified breakfast cereals in both groups. 
 
H1: Plasma hepcidin concentration will be reduced following 8 weeks vitamin D3 
supplementation, and results in increased iron stores.  
H0: Plasma hepcidin concentration will not be reduced following 8 weeks vitamin D3 
supplementation, and did not result in increased iron stores.  
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4.3 RESULTS 
4.3.1 BASELINE CHARACTERISTICS OF PARTICIPANTS 
A total of 50 women initially commenced the study, and 44 women completed the 
whole study at 8 weeks. Four participants dropped out after the first clinic due to 
feeling unwell (n=2) or without reason and did not respond to emails (n=2). The 
remaining two participants dropped out after interim clinics due to falling sick. The 
baseline characteristics are reported based on the data available for the total of 50 
participants which included the drop-outs. Figure 4.1 summarises the allocation of 
participants throughout the study. From the screening questionnaire, 11 participants 
considered themselves to be a vegetarian (22%). The participants recruited were 
aged between 19-49 years, with a mean (±S.D) age of 27.4 ± 9.4 years. More than 
half of the participants (56%) were in the 19-24 years age group, followed by 20% in 
the 25-34 years age group and the remaining 24% were in the 35-54 years age 
group. The majority of participants were white (80%), followed by Asian (12%) and 
others (8%).  
Two blood biomarkers (plasma ferritin and 25(OH)D concentrations) were measured 
at the screening clinic to assess eligibility of the participants. The mean (±S.D) 
plasma ferritin concentration was 11.5 ± 5.6 µg/l and 25(OH)D concentration was 
38.28 ± 21.40 nmol/l. This indicates that the participants were iron deficient (plasma 
ferritin < 15 µg/l) and vitamin D inadequate (plasma 25(OH)D between 30-50 nmol/l) 
at screening and eligible for the study. The mean (±S.D) plasma 25(OH)D 
concentration did not change from  screening to when eligible participants 
commenced the study at baseline (p=0.205). On the contrary, it was observed that 
there was a significantly higher mean (±S.D) of plasma ferritin concentration at 
baseline (13.2 ± 7.8 µg/l) compared to during screening (11.5 ± 5.6 µg/l) (p=0.012).  
The baseline characteristics of participants are summarised in Table 4.1. There 
were no significant differences in the participants’ baseline physical characteristics 
(height, weight and BMI) between the vitamin D group and the placebo group. It was 
also observed that there were no significant differences in participants’ iron and 
vitamin D status (haemoglobin, plasma ferritin, hepcidin and 25(OH)D 
concentrations) between the vitamin D group and the placebo group (p>0.05). In 
reference to dietary intake, there were no significant differences in nutrients (energy, 
protein, carbohydrate, fats, iron and vitamin D) between the vitamin D group and the 
placebo group, except for carbohydrate (% of energy).  
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Excluding drop-outs (n=44), there were no significant difference in physical 
characteristics, iron and vitamin D status, and dietary intakes at baseline between 
the two groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Allocation of participants throughout the 8-week intervention 
period 
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Table 4.1 Participant baseline physical characteristics, iron & vitamin D 
status and dietary intake (n=50) 
Variables All  
(n=50) 
Vitamin D 
group 
(n=25) 
Placebo group 
(n=25)  
p-
value 
Physical characteristics 
Age (years) 27.4 ± 9.4 28.0 ± 9.0 26.9 ± 9.9 0.280 
Height (cm) 165.6 ± 5.8 165.2 ± 6.4 166.0 ± 5.3 0.623 
Weight (kg) 67.2 ± 14.8 68.3 ± 17.9 66.1 ± 11.1 0.930 
BMI (kg/m2) 24.4 ± 4.8 24.9 ± 5.7 24.0 ± 3.7 0.930 
Iron & vitamin D status 
Haemoglobin (g/dl) 13.4 ± 1.4  13.6 ± 1.2 13.2 ± 1.5 0.210 
Plasma ferritin (µg/l) 13.2 ± 7.8 14.1 ± 7.7 12.4 ± 8.0 0.467 
Plasma hepcidin (ng/ml)  3.5 ± 4.3  4.2 ± 5.7 2.9 ± 2.2 0.968 
Plasma 25(OH)D (nmol/l) 36.8 ± 23.6 35.0 ± 19.8 38.6 ± 27.2 0.992 
Mean daily dietary intake  
Energy (kcal) 1671.3 ± 376.9  1722.5 ± 314.9 1628.3 ± 423.7 0.447 
Energy (MJ) 6.9 ± 1.6 7.2 ± 1.3 6.8 ± 1.8  0.404 
Protein (g) 70.0 ± 16.4 74.7 ± 16.4 66.1 ± 15.6 0.155 
Carbohydrate (g) 224.2 ± 46.3  220.4 ± 30.6 227.4 ± 56.7 0.618 
Carbohydrate (%) 51.8 ± 6.3 49.5 ± 6.3 53.6 ± 5.7 0.025 
Fats (g) 57.5 ± 22.2 61.3 ± 23.7 54.2 ± 20.7 0.337 
Fats (%) 30.6 ± 7.0 31.1 ± 6.8 30.1 ± 7.2 0.626 
Iron (mg) 16.4 ± 2.3 16.5 ± 1.8 16.4 ± 2.6 0.108 
Vitamin D (µg) 1.7 ± 1.6 1.6 ± 1.2 1.7 ± 1.9 0.604 
All values are mean (±S.D) except for for carbohydrate & fats with additional % of total energy intake 
p-value of > 0.05 indicates no significant difference at baseline between the 2 groups  
 
4.3.1.1 Prevalence of anaemia, iron deficiency and vitamin D deficiency at 
baseline  
Different thresholds were used to classify anaemia (haemoglobin < 11 g/dl), iron 
deficiency (plasma ferritin < 15 µg/l) and vitamin D deficiency (plasma 25(OH)D < 30 
nmol/l). Prevalence of anaemia, iron deficiency and vitamin D deficiency at baseline 
were 12% (n=6), 64% (n=32) and 62% (n=31). Figure 4.2 shows anaemia and iron 
deficiency proportions in participants based on the vitamin D status, at baseline.  
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It can be observed that 13% of the vitamin D deficient (VDD) participants were also 
anaemic and higher proportion of them was iron deficient (ID) (61%). This indicates 
the possible association between iron status and vitamin D status, which has been 
shown in previous observational studies.  
 
Figure 4.2 Anaemia and iron deficiency prevalence at baseline stratified by 
vitamin D status 
 
4.3.2 COMPLIANCE & ADVERSE EVENTS OF VITAMIN D 
SUPPLEMENTATION 
Compliance was measured based on the number of capsules remaining in the 
supplement pot returned by the participants at the final clinic. Overall mean (±S.D) 
compliance was 92.9 ± 8.0%, which indicates good compliance of the 
supplementation. Compliance was similar in both groups with 93.2% in vitamin D 
group compared to 92.6% in placebo group. No participants reported any adverse 
events associated with the consumption of supplements.  
The consumption of iron-fortified breakfast cereal was examined using the diary 
record by the participants at baseline and before study completion. All participants 
recorded consumption of the supplied iron-fortified cereal at breakfast every day in 
both diaries. There were also no adverse events reported by the participants 
connected to cereal consumption. 
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4.3.3 EFFECT OF VITAMIN D SUPPLEMENTATION ON IRON STATUS 
4.3.3.1 Improvement in iron biomarkers from baseline to post-intervention 
following vitamin D intervention 
Table 4.2 shows the effect of intervention on iron status biomarkers. There was a 
significant increase in the two main iron status biomarkers: haemoglobin 
concentration and haematocrit % from baseline (Week 0) to post-intervention (Week 
8) in the vitamin D group, compared to the placebo group. Figure 4.3 shows the 
increase in haemoglobin concentration (0.36 g/dl) in the vitamin D group was 
significantly higher from the increase in the placebo group (-0.28 g/dl) (p=0.037). 
The increase was also significantly higher in haematocrit % in the vitamin D group 
(1.82%) compared to the placebo group (-0.51%) (p=0.032). 
In the vitamin D group, consumption of vitamin D3 supplements with the iron fortified 
cereals however did not have impact on the change in other main iron status 
biomarkers including RBC, MCV, MCH, MCHC, plasma ferritin, plasma hepcidin and 
plasma sTfR, compared to the placebo group. 
 
 
Figure 4.3 Effect of intervention on iron status biomarkers from baseline to 
post-intervention  
-6
-4
-2
0
2
4
6
Haemoglobin (g/dl) Haematocrit (%)
Δ
w
e
e
k
 0
 t
o
 w
e
e
k
 8
Vitamin D
Placebo
 142 
 
Table 4.2 Effect of intervention on iron status biomarkers from baseline to post-intervention (n=44) 
Biomarkers Vitamin D group Placebo group p-value 
 Baseline Post-intervention Change Baseline Post-intervention Change  
Hb (g/dl) 13.48 ± 1.08 13.84 ± 0.98 0.36 ± 0.71 13.11 ± 1.53 12.83 ± 1.25 -0.28 ± 1.16 *0.037 
Hct (%) 42.01 ± 2.95 43.83 ± 3.41 1.82 ± 3.12 41.16 ± 4.29 40.65 ± 3.56 -0.51 ± 3.74 *0.032 
RBC (x1012/l) 4.61 ± 0.25 4.77 ± 0.27 0.16 ± 0.24 4.60 ± 0.44 4.58 ± 0.33 -0.03 ± 0.37 0.055 
MCV (fl) 91.25 ± 5.05 91.93 ± 5.70 0.68 ± 3.32 89.65 ± 7.39 89.03 ± 7.84 -0.61 ± 3.11 0.117 
MCH (pg) 29.30 ± 2.00 29.06 ± 1.92 -0.24 ± 0.56 28.57 ± 2.96 28.13 ± 3.00 -0.44 ± 0.73 0.328 
MCHC (g/dl) 32.10 ± 0.73 31.59 ± 0.98 -0.51 ± 0.96 31.82 ± 1.08 31.54 ± 1.14 -0.28 ± 0.91 0.425 
Fer (µg/l) 14.08 ± 8.16 15.95  ± 10.80 1.87 ± 11.14 12.32 ± 8.12 13.76  ± 13.28 1.46 ± 9.14 0.540 
Hep (ng/ml) 3.67 ± 4.92 4.12  ± 4.08 0.46 ± 5.79  2.87 ± 2.23 3.44  ± 5.57 0.57 ± 4.52 0.451 
sTfR (mg/l) 1.61 ± 0.72 1.75  ± 0.96 0.15 ± 0.33 1.91 ± 1.17 2.01  ± 1.39 0.10 ± 0.29 0.724 
All values are means (±S.D)  
Changes are from baseline to post-intervention (week 0-week 8) 
P-value represents the difference in changes observed between vitamin D and placebo groups, *= p ≤ 0.05 
Hb: haemoglobin; Hct: haematocrit; RBC: red blood cells; MCV: mean corpuscular volume; MCH: mean corpuscular haemoglobin; MCHC: mean corpuscular haemoglobin 
concentration; Fer: ferritin; Hep: hepcidin; sTfR: soluble transferrin receptor  
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4.3.3.2 Time and group interaction  
No participants had elevated plasma CRP concentrations (<10 mg/l) at all time 
points. The mean (±S.D) plasma CRP concentration was below than 4 mg/l in both 
groups, at all time points. Table 4.3 shows the mean (±S.D) concentrations of 
participants’ iron status biomarkers at baseline, interim and post-intervention. All full 
blood count parameters measured (haemoglobin, haematocrit, RBC, MCV, MCH 
and MCHC) were within the normal range, in both groups, at all time points.  
No significant difference was observed between the vitamin D group and the 
placebo group in plasma ferritin, plasma hepcidin, and plasma sTfR concentrations. 
No significant difference was also observed between the two groups in the principal 
iron status biomarkers, haemoglobin concentrations. There was no significant 
difference in all the other full blood count parameters including the haematocrit, 
RBC, MCV, MCH and MCHC.  
3.3.3.3 Time effect within groups 
In the vitamin D group, the mean (±S.D) haemoglobin concentration was 
significantly higher at post-intervention (13.84 ± 0.98 g/dl) compared to baseline 
(13.60 ± 1.15 g/dl) (p=0.035). No significant difference in haemoglobin concentration 
was observed within the placebo group, between each time point. In the vitamin D 
group, mean (±S.D) haematocrit % was significantly higher at post-intervention 
(43.83 ± 3.41%) compared to both; baseline (42.51 ± 3.21%, p=0.017) and 4-weeks 
(42.65 ± 3.15%, p=0.044). No significant difference in haematocrit % was observed 
within the placebo group, between each time point.  
In the vitamin D group, mean (±S.D) RBC count was significantly higher at post-
intervention (4.77 ± 0.27 x1012/l) compared to baseline (4.63 ± 0.33 x1012/l) 
(p=0.007). No significant difference in RBC count was observed within the placebo 
group, between each time point. In the vitamin D group, mean (±S.D) MCHC was 
significantly lower at post-intervention (31.59 ± 0.98 g/dl) compared to both baseline 
(32.00 ± 0.75 g/dl, p=0.028) and 4-weeks (32.04 ± 0.78, p=0.032). No significant 
difference in MCHC was observed within the placebo group, between each time 
point.  
Difference within groups in MCH was observed in both groups. In the vitamin D 
group, mean (±S.D) MCH was significantly lower at post-intervention (29.06 ± 1.92 
pg) compared to 4-weeks (29.27 ± 1.78 pg) (p=0.017). In the placebo group, mean 
(±S.D) MCH was significantly lower at post-intervention (28.13 ± 3.00 pg) compared 
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to both baseline (28.72 ± 3.00 pg, p=0.008) and 4-weeks (28.68 ± 2.99 pg, 
p=0.0001).  
No significant difference was observed within both groups in MCV, plasma ferritin, 
plasma hepcidin and plasma sTfR concentrations, between each time point.  
However, a trend of increased plasma ferritin concentration was observed within the 
vitamin D group, as mean (±S.D) plasma ferritin concentration was not within the 
normal range at baseline (14.07 ± 7.68 µg/l) and 4-weeks (13.85 ± 9.62 µg/l), but 
increased to normal range (15.95 ± 10.80 µg/l) at post-intervention. The similar non-
significant increased trend was also observed in the placebo group, however, 
participants in the placebo group remained iron deficient (based on WHO threshold 
of <15 µg/l) at post intervention, indicated by the mean (±S.D) plasma ferritin 
concentration of 13.76 ± 13.28 µg/l.  
A trend of reduced plasma hepcidin concentration was observed within the vitamin 
D group, as the mean (±S.D) reduced at post-intervention (4.12 ± 4.08 ng/ml), 
compared to baseline (4.20 ± 5.65 ng/ml) and 4-weeks (2.93 ± 2.63 ng/ml). In the 
placebo group, an increased non-significant trend was observed in plasma hepcidin 
concentration.  
An increase was observed in plasma sTfR concentration in both groups (trend), but 
did not reached the normal range at post intervention, compared to baseline or 
interim time points.  
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Table 4.3 Effect of vitamin D supplementation on iron status biomarkers at 3 time points over 8-weeks intervention period  
 Groups Baseline (Week 0) 
(n=50) 
Interim (Week 4) 
(n=46) 
Post-intervention 
(Week 8) (n=44) 
Time 
(p-value) 
Time x Group 
(p-value) 
Haemoglobin (g/dl) Vitamin D 13.60 ± 1.15a 13.64 ± 1.08 13.84 ± 0.98b <0.05 *0.037 
 Placebo 13.16 ± 1.52 13.10 ± 1.12 12.83 ± 1.25 NS  
Haematocrit (%) Vitamin D 42.51 ± 3.21a 42.65 ± 3.15a 43.83 ± 3.41b <0.05 *0.032 
 Placebo 41.27 ± 4.23 41.22 ± 2.98 40.65 ± 3.56 NS  
RBC (x1012/l) Vitamin D 4.63 ± 0.33a 4.67 ± 0.25 4.77 ± 0.27b <0.001 0.055 
 Placebo 4.60 ± 0.43 4.58 ± 0.33 4.58 ± 0.33 NS  
MCV (fl) Vitamin D 91.96 ± 5.77 91.31 ± 4.26 91.93 ± 5.70 NS 0.190 
 Placebo 90.02 ± 7.47 90.23 ± 7.81 89.03 ± 7.84 NS  
MCH (pg) Vitamin D 29.42 ± 1.95 29.27 ± 1.78a 29.06 ± 1.92b <0.05 0.328 
 Placebo 28.72 ± 3.00a 28.68 ± 2.99a 28.13 ± 3.00b <0.0001  
MCHC (g/dl) Vitamin D 32.00 ± 0.75a 32.04 ± 0.78a 31.59 ± 0.98b <0.05 0.425 
 Placebo 31.86 ± 1.07 31.73 ± 0.99 31.54 ± 1.14 NS  
Plasma ferritin (µg/l) Vitamin D 14.07 ± 7.68 13.85  ± 9.62 15.95  ± 10.80 NS 0.890 
 Placebo 12.39  ± 7.96 12.64  ± 8.82 13.76  ± 13.28 NS  
Plasma hepcidin (ng/ml) Vitamin D 4.20  ± 5.65 2.93  ± 2.63 4.12  ± 4.08 NS 0.941 
 Placebo 2.93  ± 2.20 3.11  ± 2.78 3.44  ± 5.57 NS  
Plasma sTfR (mg/l) Vitamin D 1.52  ± 0.67 1.68  ± 0.88 1.75  ± 0.96 NS 0.625 
 Placebo 1.87  ± 1.16 1.89  ± 1.34 2.01  ± 1.39 NS  
 
Values are significantly different at specified time points if not sharing a common letter in the same row,   *= p ≤ 0.05
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4.3.3.4 Effect of vitamin D supplementation on iron status biomarkers when 
stratified for plasma ferritin concentration of <15 µg/l  
Further analyses were carried out in participants who were iron deficient based on a 
plasma ferritin threshold of <15 µg/l at baseline (n=15 : vitamin D group, n=17: 
placebo group), to ascertain whether the severity of iron deficiency influenced 
participants’ iron status following the consumption of vitamin D3 supplements and 
iron-fortified cereal. No significant effect of vitamin D3 supplementation on all 
biomarkers of iron status was observed in the two groups.  
Table 4.4 shows the effect of vitamin D supplementation on all iron biomarkers 
within both groups when only participants with a ferritin threshold of <15 µg/l at 
baseline were included in analyses (n=32). The analyses were carried out to 
ascertain whether the severity of iron stores affected participants’ response to the 
intervention. With the adjustment to the lower ID threshold, it was observed that 
there was a significant increase within the vitamin D group in mean (±S.D) RBC 
count from baseline (4.57 ± 0.25) to post-intervention (4.75 ± 0.26) (p=0.024). A 
significant increase within the vitamin D group was also observed in mean (±S.D) 
haematocrit % at post-intervention (43.53 ± 3.61%) from baseline (41.43 ± 3.15%, 
p=0.024) and 4-weeks (42.47 ± 3.26%, p=0.04).  
It was also observed that there was a significant decrease within the vitamin D 
group in mean (±S.D) MCH from 4-weeks (29.21 ± 2.05 pg) to post-intervention 
(28.91 ± 2.19 pg) (p=0.04). In the vitamin D group, there was a significant decrease 
in mean (±S.D) MCHC at post-intervention (31.53 ± 1.05 g/dl) from baseline (32.19 
± 0.79, p=0.017) and 4-weeks (32.06 ± 0.90%, p=0.042). A significant decrease was 
observed in mean (±S.D) MCH at post-intervention (27.64 ± 3.43 pg) from baseline 
(28.11 ± 3.39 pg (p=0.036) and 4-weeks (28.00 ± 3.38 pg) (p=0.003) within the 
placebo group.  
The improvement in the iron status biomarkers may be observed in both vitamin D 
and placebo groups, as both groups received iron-fortified breakfast cereals. No 
other significant improvement was observed within placebo group in any other iron 
status biomarkers.  
Table 4.5 shows the effect of intervention on iron status biomarkers, when the lower 
threshold of plasma ferritin concentration is used in the analyses. There was no 
significant impact of intervention from baseline to post-intervention, on all of the iron 
status biomarkers.  
 147 
 
Table 4.4 Effect of vitamin D supplementation on iron status biomarkers stratified by ferritin threshold of <15µg/l (n=32) 
 Groups Baseline (Week 0) 
(n=32) 
Interim (Week 4) 
(n=32) 
Post-intervention 
(Week 8) (n=32) 
Time 
(p-value) 
Time x Group 
(p-value) 
Haemoglobin (g/dl) Vitamin D 13.34 ± 1.21 13.60 ± 1.16 13.05 ± 2.66 NS 0.368 
 Placebo 12.99 ± 1.67 12.86 ± 1.26 12.84 ± 1.39 NS  
Haematocrit (%) Vitamin D 41.43 ± 3.15a 42.47 ± 3.26a 43.53 ± 3.61b <0.05 0.160 
 Placebo 40.83 ± 4.55 40.67 ± 3.26 40.72 ± 3.70 NS  
RBC (x1012/l) Vitamin D 4.57 ± 0.25a 4.67 ± 0.25 4.75 ± 0.26b <0.05 0.354 
 Placebo 4.64 ± 0.46 4.62 ± 0.39 4.67 ± 0.34 NS  
MCV (fl) Vitamin D 90.65 ± 5.25 91.01 ± 4.87 91.67 ± 6.36 NS 0.187 
 Placebo 88.19 ±8.35 88.49 ± 8.59 87.56 ± 8.64 NS  
MCH (pg) Vitamin D 29.20 ± 2.25 29.21 ± 2.05a 28.91 ± 2.19b <0.05 0.688 
 Placebo 28.11 ± 3.39a 28.00 ± 3.38a 27.64 ± 3.43b <0.05  
MCHC (g/dl) Vitamin D 32.19 ± 0.79a 32.06 ± 0.90a 31.53 ± 1.05b <0.05 0.338 
 Placebo 31.81 ± 1.24 31.59 ± 1.14 31.47 ± 1.27 NS  
Plasma ferritin (µg/l) Vitamin D 12.40 ± 8.55 10.20 ± 5.71 12.45 ± 6.94 NS 0.515 
 Placebo 9.18 ± 6.69 9.71 ± 7.08 9.86 ± 9.22 NS  
Plasma hepcidin (ng/ml) Vitamin D 3.10 ± 4.81  2.59 ± 2.69 3.00 ± 2.46 NS 0.758 
 Placebo 2.03 ± 1.99 2.15 ± 2.47 2.87 ± 6.40 NS  
Plasma sTfR (mg/l) Vitamin D 1.71 ± 0.80 1.85 ± 0.99 1.91 ± 1.05 NS 0.602 
 Placebo 2.15 ± 1.32 2.18 ± 1.55 2.25 ± 1.59 NS  
 
Values are significantly different at specified time points if not sharing a common letter in the same row
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Table 4.5 Effect of intervention on iron status biomarkers from baseline to post-intervention stratified by plasma ferritin <15 µg/l 
(n=32) 
Biomarkers Vitamin D group Placebo group p-value 
 Baseline Post-intervention Change Baseline Post-intervention Change  
Hb (g/dl) 13.34 ± 1.21 13.05 ± 2.66 0.37 ± 0.76 12.99 ± 1.67 12.84 ± 1.39 -0.16 ± 1.26 0.167 
Hct (%) 41.43 ± 3.15 43.53 ± 3.61 2.09 ± 3.20 40.83 ± 4.55 40.72 ± 3.70 -0.11 ± 4.00 0.099 
RBC (x1012/l) 4.57 ± 0.25 4.75 ± 0.26 0.18 ± 0.27 4.64 ± 0.46 4.67 ± 0.34 0.02 ± 0.39 0.210 
MCV (fl) 90.65 ± 5.25 91.67 ± 6.36 1.01 ± 3.24 88.19 ± 8.35 87.56 ± 8.64 -0.64 ± 3.27 0.164 
MCH (pg) 29.20 ± 2.25 28.91 ± 2.19 -0.29 ± 0.58 28.11 ± 3.39 27.64 ± 3.43 -0.47 ± 0.85 0.486 
MCHC (g/dl) 32.19 ± 0.79 31.53 ± 1.05 -0.67 ± 0.95 31.81 ± 1.24 31.47 ± 1.27 -0.34 ± 0.97 0.338 
Fer (µg/l) 12.40 ± 8.55 12.45 ± 6.94 0.05 ± 8.65 9.18 ± 6.69 9.86 ± 9.22 0.70 ± 7.18 0.817 
Hep (ng/ml) 3.10 ± 4.81 3.00 ± 2.46 -0.11 ± 4.17 2.03 ± 1.99 2.87 ± 6.40 0.85 ± 5.22 0.576 
sTfR (mg/l) 1.71 ± 0.80 1.91 ± 1.05 0.20 ± 0.36 2.15 ± 1.32 2.25 ± 1.59 0.10 ± 0.33 0.418 
All values are means (±S.D)  
Changes are from baseline to post-intervention (week 0-week 8) 
P-value represents the difference in changes observed between vitamin D and placebo groups 
Hb: haemoglobin; Hct: haematocrit; RBC: red blood cells; MCV: mean corpuscular volume; MCH: mean corpuscular haemoglobin; MCHC: mean corpuscular haemoglobin 
concentration; Fer: ferritin; Hep: hepcidin; sTfR: soluble transferrin receptor 
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4.3.3.5 Effect of baseline iron status on changes in biomarkers of iron status 
Figure 4.4 shows that baseline haemoglobin concentrations have a significant 
impact on the participants’ response to iron-fortified breakfast cereal consumption. 
The more anaemic the participants were at baseline, the higher the improvement in 
RBC counts, haemoglobin concentrations and haematocrit %. It was observed that 
there were strong and moderate inverse correlations between baseline haemoglobin 
concentration and change of RBC, haemoglobin concentration and haematocrit 
levels. No significant association was observed between baseline plasma ferritin 
concentrations with any of the changes in iron status biomarkers. 
  
 
 
Figure 4.4 Association between baseline haemoglobin concentration with 
change in (A) RBC count (B) haemoglobin concentration and (C) 
haematocrit % (n=44) 
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4.3.3.6 Association between improvements in iron status biomarkers  
All iron status biomarkers are hypothesised to be improved following iron-fortified 
breakfast cereal, impartial of intervention received in each group. Strong and linear 
associations were observed between several of the principal iron biomarkers 
(Figure 4.5).  
The RBC improvement was found to be positively and strongly associated with the 
improvement in haemoglobin concentrations (r=0.950, p=0.0001) and haematocrit % 
(r=0.910, p=0.0001), indicating the expansion in RBC counts lead to recovery of 
haemoglobin concentrations and haematocrit %.  
A significant strong and positive correlation was observed between the recovery of 
haemoglobin concentration with the improvement in haematocrit % (r=0.933, 
p=0.0001). The increase in haemoglobin concentration was also found to be 
moderately but significantly associated with the MCV (r=0.359, p=0.017).  
A strong and positive association was observed between plasma ferritin and plasma 
hepcidin concentrations (r=0.605, p=0.0001), indicating the role of hepcidin in 
suppressing the iron uptake once the participants’ iron stores is replete.  
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Figure 4.5 Association between change in RBC with (A) Hb concentration and (B) Hct %; between change in Hb concentration with 
(C) Hct % and (D) MCV; and (E) between change in ferritin and hepcidin concentrations (n=44)
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4.3.4 EFFECT OF VITAMIN D SUPPLEMENTATION ON VITAMIN D STATUS 
4.3.4.1 Time and group interaction  
Table 4.6 shows the effect of intervention on participants’ vitamin D status 
biomarkers at baseline, interim and post-intervention time points. Mean (±S.D) 
plasma 25(OH)D concentration was considered insufficient (30-50 nmol/l) at 
baseline, and was sufficient (>50 nmol/l) at 4-weeks and post-intervention in the 
vitamin D group. However, as expected, the mean (±S.D) plasma 25(OH)D 
concentration remained insufficient in the placebo group, at all time points. The 
mean (±SD) plasma PTH concentration was outside the normal range at all time 
points, in both groups. In addition, mean (±S.D) plasma VDBP concentration was 
within the normal range in the placebo group at all time points, but not in the vitamin 
D group. Mean (±S.D) plasma VDBP concentrations at 4-weeks and post-
intervention were slightly lower than the normal range of plasma VDBP threshold 
(300-600 µg/ml) in the vitamin D group.  
As expected, plasma 25(OH)D concentration was significantly higher in the vitamin 
D group, as opposed to the placebo group at 4-weeks and post-intervention, in 
relative to baseline. The increase from baseline to post-intervention in plasma 
25(OH)D concentration in the vitamin D group (28.03 nmol/l) was significantly higher 
than the change in the placebo group (-5.65 nmol/l) (p=0.0001). The increase from 
baseline to 4-weeks in plasma 25(OH)D concentration in the vitamin D group (23.06 
nmol/l) was also significantly higher than the change in the placebo group (0.22 
nmol/l) (p=0.0001). In addition, the increase at post-intervention from 4-weeks in the 
vitamin D group (4.98 nmol/l) was also significantly higher than the change in the 
placebo group (-5.87 nmol/l) (p=0.003) (Figure 4.6). However, no significant 
difference between vitamin D group and placebo group in plasma PTH and plasma 
VDBP concentrations. The intervention did not affected the plasma PTH and plasma 
VDBP concentrations (Table 4.7).  
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Table 4.6 Effect of vitamin D supplementation on vitamin D status biomarkers at 3 time points over 8-weeks intervention period 
 Groups Baseline (Week 0) 
(n=50) 
Interim (Week 4) 
(n=46) 
Post-intervention (Week 8) 
(n=44) 
Time  
(p-value) 
Time x Group  
(p-value) 
25(OH)D (nmol/l) Vitamin D 35.01 ± 19.78aΨ 55.99 ± 11.02bΨ  62.16 ± 16.13bΨ <0.0001 0.0001 
 Placebo 38.57 ± 27.24aΨ 38.25 ± 27.10aΨ 34.15 ± 23.56bΨ   
PTH (pmol/l) Vitamin D 7.77 ± 8.11a 6.81 ± 7.03b  7.24 ± 7.84b <0.05 0.198 
 Placebo 7.61 ± 4.43 6.81 ± 3.08 7.63 ± 3.68 NS  
VDBP (µg/ml) Vitamin D 307.82 ± 135.78 272.32 ± 90.12 289.07 ± 118.67 NS 0.413 
 Placebo 367.39 ± 144.77 368.52 ± 131.58 382.65 ± 138.14 NS  
 
Values are significantly different at specified time points if not sharing a common letter in the same row 
Values are significantly different between groups (vitamin d and placebo) if sharing a common symbol (Ψ) in the same column 
 
Table 4.7 Effect of intervention on vitamin D status biomarkers from baseline to post-intervention (n=44) 
Biomarkers Vitamin D group Placebo group p-
value 
 Baseline Post-intervention Change Baseline Post-intervention Change  
25(OH)D (nmol/l) 35.21 ± 18.43 62.16 ± 16.13 28.03 ± 28.01 39.33 ± 27.55 34.15 ± 23.56 -5.65 ± 9.73 *0.0001 
PTH (pmol/l) 8.34 ± 8.94 7.24 ± 7.84 -1.11 ± 2.00 7.80 ± 4.42 7.63 ± 3.68 -0.17 ± 2.62 0.198 
VDBP (µg/ml) 294.94 ± 131.20 289.07 ± 118.67 -5.87 ± 52.23 374.03 ± 143.95 382.65 ± 138.14 8.62 ± 62.16 0.413 
 
All values are means (±SD), P-value represents the difference in changes observed between vitamin D and placebo groups, *= p ≤ 0.05 
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Figure 4.6 Effect of intervention on vitamin D status from baseline to post-
intervention 
4.3.4.2 Time effect within groups 
In the vitamin D group, mean (±S.D) plasma 25(OH)D concentration was 
significantly higher at post-intervention (62.16 ± 16.13 nmol/l) compared to both; 
baseline (35.01 ± 19.78 nmol/l, p=0.0001) and 4-weeks (55.99 ± 11.02 nmol/l, 
p=0.0001). A significantly decrease in mean (±S.D) plasma 25(OH)D concentration 
was observed in the placebo group at post-intervention (34.15 ± 23.56 nmol/l) 
compared to both; baseline (38.57 ± 27.24 nmol/l, p=0.008) and 4-weeks (38.25 ± 
27.10 nmol/l, p=0.001). In the vitamin D group, mean (±S.D) plasma PTH 
concentration was significantly lower at 4-weeks (6.81 ± 7.03 pmol/l, p=0.022) and 
post-intervention (7.24 ± 7.84 pmol/l, p=0.023) compared to baseline (7.77 ± 8.11 
pmol/l). No significant difference in plasma PTH concentration was observed within 
the placebo group, between each time point. No significant difference in plasma 
VDBP concentration was observed within both vitamin D and placebo groups, at all 
time points. 
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4.3.4.3 Associations between baseline vitamin D status and iron status 
biomarkers 
A weak but significant positive association was observed between baseline plasma 
25(OH)D concentrations with the following iron status biomarkers: RBC count 
(r=0.339, p=0.0001), haemoglobin concentration (r=0.208, p=0.014) and 
haematocrit % (r=0.199, p=0.018). In addition, a weak but significant inverse 
association was observed between baseline plasma 25(OH)D concentrations and 
plasma PTH concentration (r=-0.229, p=0.006), as expected (Figure 4.7). No 
significant association was observed between the baseline plasma 25(OH)D 
concentrations with the other iron status biomarkers including MCV, MCH, MCHC, 
plasma ferritin, plasma hepcidin, and plasma sTfR concentration. Baseline plasma 
25(OH)D concentration was also not significantly associated with plasma VDBP 
concentrations. 
 
In the vitamin D group (n=20), there was no significant association between baseline 
plasma 25(OH)D concentration and the mean changes (Δ wk0 - wk8) in plasma 
25(OH)D concentration. To determine the potential effect of the improvement in 
vitamin D status in the vitamin D group on participants’ iron status, a further 
correlation test was carried out between the mean changes (Δ wk0 - wk8) in plasma 
25(OH)D concentration with mean changes (Δ wk0 - wk8) of all iron status 
biomarkers, however, no significant association was observed.  
 
Significant associations were however, observed between mean changes (Δ wk0 - 
wk8) of plasma VDBP concentrations with RBC count, haemoglobin concentration, 
haematocrit, MCV and MCHC concentrations (Figure 4.8).   
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Figure 4.7 Association between baseline plasma 25(OH)D concentrations 
with (A) RBC count (B) haemoglobin concentration (C) 
haematocrit % and (D) plasma PTH concentration in both groups 
combined (n=44) 
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Figure 4.8 Association between change in plasma VDBP concentrations with change in (A) RBC count (B) haemoglobin 
concentration (C) MCHC concentration (D) haematocrit % and (E) MCV in the vitamin D group (n=20) 
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4.3.5 DIETARY INTAKE FOLLOWING VITAMIN D SUPPLEMENTATION AND 
IRON-FORTIFIED BREAKFAST CEREAL CONSUMPTION  
Participants’ dietary intake of the was measured twice using a 3-day food diary, 
provided after the baseline and interim clinics in order to monitor the dietary pattern 
of participants and to ascertain habitual food intake.  
Table 4.8 summarises the energy and dietary intake of participants in both groups at 
2 time points during the 8-weeks intervention period. At post-intervention, no 
significant differences were observed between the two groups in the energy, protein, 
carbohydrate, fat, iron, vitamin D, calcium and vitamin C daily intake.  
Within each group, no significant difference was observed between baseline and 
post-intervention in the energy, protein, carbohydrate, fats, iron, vitamin D, calcium 
and vitamin C daily intake. Despite showing increase trend particularly in the iron 
intake, in both group, the changes were not significantly higher at post-intervention. 
In the vitamin D group, there was a non-significant change in mean (±S.D) dietary 
iron intake from 16.5 ± 1.8 mg (baseline) to 16.8 ± 2.3 (post-intervention) (+0.29 mg, 
p=0.6). The same non-significant trend was also observed in the placebo group, 
with mean (±S.D) dietary iron intake of 17.5 ± 2.9 mg (post-intervention) compared 
to 16.6 ± 2.7 mg (baseline) (+0.98 mg, p=0.134). Increase in the dietary iron intake 
was expected in both groups, as both groups received iron-fortified cereals.  
The overall participants’ estimated dietary intakes at post- intervention (week 8) 
(n=41) were compared to population data reported in the NDNS and also Dietary 
Reference Values (DRV) recommended by the UK SACN for women aged 19-64 
years (British Nutrition Foundation, 1995) (Table 4.9, Figure 4.9). Mean daily 
energy, carbohydrate (% of total energy intake), protein, iron, vitamin C and calcium 
daily intake was higher compared to the NDNS population data. However, mean fat 
(% of total energy intake) and vitamin D intake was lower compared to the NDNS 
population data. It was observed that the estimated dietary iron daily intake of 
participants was higher than the RNI of 14.8 mg recommended for women aged 19-
50 years. Baseline dietary iron intake was estimated based on participants’ 3-day 
dietary intake after they attended baseline clinic, which explains the higher 
estimated dietary iron intake (in comparison to typical intake reported by NDNS) due 
to consumption of the supplied iron-fortified breakfast cereals which contributed 9 
mg iron if consumed.  
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Table 4.8 Daily dietary intakes of macronutrients and selected micronutrients 
following iron-fortified cereal intervention 
Intake/day Groups Baseline  Post-intervention  Change  
Energy (kcal) Vitamin D 1738.4 ± 311.9 1729.7 ± 332.1 -8.61 
 Placebo 1661.7 ± 435.4 1726.7 ± 470.5 65.04 
Energy (MJ) Vitamin D 7.3 ± 1.3 7.2 ± 1.4 -0.04 
 Placebo 7.0 ± 1.8 7.2 ± 2.0 0.27 
Protein (g) Vitamin D 74.1 ± 16.0 73.2 ± 19.2 -8.69  
 Placebo 67.4 ± 16.2 74.8 ± 21.2 7.34 
Carbohydrate (g) Vitamin D 222.8 ± 31.2  224.7 ± 51.8 1.88 
 Placebo 231.0 ± 57.3 225.5 ± 60.4 -5.55 
Carbohydrate (%) Vitamin D 49.5 ± 5.5 50.1 ± 7.5 0.63 
 Placebo 53.4 ± 5.7 50.3 ± 5.1 -3.09 
Fat (g) Vitamin D 61.9 ± 23.1 61.9 ± 17.5 0.03 
 Placebo 55.9 ± 21.4 58.6 ± 22.4 2.70 
Fat (%) Vitamin D 31.3 ± 6.4 31.9 ± 4.9 0.63 
 Placebo 30.5 ± 7.4 30.4 ± 6.3 -0.09 
Iron (mg) Vitamin D 16.5 ± 1.8 16.8 ± 2.3 0.29 
 Placebo 16.6 ± 2.7 17.5 ± 2.9 0.98 
Vitamin D (µg) Vitamin D 1.4 ± 1.0 1.9 ±1.9  0.51 
 Placebo 1.8 ± 2.0 2.0 ± 3.0 0.18 
Calcium (mg) Vitamin D 817.8 ± 170.1 834.5 ± 209.6 16.69 
 Placebo 858.4 ± 300.8 875.0 ± 237.0 16.51 
Vitamin C (mg) Vitamin D 81.7 ± 42.6  103.0 ± 63.6 21.34 
 Placebo 85.1 ± 39.9 82.8 ± 54.3 -2.37 
All values are mean (±SD) except for for carbohydrate & fats with additional % of total energy 
intake 
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Table 4.9 Comparison of participants’ mean (±S.D) daily intake to UK 
population means (NDNS) and RNIs 
 
Intake/day Post-intervention (n=41) NDNSa % RNI 
Energy (kcal) 1728.1 ± 407.28 1613 ± 455 80.23 
Energy (MJ) 7.2 ± 1.7 6.8 ± 1.9  
Protein (g) 74.1 ± 20.1 65.4 ± 18.3 156.08 
Carbohydrate (g) 225.1 ± 55.9 197 ± 61  
Carbohydrate (%) 50.2 ± 6.2 46.3 ± 7.7 100.44 
Fat (g) 60.1 ± 20.1 60.1 ± 22.7  
Fat (%) 31.1 ± 5.7 33.0 ± 6.6 88.85 
Iron (mg) 17.2 ± 2.6 9.6 ± 3.0 116.01 
Vitamin D (µg) 2.0 ±2.6 2.6 ± 1.9 19.52 
Calcium (mg) 856.2 ± 222.9 728 ± 260 122.31 
Vitamin C (mg) 92.2 ± 58.9 81.6 ± 59.8 230.41 
aNDNS population data from Year 1-3 (Bates et al., 2014) 
 
Further analysis was carried out to assess if there will be a difference between the 
mean daily iron intake if the baseline dietary intake estimation excluded the 
consumption of the specified study breakfast cereal. The mean (±S.D) baseline 
dietary iron intake was estimated to be 7.4 ± 2.3 mg (n=41). No significant difference 
was observed between the mean (±S.D) baseline dietary intake of vitamin D group 
(7.5 ± 1.8 mg) and placebo group (7.6 ± 2.7 mg). However, significantly higher 
dietary iron intake was observed between baseline and post-intervention, within both 
groups (p=0.0001), with the adjustment to the baseline dietary intake estimation 
(excluded study breakfast cereal). 
 
3.3.5.1 Association between dietary intake and blood biomarkers 
Baseline plasma 25(OH)D concentrations were not significantly associated with 
mean changes in dietary iron intake. In addition mean dietary iron intake was not 
associated with the change in plasma 25 (OH)D and any of the iron status 
parameter  concentrations. However, non-significant trend of association was 
observed between changes in plasma VDBP concentration with the mean changes 
in dietary iron intake (p=0.092), indicating that upregulation in VDBP may have a 
role in the iron regulation, as demonstrated in blood parameters (Figure 4.8). 
161 
 
 
 
Figure 4.9 Participants’ percentage mean daily intake of energy, protein, fat, carbohydrate, iron, vitamin C, calcium and vitamin D 
compared to UK DRVs 
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CHAPTER 5 
General Discussion and Conclusion 
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5.1 DISCUSSION 
Anaemia occurs predominantly in premenopausal women and affects approximately 
25% of the general population in the world. A key aetiology of anaemia is ID, and 
dietary elements play a crucial role in the development of ID and IDA (Beck et al., 
2014). One of the immediate determinants of IDA is dietary iron intake, which 
depends on several factors including (i) amount of iron in the diet; (ii) type of iron 
(haem or non-haem); (iii) inclusion of dietary iron inhibitors or enhancers in the diet 
and (iv) iron bioavailability (Pasricha et al., 2013). In the UK population, it is evident 
that the dietary iron intake is lower in women as opposed to men (Bates et al., 
2014), and premenopausal women, in particular, are one of the at-risk groups 
susceptible to iron deficiency (WHO, 2008).  
Ascorbic acid and muscle tissue from animal-based sources are the recognised iron 
absorption enhancers, whilst polyphenols, phytates, and calcium are classified as 
iron absorption inhibitors (Abbaspour et al., 2014). These dietary components have 
been shown in various intervention studies to be capable of either facilitating or 
impeding iron absorption, causing iron to be available or unavailable for utilisation, 
thus affecting individual’s iron status. The upregulation of iron absorption is 
determined by the presence of ID and enhanced erythropoiesis, and downregulation 
occurs when infection is present or iron stores are at adequate levels. One of the 
many reasons that anaemia, ID or IDA are still prevalent across the world is due to 
technical challenges in the implementation of strategies to recover normal iron 
status in population (Lynch, 2011). The main strategies in the management of ID 
revolve around a (i) dietary approach that includes dietary modification and iron 
fortification or a (ii) therapeutic approach involving iron supplementation 
(WHO/UNICEF/UNU, 2001). Despite the implementation of these strategies, 
anaemia is still prevalent, especially in the at-risk groups such as women, young 
children and adolescents (Beck et al., 2014). A successful iron supplementation 
strategy is often limited to poor adherence due to classic gastrointestinal adverse 
events (Souza et al., 2009), therefore, the present research adopted the exploitation 
of a dietary approach by focussing on iron absorption inhibition (Chapter 3) and iron 
absorption enhancement (Chapter 4). The overall aims of the present research were 
to improve iron status of premenopausal women, by modulating the effect of tea 
containing polyphenols as iron inhibitor, and a potentially-novel iron enhancer, 
vitamin D supplements.  
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The first clinical trial as part of the overall research was carried out in the attempt to 
counteract the influence of tea containing polyphenols on iron absorption in healthy 
premenopausal women, using a single stable iron isotope technique (57Fe) to 
assess iron absorption. The second clinical trial was carried out in iron deficient 
premenopausal women, to investigate the effect of vitamin D supplementation, as a 
potential novel iron absorption enhancer, consumed with iron-fortified breakfast 
cereal as part of daily diet, on the recovery of iron status.  
The first part of the research was designed specifically to address the iron 
absorption aspect, by measuring both the fractional and absolute amount of iron 
absorbed, following administration of isotope labelled porridge meal with water and 
tea at different time intervals. Whilst a large number of studies have shown that tea 
containing polyphenols can render iron absorption, it remains uncertain whether the 
time interval of tea consumption relative to a meal has an impact on iron absorption, 
with a paucity of published evidence, especially in human interventions, 
investigating the subject matter.  
The main research hypothesis of this first part of the research was to investigate the 
effect of employing 1-hour time interval between the consumption of porridge meals 
extrinsically-labelled with stable iron isotope 57Fe and administration of tea on iron 
absorption in a healthy cohort of premenopausal women. Iron absorption can be 
predicted using series of algorithm (Hallberg & Hulthén, 2000), or estimated using a 
probability analysis based on ferritin concentration and dietary iron intake (Dainty, 
Berry, Lynch, Harvey, & Fairweather-Tait, 2014), however, the present study utilised 
a stable isotope technique which is the reference method to determine fractional iron 
absorption. The present study also was carried out to investigate the impact of tea 
consumption on non-haem iron absorption from a porridge meal using stable iron 
isotope (57Fe).  
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5.2 EXPERIMENTAL STUDY 1 (CHAPTER 3) 
In agreement with the previous studies, our findings suggest that tea consumption, 
reduces non-haem iron absorption, by at least 37% in comparison to water used as 
a control beverage. The study also demonstrates that a 1-hour time interval between 
tea consumption and a meal has a substantial impact on counteracting this inhibition 
effect, by at least 1.6 fold. 
Iron absorption from the porridge meal was as low as 5.69% when consumed with 
water, and consuming the similar porridge simultaneously with tea aggravated the 
impact on iron absorption with a substantial reduction of iron absorption to 3.57%. 
The total amount of iron absorbed when porridge was administered with water was 
0.23 mg, and the amount was reduced by 50% to 0.14 mg with consumption of tea. 
This shows that when the porridge meal is consumed with water, only 1.4% of RNI 
(14.8 mg) is achieved, and the percentage of meeting the RNI is even lesser when 
tea is consumed with the porridge meal.  
The key finding in the present study is that with 1-hour interval between consuming 
the meal and tea will improve iron absorption by attenuating the inhibition effect of 
tannin component in tea. With 1-hour time interval, total iron absorbed is increased 
and found to be almost equal to when water is consumed with the meal (0.19 mg). 
Consistent with the extensive body of literature, this study also demonstrated that 
higher body iron storage (represented by plasma ferritin concentrations) is linked to 
low total iron absorbed. Interestingly, with little evidence available from the previous 
iron absorption studies, it was shown in the present study that higher plasma 
hepcidin concentrations are also associated to low total iron absorbed, 
strengthening the existing body of literature that demonstrated the role of hepcidin 
as an iron absorption regulator at systemic levels.  
5.2.1 Inhibition effect of tea consumption on iron absorption 
In agreement with the previous studies, the present study showed that tea plays a 
significant role in reducing non-haem iron absorption, by at least 37%. Despite the 
differences in test meal used, study population or isotopes used, with previously 
published studies, a similar outcome of reduced iron absorption with tea 
consumption was demonstrated. Table 5.1 compares the iron absorption (%) 
reported in previous studies in which test meals were administered with either water 
(as a control) or tea (intervention) to illustrate the inhibition effect (%). The 
percentage of inhibition effect shown in the current study was relatively low (37%), 
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compared to a range of between 26-99% from the previous studies. The wide range 
of inhibition effects reported in these studies may be due to the fact that there were 
differences in tea brewing time, tea brands, and also total amount of tea used during 
the intervention which may have influence the phenolic concentration when tea is 
administered (Hallberg & Hulthén, 2000).  
The present study also demonstrated that the iron absorption ratio was 0.65 when 
the test meal administered with tea, compared to when administered with water 
(control) which indicates a relatively low inhibition effect of tea. A lower  absorption 
ratio of 0.28 was reported by Morck et al. (1983) when a standard meal of 
hamburger was administered with tea, compared to water, which amounts to a 64% 
inhibition effect. The same study found a much lower absorption ratio of 0.09 with 3 
grams of coffee, compared to ratio of 0.17 when 1.5 grams coffee was used, 
indicating a lower percentage of inhibition effect. Thankachan, Walczyk, Muthayya, 
Kurpad, and Hurrell (2008) compared different concentrations of tea and also found 
a lower absorption ratio of 0.51 (150 ml) compared to 0.34 when using a higher 
concentration of tea (300 ml) and it was suggested that an absorption ratio of <1.0 
implies an inhibition effect of tea. A similar absorption ratio (tea/water) was reported 
by other studies using different test meals with 0.3 (Kaltwasser et al., 1998), 0.03-
0.53 (Hurrell et al., 1999) and 0.7 (Samman et al., 2001).  
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Table 5.1 Inhibition effect (%) of tea consumption on iron absorption (%) in comparison to water as control beverage 
Study Population / Mean age (±SD) or range (years) Test meals Absorption (%) 
   Meal 
(water) 
Meal 
(tea) 
Inhibition 
% 
Reference 
iron dose 
Present  Healthy women (n=12) / 24.8 ± 6.9 Porridge + 200 ml tea  5.7 3.6 37 25.36% 
[1]  Healthy women (n=8) / 26-60 Bread + 200 ml black tea 10.4 3.3 68 35.8%. 
  Rice & soup + 200 ml black tea 10.8 2.5 77 34.7%. 
[2]  Healthy women (n=22) / 21-71 Maize porridge + 150 ml black tea 3.8 2.1 45 50.5%. 
[3]  Thalassemia patients (n=5) / 11-23 Hamburgers + 240 ml tea 15.6 5.2 67 NA 
[4]  Healthy adults (n=37) / 18-50 Beef hamburger + 200 ml tea 3.71 1.32 64 15.73%. 
[5]  Haemochromatosis patients (n=18) / 47.4 ± 
16.1 
Homogenised rice & beef + 200 ml tea 22.1 6.9 69 NA 
[6]  
 
Healthy adults (n=77) / 19-40 
 
 
 
 
 
 
 
 
 
 
Bread  roll + 275 ml tea 
275 ml tea (n=9) 
275 ml tea (n=10) 
275 ml tea (n=10) 
275 ml tea (n=10) 
100% strength (n=9) 
50% strength 
25% strength  
25% strength (n=9) 
10% strength 
5% strength 
 
12.9 
5.63 
4.46 
8.64 
6.58 
 
 
4.33 
 
0.74 
0.89 
0.92 
0.83 
0.59 
1.05 
0.06 
1.18 
1.48 
1.47 
 
94 
84 
79 
90 
91 
84 
99 
73 
66 
66 
 
NA 
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[7]  Healthy women (n=10) / 26 ± 4 Pasta + bread + 4ml green tea extract 12.1 8.9 26 38.6 
[8]  
 
IDA and healthy women (n=20)/ 18-35 
Iron deficient anaemia group (22.6 ± 3.5) 
 
Iron replete group (24.3 ± 2.9) 
Tomato rice + tea (different amount) 
150 ml tea 
300 ml tea 
150 ml tea 
300 ml tea 
 
18.2 
19.7 
7.5 
5.2 
 
7.1 
5.6 
3.5 
1.6 
 
61 
72 
53 
69 
 
NA 
*[1] Disler et al., 1975 (India), [2] Derman et al.,1977 (India), [3] De Alarcon., 1979 (Italy), [4] Morck et al., 1983 (USA), [5] Kaltwasser et al., 1998 (Germany), [6] Hurrell et al., 
1999 (USA), [7] Samman et al., 2001 (Australia), [8] Thankachan et., al 2008 (India) 
*Inhibition effect (%) = [meal (water) – meal (tea)] x 100 
      meal (water)  
*All meals were extrinsically labelled with either stable or radio isotopes except the second sub-study of [1] 
*[1 & 9]: stable iron isotopes; [2-8]: radio iron isotopes 
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To the best our knowledge, there is limited evidence to date on the mechanism of 
how tea may inhibit iron absorption, especially based on human trials, and the 
present study was not designed to investigate the mechanism behind the inhibition 
effect of the tea component per se. The only assumption proposed to date, based 
on human data, is that polyphenol-containing tannins in tea are responsible for the 
disruption of non-haem iron absorption (Disler et al., 1975a), as a result of  the 
formation of insoluble iron-tannin complexes at luminal level that leads to 
interference of the absorption (Morck et al., 1983). The assumption was based on 
the inhibition effect observed when tea was administered with simple iron salt 
solutions, or the specific meal used in the study which is related to the Indian 
population. Our findings show similar outcomes, however, differ in the test meal 
used, which was specific to a typical UK breakfast meal, possibly explaining the 
difference in the percentages of iron absorption and the inhibition effect (Table 
2.18). To further establish that tannin in tea causes the uptake interference, Disler et 
al. (1975b) carried out an animal study using 10 Sprague-Dawley male rats that 
were fed iron salts with either (a) tea; (b) tea tannin solution; (c) tannin-free tea; (d) 
tannic acid solution and (e) caffeine. It was shown that mean (±S.D) iron was 
absorbed approximately 3-fold more with tannin-free tea (49.6 ± 7.5%) compared to 
tea (13.8 ± 5.6%), verifying the effect of tannin content in tea on iron absorption. It 
was further suggested that apart from just tannin, the inhibition effect was due to 
high concentrations of galloyl esters (3 galloys) (Brune et al., 1989) in black tea, 
after Hurrell et al. (1999) observed a higher inhibition effect in black tea compared to 
herbal teas, wine or cocoa (Table 5.1).  
However, it should be noted that these iron absorption studies that investigated the 
mechanism were carried out in cell lines or animal models, not humans, and findings 
cannot be extrapolated directly to humans. 
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5.2.2 One-hour time interval effect of tea consumption on iron absorption 
In addition to investigating the effect of tea in diminishing iron absorption, the 
present study also aimed to explore the time interval effect between tea 
consumption and an iron-containing meal. To the best of our knowledge, the impact 
of time interval has not been investigated in human subjects, with respect to a 
specific UK diet, and the outcome may be particularly beneficial for the controlling of 
iron deficiency in at-risk groups such as reproductive-aged women. Findings in the 
present study that a 1-hour time interval between administering tea and a porridge 
meal substantially reduces the inhibition effect by increasing iron absorption by at 
least 1.6-fold supports the findings from previous studies carried out in rats (Disler et 
al., 1975b).   
In the present study, it was primarily postulated that iron absorption would be 
highest in TM I (meal + water), followed by TM III (meal + tea + 1 hour) and lowest 
in TM II (meal + tea) as it was predicted that tea, consumed simultaneously with a 
meal would impede iron absorption the most.  
Even though TM III (meal + tea + 1 hour) exhibited the highest percentage of 
absorption  compared to the TM I (meal + water) which serves as a control, the 
difference in iron absorption between these 2 test meals was not significantly 
different (p=0.335). This is shown in the total iron absorbed, with 0.23 mg in TM I 
and 0.19 mg in TM III. As expected, it was demonstrated that the iron absorption (%) 
was significantly higher when a 1-hour time interval was allowed before tea was 
administered after the test meal (TM III), as compared to when tea was administered 
simultaneously with the meal (TM II), which amounts to a total of 0.04 mg more iron 
was absorbed with 1-hour time interval. However, few studies have been carried 
out, providing limited evidence to support findings on the time interval effect, 
particularly in human studies. In an animal study carried out by Disler et al. (1975b), 
it was demonstrated that the time interval between administration of tea and iron salt 
solutions had a significant impact on weakening the inhibition effect, when tea was 
administered at several interval times up to the maximum of 3 hours before (as 
opposed to ‘after’ in the present study) iron solutions were administered. A linear 
association between time intervals and iron absorption was observed, and iron 
absorption was found to be approximately 2-fold higher if the tea was administered 1 
hour before. This is different in the present study because the tea was administered 
after the meal instead of before as in the Disler et al. (1975b) study, but iron 
absorption increased by a similar magnitude of 1.6-fold.  
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The findings from Disler’s study, however, need cautious interpretation as the study 
was an animal study, which cannot be directly extrapolated to humans. In addition, 
the study utilised simple salt solutions instead of a complex test meal containing 
various iron enhancers or inhibitors, which may prompt nutrient interactions that may 
also affect iron uptake. 
Another intervention employing same study design was carried out to investigate 
this time interval effect used coffee, another phenolic-containing beverage, 
administered with a hamburger as the test meal (Morck et al., 1983). However, 
coffee was found not to cause further inhibition if administered 1 hour later (4.55%) 
compared to when it was administered simultaneously with the hamburger (4.58%), 
even though iron absorption was reduced by at least 40% when water was 
administered with the hamburger meal (8.12%). 
It was postulated that the same chelating mechanism occurred at a luminal level 
caused by coffee, similar to that suggested in tea. This mechanism is explained by 
the binding between a phenolic component and iron which is believed to have 
occurred via either catechol or galloyl group (Khokhar & Apenten, 2003), by forming 
an insoluble complex with metal cations in iron (Bravo, 1998).  
There is no established mechanism relating to how a 1-hour time interval will aid in 
counteracting the inhibitory effect of tea on iron absorption, however, after the non-
haem iron has been reduced to a ferrous state and pooled together with haem iron 
in the enterocyte, iron is expected to be chelated by other compounds to form 
insoluble complex, if not bound to ferritin (Steele et al., 2005). As the tea was 
administered only 1 hour after the meal, it could be stipulated that the non-haem iron 
is absorbed normally, as when it was administered with water, without forming 
complexes with any inhibitor, which in this case is tannin in tea, and transported 
directly to basolateral membrane, leading to a higher iron absorption. This is 
observed in the present study as the similar magnitude of absorption shown 
between TM I (meal + water) and TM III (meal + tea + 1 hour) at 5.69% and 5.73%. 
It was also suggested by Miret, Simpson, and McKie (2003) that as critical as it is to 
quantify the duration that iron is in contact with the duodenal surface to determine 
iron absorption rate, there is very scarce and contradictory evidence available.  
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5.2.3 Limiting factors of iron absorption 
Depending on the conditions and chemical forms of iron itself (haem/non-haem), the 
overall fractional iron absorption (%) absorbed by individual is reported to be 
classically low, ranging from as low as 5% to as high as 35% (Abbaspour et al., 
2014). It can be presumed that the nature of the cereal-based meal is the main 
grounds of the low iron absorption observed in the present study, as the porridge is 
low in iron content but also contains phytates which has been identified as an iron 
absorption inhibitor. It is also possible that as the participants were generally iron 
replete (60% not iron deficient), the body iron requirement was minimal, thus 
explaining the low iron absorption. The low iron absorption observed may be 
attributable to two key aspects: (a) meal-related factors and (b) host-related factors.  
5.2.3.1 Meal-related factors 
It was shown in the study that iron was poorly absorbed from a porridge meal, which 
is the most consumed breakfast (38% as reported in the latest NDNS) amongst 
women in the UK (Bates et al., 2014). Based on the nutritional information provided, 
the instant porridge used in the study did not have any known native iron or added 
iron as fortifiers, but it was reported in a study carried out by Bruggraber et al. 
(2012) which re-analysed iron content of selected UK plant-based foods using 
spectrometer, that iron content of instant porridge was 13.28 mg. This shows that 
the fractional iron absorbed from the porridge in the present study may be 
acceptable, considering the native iron in the oat porridge itself is already low and 
the dose of 57Fe administered with each test meal was 4 mg. In addition, the lower 
iron absorption demonstrated in the present study is consistent with the amount iron 
absorbed (%) in previous studies that have used the cereal-based meals (Table 
5.2).  
Previous studies have reported a wide range of fractional iron absorption values, 
between 0.56 – 18.8%. The lowest absorption of 0.33% was reported in a study 
carried out in the US by Hurrell, Reddy, Burri, and Cook (2002) that used 50 g of 
extruded oats, prepared by adding 300 ml boiling water to be consumed as oat 
porridge, which is analogous to the test meal in the present study, but reported 
lower iron absorption. The highest absorption of 18.8% was demonstrated in a study 
carried out using roller-dried cereal as a test meal made from wheat flour, enriched 
with erythorbic acid:iron at molar ratio of 4:1, which explains the high iron absorption 
as the same test meal without the addition of enhancer led to an absorption of 4.1% 
(Fidler et al., 2004).   
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Table 5.2 Previous studies that have used cereal-based test meal with native iron and phytate contents  
Study/Country Participant/age 
range 
Test meals Iron absorption (%) 
 
Native iron 
content (mg) 
Phytate content 
(mg) 
Layrisse et al. (2000) 
Venezuela 
Adults (n=130) 
15-50 years 
Corn flour meal (C) 
Corn flour meal (T) 
5.1% 
7.9 – 13.2% 
1.5 mg 168 mg 
 
 
 
Mendoza et al. (2001) 
USA 
Women (n=14) 
19-42 years 
Wild porridge (C) 
Low phy porridge (T) 
1.69 - 5.73% 
1.91 - 5.40% 
3.4 mg 817 mg 
361 mg 
 
 
Davidsson et al. 
(2001) 
Peru 
Children (n=47) 
6-7 years 
Cereal drink (C) 
Cereal drink (T) 
2.2 – 2.9% 
3.5 – 3.8% 
2.3 mg 122 mg 
 
 
 
 
Hurrell et al. (2002) 
USA 
Adults (n=39) 
19-39 years 
Rice flour 
Maize flour 
High extraction wheat  
Low extraction wheat  
1.82% (C) to 1.76 - 5.49% (T) 
3.52% (C) to 2.92 – 4.17% (T) 
0.57% (C) to 0.56 – 0.99% (T) 
7.44% (C) to 4.92 – 13.6% (T) 
N/A 72.5 – 96 mg 
150 - 168 mg  
118 – 195 mg 
60 – 61 mg 
 
 
Fidler et al. (2004) 
Switzerland 
Women (n=10) 
20-26 years 
Wheat cereal (C) 
Wheat cereal (T) 
4.1% 
10.8 – 18.8% 
0.6 mg 
 
84 
 
 
(T): Test meal was treated to reduce phytate content 
(C): Control test meal without any treatment or addition of fortifiers 
Iron absorption (%) that is reported in range indicates more than one treatment were used for each test meal in the specified study 
Layrisse et al. (2000); Mendoza et al. (2001); Davidsson et al. (2001); Hurrell et al. (2002); Fidler et al. (2004) 
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According to a recent review by Beck et al. (2014), there are inconsistencies in 
findings related to non-haem iron absorption and that iron absorption is affected by 
different elements in the diet itself. For example, mineral bioavailability has been 
shown to be impaired in the presence of phytates that are found in high proportion, 
particularly in oat products (Larsson, Rossander-Hulthén, Sandström, & Sandberg, 
1996). The phosphate component in Myo-inositol (1,2,3,4,5,6)-hexakis- phosphoric 
acid, which is  negatively charged under specific physiological conditions is reported 
to be capable of forming iron-phytate complexes with cations of minerals such as 
zinc, calcium or magnesium, including iron (Nielsen et al., 2013), which results in 
chelation of the cations, causing interference in iron absorption, especially in the 
intestines where the pH is neutral, compared to the acidic environment in the 
stomach where the complex can still be absorbed (Schlemmer, Frølich, Prieto, & 
Grases, 2009). As of the most potent inhibitors of iron absorption besides 
polyphenols (Siriporn, Kunchit, Christophe, & Emorn, 2006), phytates can be found 
widely in plant-based food sources such as cereals and legumes (Schlemmer et al., 
2009). Varied in its amounts, phytates can be found at levels of between 0.05 – 
3.29% in ready-made cereal products, except instant oat porridge, which was used 
as test meal in the present study. Instant oat porridge has been analysed to contain 
a lower amount of phytates at approximate levels of 0.5 – 0.68% (Reddy, 2002). It 
was proposed that a molar ratio of <1:1 of phytates: iron in a meal will counteract 
the inhibition effect of phytates on iron absorption, even though it was shown that at 
a ratio as low as 0.2:1, phytates can still interfere with the absorption of iron (Hurrell 
et al., 2002).  
Cook, Reddy, Burri, Juillerat, and Hurrell (1997) also supported the link between 
phytate content and fractional iron absorption, by demonstrating a substantial 
inverse association between these 2 parameters from a cereal-based meal (r=-
0.801 with p<0.02). It was also demonstrated in previous studies (Table 5.2) that 
fractional iron absorption (%) was generally increased when the test meals were 
either treated with a process to reduce phytate content, or by adding certain 
enhancers such as ascorbic acid to enhance the absorption. For instance, a study 
by Hurrell, Reddy, Juillerat, and Cook (2003) using different sources of cereal-based 
meals (oat, rice, maize, wheat, wheat-soy, sorghum) established that the removal of 
a phosphatase group by a process known as dephytinitisation that reduce phytate 
content aids in improving iron absorption by at least 2-fold to a maximum of 12-fold.  
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The fractional iron absorption reported between control and treated test meal were 
1.73 to 5.34% (rice); 0.33 to 2.79% (oat); 1.8 to 8.92% (maize), 0.99 to 11.54% 
(wheat); 0.94-1.52% to 1.26-3.1% (different type of sorghums); and 1.15 to 3.75% 
(wheat-soy), showing significantly higher absorption ratios for all test meals except 
for one type of sorghum. It was also found that the highest iron absorption (11.5%) 
was exhibited with the lowest proportion of phytates from the treated wheat group 
compared to control (0.99%), establishing that reduced amount of phytates helps in 
increasing the fractional iron absorbed.  
Most of the specified studies in Table 5.2 reported a small amount of native iron, 
ranging between 0.6 – 3.4 mg per test meal and it is observed that the treated test 
meals, either with degradation of phytates content or addition of other 
enhancers/fortifiers to offset the effect of phytates in cereal-based meals showed a 
higher fractional iron absorption compared to the control test meal. However, no 
means of measuring phytates nor native iron content were carried out in the present 
study, which future research should take into account so that a fair comparison can 
be made in terms of the effect of phytates or native iron in the test meal.  
5.2.3.2 Host-related factors  
According to a review by Gibson (2007), host-related factors could be branched into 
2 different elements of (a) systemic aspects which include age, nutritional & 
physiological status; and (b) intestinal aspects which may have a substantial effect 
on iron digestion and uptake. The latter factor is controlled in the present study by 
excluding women who have a history of gastro-intestinal related illness, however, 
the individual’s systemic requirement is a difficult aspect to control, except by using 
a reference iron dose. The use of a reference iron dose which corrects inter-
variability between participants’ iron status enables comparisons to be made 
between different studies. To reduce the confounding factors, fractional iron 
absorption in the current study was normalised to 40% using a published equation 
(Bjorn-Rasmussen et al., 1977), as participants with depleted iron storage have 
been shown to have an average iron absorption of 40% (Hallberg & Hulthén, 2000).  
A potential explanation as to why a lower iron absorption was observed in the 
present study compared to other studies, based on host-related factors, with 
particular relevance to nutritional status, could be due to the fact that the majority of 
the participants (60%) in the present study were not anaemic nor iron deficient, 
based on haemoglobin and plasma ferritin concentrations.  
 176 
 
This is supported by the low mean (±S.D) absorption of the reference iron dose 
(25.36 ± 18.27%) compared to previous studies that reported a higher absorption of 
iron from both test meals and reference dose (Table 5.1). The iron status of the 
participants may be one of the reasons that influence iron absorption, which is 
consistent with findings reported in previous studies. In a study carried out by 
Derman et al. (1977), it was reported that the mean absorption from an iron 
reference dose was 50.5%, indicating that majority of the participants were deficient, 
therefore the iron requirement was high (Kuhn, Monsen, Cook, & Finch, 1968), 
leading to a higher iron absorption. Thankachan et al. (2008) measured iron 
absorption from a rice meal, comparing iron deficiency anaemia (IDA) and iron 
replete participants, and demonstrated that iron absorption was, in fact, showing a 
magnitude towards a higher absorption in the IDA group (7.1%) compared to control 
group (3.5%) (p=0.26) suggesting that iron status may have an impact on the level 
of iron absorbed and is dependent on physiological requirements. This inverse 
association between body iron storage and iron absorption has also been 
demonstrated by a large number of previous iron absorption studies, implying that 
the need for iron depends on individuals’ ferritin concentration.  
However, unlike the previous studies, in addition to measuring absorption using iron 
stable isotopes and iron status biomarkers such as plasma ferritin concentration, the 
peptide hormone plasma hepcidin concentration was also measured in the present 
study in order to examine its role in regulating iron homeostasis. It has previously 
been suggested that hepcidin is associated with regulation of iron uptake, by 
internalising ferroportin, causing it to be unavailable to transport iron into the blood 
stream (Nemeth & Ganz, 2006). A significant inverse association between hepcidin 
concentrations and iron absorption has been reported in few studies carried out to 
date, in various settings, with different test meals used.  
Our finding that iron absorption and plasma hepcidin concentrations are inversely 
associated is consistent with previous studies, even though a different test meal was 
used. Young et al. (2009) demonstrated similar associations (r value not provided) 
when sweet potato meal (p=0.038) and ferrous sulphate supplements (p=0.0296) 
were used. A study carried out by Zimmermann et al. (2009) to investigate the 
relationship between hepcidin and iron absorption using 3 different iron compounds 
labelled in a rice meal observed a significant inverse association between hepcidin 
and ferrous sulphate (r=-0.46, p<0.001) and ferrous fumarate (r=-0.44, p<0.001). An 
inverse association was also observed, in healthy male subjects who consumed 
fortified cereal products (r=-0.55, p<0.001) in a different study by Roe et al. (2009).  
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It should be noted that, to the best of our knowledge, there are limited studies that 
measure hepcidin concentration in iron absorption studies. The present study was 
the only iron absorption study carried out in the UK population investigating the 
effect of tea consumption, assessing two different time intervals, on iron absorption 
which measured plasma hepcidin concentration, hence limited comparison can be 
made with existing published evidence. 
5.2.4 Clinical implications of findings  
On the strength of the findings of the present study, it may be practical to advise the 
at-risk groups of iron deficiency to allow at least 1-hour time interval between tea 
and meal consumption. This is to avoid probability of complex formation between 
tannin in tea and iron in meal which may render iron absorption, and ultimately 
improves the iron uptake leading to better iron status overall. In a country where 
drinking tea is considered to be a norm, if not tradition, with 67% of the population 
older than 10 years reported to consume an average of 3 cups of tea daily (Khokhar 
& Magnusdottir, 2002), these findings should be critically addressed. In 
consequence, this findings, consistent with existing body of literature, may have 
major implication especially when tea is not only widely consumed in the UK (Nelson 
& Poulter, 2004), but extensively consumed worldwide.  
The clinical aspects of the findings in the present study may be particularly applied 
to iron deficient at-risk groups or in areas where iron deficiency is prevalent and 
daily iron intake is predominantly from plant-based sources. Even though the 
western diet, or in particular, the UK diet, did not predominantly consist of plant-
based sources as the main component, a European Prospective Investigation into 
Cancer and Nutrition (EPIC)-Oxford cohort study showed that 33% (n=15459) of the 
adults aged ≥ 20 years recruited in the study were vegetarian. A higher proportion of 
the vegetarians were women (n=11519) as opposed to men (n=3940), with 60% of 
the women vegetarian were in the 20-39 years age group and 41% had university 
degree or equivalent (Crowe, Appleby, Allen, & Key, 2011). Premenopausal women 
are known as one of the at-risk groups of iron deficiency, and it was showed that 
vegetarian trend is growing popular in the UK adults especially young 
premenopausal women, hence the importance of findings demonstrated in our 
study.  
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It is well-established that with iron deficiency, the iron demands are physiologically 
high, and the implication on the iron absorption, or iron status in general, would be 
even more significant as drinking tea with the meal will intensify the inhibition effect. 
The consumption of orange juice, which is known to be high in vitamin C with the 
meal may be one of the alternatives as a means of enhancing iron absorption in 
addition to allowing at least a 1-hour time interval.  
The DRV of iron dietary intake for women was recommended as 14.8 mg/day taking 
into consideration the menstrual losses, but with the assumption that there will be 
15% of iron absorbed from dietary-based sources (SACN, 2010). However, the 
present study demonstrated that the overall iron absorption from a porridge meal 
was no higher than 6%. Cereal and cereal-based products has been reported to be 
the most consumed breakfast by UK women in the NDNS population data (Bates et 
al., 2014). Geissler and Singh (2011) in the review on iron argued that the DRV 
proposed for dietary iron intake was on the higher side, and the recommendation 
was generated by not considering the adaptive response, and based on short-
duration studies. The authors suggested that re-appraisals of the DRV are required 
(Geissler & Singh, 2011), and it would be practical for policy makers related to 
nutrition to take into account the strength of findings of the present study. The 
present study also demonstrated that a 1-hour time   interval between meal and tea 
consumption is a successful strategy to counteract the tea inhibitory effect on iron 
absorption, therefore, the findings are beneficial and can be utilised as one of the 
ways to maximise iron absorption, in addition to the existing general advice 
recommended by the WHO in the report on the management of IDA 
(WHO/UNICEF/UNU, 2001). The finding may be crucially useful and can be 
incorporated as part of dietary advice at healthcare level to improve quality of diet in 
general, or in particular on how to ensure optimal iron absorption. 
It will be particularly useful in population that is prone to iron deficiency, to avoid the 
possibility to advance into the use of iron supplements as means of controlling iron 
deficiency which is known to associate with various adverse events and low 
compliance. Additionally, the findings can be particularly beneficial in preventing the 
development of iron deficiency or anaemia, by alerting the healthy population on the 
effect of consuming tea simultaneously with meal.    
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Tea consumption, however, should not be completely omitted in individual’s dietary 
intake as tea has been demonstrated in various studies to have health benefits, for 
instance, in the prevention of cardiovascular disease or cancer and also its potential 
role as antioxidants (Vuong, 2014). Additionally, tea has been found to be clinically 
useful in thalassemia patients, for the management of iron overload (de Alarcon, 
Donovan, Forbes, Landaw, & Stockman III, 1979), despite its potent inhibitory effect 
in iron absorption.  
The links between iron absorption, iron stores (plasma ferritin concentrations) and 
iron regulator (plasma hepcidin concentrations) demonstrated in the first part of the 
research (Chapter 3), is connected to the hypothesis formulated in the second part 
of the research (Chapter 4).  
The second part of the research was designed to address the iron utilisation aspect, 
by measuring iron status of iron deficient women including the concentration of 
plasma hepcidin that is known for its role as systemic iron regulator. It is evident in 
the body of literature that ascorbic acid is capable of increasing iron absorption, and 
vitamin D has recently been demonstrated to have a similar potential, but with an 
unclear underpinning mechanism. Hepcidin is known for its role in regulating iron 
metabolism, and the role of vitamin D is recently postulated to occur by suppression 
of hepcidin expression (Smith et al., 2016a), however, little evidence is available 
especially from human trials. The main research hypothesis of the second study was 
to investigate the effect of daily vitamin D3 supplementation, as a potential novel 
iron absorption enhancer, on the iron status recovery of women with low iron stores.  
The study was an 8-week double-blind randomised controlled trial, in which 
participants were required to consume vitamin D3 or placebo with iron-fortified 
breakfast cereals and iron status was assessed at week 0, 4 and 8. The key findings 
of the present study support the study hypothesis and verify the role of vitamin D in 
iron regulation, by demonstrating a conclusive effect of vitamin D3 in improving 
participants’ iron status, indicated by increased in haemoglobin concentrations and 
haematocrit levels. It was also demonstrated that the upregulation of vitamin D 
binding protein, which is the carrier of the circulating form of vitamin D, led to 
improvement in participants’ iron status biomarkers. The supporting mechanism that 
connects the vitamin D, upregulation of vitamin D binding protein and improvement 
of iron status is unclear, but the information gathered is sufficient to warrant future 
investigations.  
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5.3 EXPERIMENTAL STUDY 2 (CHAPTER 4) 
The present study investigated the effect of supplementation with a high daily dose 
of vitamin D3 (1500 IU), consumed with an iron-fortified breakfast cereal (9 mg/day) 
on iron status. The study was designed to determine the effect of vitamin D as a 
potential novel iron absorption enhancer, as well as to assess the efficacy of using 
an iron-fortified breakfast cereal as a tool for improving iron status in women with 
marginal and low iron stores.  
The study used a combination of supplementation and fortification strategies to 
improve iron status of iron deficient women. Improvement in the iron status was 
presumed to occur in both, vitamin D and placebo groups, as both groups 
consumed the fortified cereal, though it was hypothesised that there would be a 
greater improvement in the vitamin D group. To the best of our knowledge, there is 
no evidence from RCTs investigating the effect of vitamin D, as a potential novel 
iron absorption enhancer, consumed in supplement form simultaneously with iron-
fortified foods, on iron status. The present study found that daily consumption of 
vitamin D3, with iron-fortified breakfast cereal, led to improvement in haemoglobin 
concentrations and haematocrit levels in women with marginal and low iron stores. 
5.3.1 Effect of vitamin D supplementation, consumed with an iron-fortified 
breakfast cereal on participants’ iron status 
Overall compliance of vitamin D3 supplementation was good (93%), and not 
significantly different between the groups. As expected, plasma 25(OH)D 
concentration increased at each time point in the vitamin D group, and was 
significantly higher compared to the placebo group. This shows that the vitamin D3 
supplements used in the study were effective in improving participants’ mean ±S.D 
vitamin D status, from insufficient levels at baseline (35.0 ± 19.8 nmol/l) to sufficient 
levels at post-intervention (62.2 ± 16.1 nmol/l) based on the threshold proposed by 
the IOM (Ross et al., 2011). Interestingly, there was a significantly lower mean 
(±S.D) plasma 25(OH)D concentration at post-intervention (34.15 ± 23.56 nmol/l) 
compared to 4-weeks (38.25 ± 27.10 nmol/l) in the placebo group. Recent NDNS 
population data reported that mean (±S.D) serum 25(OH)D concentrations in adults 
aged 19-64 years were 45.6 ± 22.7 (Oct-Dec) and 34.8 ± 22.9 nmol/l (Jan-Mar) 
(Bates et al., 2014). The plasma 25(OH)D concentrations observed in the placebo 
group at all time points were consistent with the NDNS data, as the study 
commenced in September, paused during the Christmas period, resumed in 
January and was complete by April.  
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The key finding of the present study was that vitamin D3 supplementation was found 
to be effective in the improvement of two key iron status indices; haemoglobin 
concentration and haematocrit level. Haemoglobin concentrations reflect the 
presence or absence of anaemia and oxygen-carrying capacity required for normal 
cell functions, whilst haematocrit levels indicates the proportion of circulating RBCs 
relative to whole blood total volume. The shifts (increase or decrease) in these two 
key indices of iron status are typically interrelated (George-Gay & Parker, 2003). 
The change in haemoglobin concentration and haematocrit levels were significantly 
higher in the intervention group (0.36 g/dl, 1.82%) as opposed to the placebo group 
(-0.28 g/dl, -0.51%). It can be observed that these two biomarkers were improved in 
the intervention group, whilst diminishing in the placebo group, suggesting that daily 
consumption of iron-fortified cereal with vitamin D supplements, compared to only 
iron-fortified cereal, exerts additional effect on iron absorption and iron status.  
Additionally, it was observed in the present study that baseline concentrations of 
both haemoglobin and plasma 25(OH)D significantly influenced participants’ 
response to the intervention. It was observed that there were larger and significant 
improvements in the RBC counts (r=-0.534, p=0.0001), haematocrit levels (r=-0.388, 
p=0.009), and haemoglobin concentrations (r=-0.486, p=0.001) if the participants 
were anaemic at baseline. The mean (±S.D) baseline concentration of haemoglobin 
was 13.4 ± 1.4 g/dl, and 1/8 of the participants were anaemic based on the WHO 
threshold of <12 g/dl (WHO/UNICEF/UNU, 2001). A greater improvement in these 
biomarkers may have been observed with a higher proportion of anaemic 
participants at baseline, however, it was evident in the present study that the 
baseline concentration of haemoglobin dictates the participants’ response to the 
intervention. The mean (±S.D) baseline concentration of plasma 25(OH)D was also 
found to influence the response to intervention. Greater improvement was observed 
in the RBC counts (r=0.339, p=0.0001), haematocrit levels (r=0.199, p=0.018), and 
haemoglobin concentrations (r=0.208, p=0.014), if the participants were not vitamin 
D deficient at baseline. The mean (±S.D) baseline concentration of plasma 25(OH)D 
concentration was 36.8 ± 23.6 nmol/l, and 62% of the participants were vitamin D 
deficient based on the threshold of <30 nmol/l by the IOM (Ross et al., 2011). This 
shows that consumption of the iron-fortified breakfast cereal provided in the present 
study, with that additional vitamin D, may have led to the recovery of iron status, 
aided by improving participants’ vitamin D status. 
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Interestingly, it was also observed in the present study that the improvement in 
plasma VDBP concentrations were strongly associated with the recovery of the RBC 
counts (r=0.653, p=0.002), MCV (r=0.612, p=0.004), haematocrit levels (r=0.751, 
p=0.0001), haemoglobin (r=0.638, p=0.002) and MCH concentrations (r=-0.592, 
p=0.006). This suggests a possible indirect connection of the potential role of 
vitamin D as an iron absorption enhancer, as VDBP is known as its role as the 
25(OH)D transporter in the vitamin D metabolism. VDBP is a carrier protein that 
functions as the 25(OH)D transporter, and approximately 90% of 25(OH)D or 
1,25(OH)D are reported to be bound to VDBP, with the remaining 10% normally 
bound to albumin, and 1% as the free form (Chun et al., 2014). The upregulation in 
the concentration of plasma VDBP may have contributed in the mechanism of action 
of plasma 25(OH)D in the enhanced participants’ iron status observed in the current 
study.  
In the present study, it was observed that anaemia (13%) and iron deficiency (61%) 
was present in the participants with plasma 25(OH)D concentrations <30 nmol/l at 
baseline, which is the threshold that the present study used to define VDD. As 
anticipated, the proportion of VDD participants, was halved at post-intervention. 
Supporting the existing literature from various observational studies that 
demonstrated concurrent incidence of both anaemia and vitamin D deficiency (VDD) 
in the same individuals (Jin et al., 2013; Sharma et al., 2015; Shin & Shim, 2013; 
Sim et al., 2010) (detail is discussed in Section 3.1.3.1, page 126), the reduction in 
VDD prevalence in the present study also led to slightly reduced in anaemia 
prevalence (12%). This observation may have also supported the role of vitamin D 
in improving iron status in participants in the present study. However, the 
mechanism of action of vitamin D on iron regulation is unclear.    
It was hypothesised in the present study that the action of vitamin D on the recovery 
of iron status occurs via the mechanism by which vitamin D suppresses plasma 
hepcidin expression, which leads to increase in ferroportin availability for iron uptake 
and ultimately increases plasma ferritin concentration in participants with low iron 
stores. The hypothesis was based on a recent in vivo study by Bacchetta et al. 
(2013) which observed that single bolus oral ingestion of 100 000 IU vitamin D2 led 
to significant decrease in serum hepcidin concentrations at 24 (34%, p<0.05) and 72 
hours (33%, p<0.01). It was also observed in the same study that vitamin D had a 
potent effect of on transcription of the HAMP, the gene that regulates hepcidin 
expression.  
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However, in the present study, no significant effect of vitamin D supplementation on 
hepcidin response was observed, despite the non-significant decrease observed in 
the vitamin D group at post-intervention. It was noted in the present study that 
plasma hepcidin concentrations measured were lower than the normal range 
suggested by Ganz et al. (2008) for a healthy population, however, this is expected 
as the participants recruited in the study were iron deficient. Serum hepcidin 
concentrations were reported to be undetectable in 18-19 iron deficient patients in 
the study carried out by Ganz et al. (2008) who developed and validated the first 
ELISA assay specific for hepcidin. The non-significant observation is postulated to 
contribute to the fact that insufficient dose of vitamin D3 was used in the present 
study. Bolus high dose of vitamin D2 used in the pilot study by Bacchetta et al. 
(2013) was probably sufficient to suppress the hepcidin expression, as opposed to 
1500 IU dose utilised in the study, hence, the non-significant impact observed in the 
plasma hepcidin concentrations. A specific dose of 1500 IU vitamin D3 was used in 
the present study as the study carried out by Toxqui et al. (2013), which to the best 
of our knowledge, was the only study that was carried out using a similar study 
design have used a low vitamin D dose of 200 IU that was incorporated in the 
fortified foods, and did not include the measurement of plasma hepcidin 
concentration in the study. 
The concentration of plasma ferritin, which is used to signify iron stores in the 
present study was found to be similar at post-intervention relative to baseline, 
following the intervention indicating no improvement was observed in recuperating 
participants’ iron stores. Despite the non-significant recovery of iron stores, mean 
(±S.D) plasma ferritin concentration showed an increasing trend in the intervention 
group from baseline (14.07 ± 7.68 µg/l) to post-intervention (15.95 ± 10.80 µg/l), and 
participants were no longer deficient at the end of study period, if ferritin threshold of 
<15 µg/l by WHO is used (WHO/UNICEF/UNU, 2001). The improvement in plasma 
ferritin concentration was higher, but not significant in the intervention group (1.87 
µg/l), as opposed to placebo group (1.46 µg/l). The present study included 
participants with a wide range of iron stores background (plasma ferritin 
concentration < 20 µg/l), which extends from marginally low to low iron stores, which 
may have contributed to the non-significant observation in the plasma ferritin 
concentration. The threshold used in the present study was justified based on 
studies that defined marginal ID as between 12-20 µg/l (Ahmed, Coyne, Dobson, & 
McClintock, 2008; DellaValle & Haas, 2011).  
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However, additional analysis carried out in sub-sample of participants who had 
plasma ferritin concentration of < 15 µg/l at baseline, revealed only a slight increase, 
(albeit non-significant) from baseline to post-intervention in both groups. This may 
indicate that the severity of ID did not affect the response of iron stores to the 
intervention.  
Hepcidin and ferritin are the two principal iron biomarkers that are important in iron 
metabolism, and have been demonstrated to be well-associated (Ganz et al., 2008). 
Both of these biomarkers were not affected by the vitamin D intervention in the 
present study, however, it was observed that there was a significant and strong 
positive association between the increase in plasma ferritin and hepcidin 
concentrations (r=0.605, p=0.0001). This observation indicates that replenishment in 
the iron stores, signified by plasma ferritin concentration, is linear with the increase 
in plasma hepcidin concentration, to regulate intestinal iron uptake and avert the 
presence of iron overload. The non-significant observation in both biomarkers may 
be interrelated, and it may have not been sufficient for the vitamin D used in the 
present study to act on both biomarkers on a short study duration of 8-weeks, to 
allow the effect to be substantially observed.   
Due to paucity in well-designed intervention studies, especially RCTs investigating a 
possible mechanism linking vitamin D and iron metabolism, it is still unclear whether 
the influence of vitamin D on iron regulation occurred as a result of suppressed 
HAMP gene expression which controls hepcidin expression, as postulated and 
demonstrated in a study by Bacchetta et al. (2013). As previously discussed in 
Section 1.8.2.5, the mechanism of action of vitamin D in exerting additional effect on 
the recovery on iron status was proposed to revolve around suppression of hepcidin 
expression, pro-inflammatory cytokine production, and rate of erythropoiesis.  
Under normal circumstances, iron homeostasis involves the circulation of 
transferrin-iron complexes that move to the bone marrow to produce red blood cells 
in erythropoiesis. The senescent erythrocytes will degenerate and will be engulfed 
by macrophages. Iron is then reutilised and released back into the circulation to 
repeat the same erythropoiesis process (Smith et al., 2016a). Depending upon 
physiological demands, haem and non-haem dietary iron will enter the labile iron 
pool from intestinal iron uptake. When there are increased concentrations of pro-
inflammatory cytokines, production of the RBCs in the bone marrow is suppressed. 
This will then lower half-life of RBCs as a result of elevated macrophages and 
phagocytic activity activation.  
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IL-6 and IL-1β are among the cytokines that are capable of stimulating the liver into 
increasing production of the HAMP gene, which leads to increased or decreased 
iron uptake (Smith et al., 2016a). Vitamin D has been demonstrated in previous 
studies to be capable of increasing proliferation of erythroid precursors in the bone 
marrow to support erythropoiesis by decreasing the expression of pro-inflammatory 
cytokines which cause the suppression of hepcidin. Decreased cytokines and 
suppressed hepcidin leads to higher iron bioavailability for RBC production and 
haemoglobin synthesis (Smith et al., 2016a). Figure 5.1 illustrates the proposed 
mechanism on the effect of vitamin D supplementation on iron homeostasis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Proposed mechanism of vitamin D action on iron metabolism - 
adapted from Smith et al. (2016a) 
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In the present study, there was no change in the participants’ energy, 
macronutrients, iron, and vitamin D intake at baseline and post-intervention, which 
shows that participants did not modify their daily intake during the intervention 
period to iron-rich or vitamin D-rich food selections that may have influenced the 
findings. The mean (±S.D) daily iron intake, in particular, was 1.7-fold higher at 
baseline (16.5 ± 2.3 mg), relative to typical iron intake of adult women reported in 
the NDNS (9.6 ± 3.0 mg), and remained similar at post-intervention (17.2 ± 2.6 mg), 
suggesting good compliance of iron-fortified breakfast consumption, as reflected in 
the food diary provided at the beginning and end of study period. Despite the non-
significant increase in mean daily iron intake, it was observed that the overall iron 
intake at post-intervention, irrespective of groups, was 116% of the UK RNI. This 
implies that 9 mg added iron in the breakfast cereal provided in study may have 
improved participants’ dietary iron intake, as the recent NDNS population data 
reported an iron intake of  approximately 9.6 mg daily in adult women which 
approximates to only 65% of RNI.  
Findings in the present study show that iron-fortified breakfast cereal consumption 
can lead to iron status recovery, by 5 components of full blood count indices, 
observed within the groups. The significant improvement in MCH was observed 
within both vitamin D and placebo groups, but the improvement in the haemoglobin, 
haematocrit, RBC, MCH and MCHC was observed only within the intervention 
group. However, none of the improvements observed in iron status biomarkers 
measure in the present study were associated with mean daily iron intake. Findings 
in the present study that showed significant improvement in haemoglobin 
concentrations and haematocrit levels following vitamin D supplementation is 
consistent with findings reported in a study by Toxqui et al. (2013) which 
investigated the effect of iron and vitamin D-fortified skimmed milk consumption on 
iron status in Spanish women with low iron status. The participants were 
randomised to receive 500 ml/day of iron/vitamin D fortified skimmed milk (Fe/D 
group) or iron-fortified skimmed milk (Fe group). No significant difference was 
observed in the increase of haemoglobin concentrations between the groups at 
post-intervention relative to baseline. However, at interim (week-8), mean (±S.D) 
haemoglobin concentration and haematocrit levels were significantly higher in the 
Fe/D group (13.3 ± 0.8 g/dl and 39.5 ± 2.3%) compared to the Fe group (13.0 ± 0.7 
g/dl and 38.7 ± 2.2%) (p<0.05), respectively.  
 
 187 
 
The study was a longer 16-week controlled trial, however, the significant increase in 
haemoglobin concentration and haematocrit levels in the Fe+D group were 
observed at the interim point of the study (8-week), which is total duration of the 
present study. The study found significantly higher mean (±S.D) RBC in the Fe+D 
group (4.41 ± 0.28 x 1012/L) as opposed to the Fe group (4.28 ± 0.29 x 1012/L), at  
interim point, however, the RBC increase in the present study observed in the 
vitamin D group showed distinct trend towards significance (p=0.055). Despite a 
longer study duration in comparison to the present study, the study did not show a 
significantly higher mean (±S.D) plasma ferritin concentration at post-intervention in 
the Fe+D group (23.8 ± 11.3 µg/l), compared to the Fe group (24.3 ± 12.0 µg/l) 
(Toxqui et al., 2013), which is also comparable to the findings in the present study. 
In spite of disparity in the iron and vitamin D amount used in the fortified food 
vehicle, study duration, and type of fortification food vehicle used in both studies, the 
findings were found to be comparable, particularly in relation to the fact that the 
significant impact of vitamin D was observed as early as at 8-week point, which was 
the interim point in the study which is equal to post-intervention in the present study.  
A study by Madar et al. (2016) also carried out over period of 16 weeks observed no 
significant improvement in plasma ferritin or haemoglobin concentrations following 
vitamin D3 supplementation. The study was carried out in 251 adults, randomised 
into 3 groups of vitamin D3 (1000 IU), vitamin D3 (400 IU) and placebo. No 
significant effect of the intervention was observed between the vitamin D and 
placebo groups, on all iron status biomarkers including serum ferritin and 
haemoglobin concentrations.  Similar non-significant observations were 
demonstrated when both groups of vitamin D3 were analysed as pooled (1000 and 
400 IU) or separately in comparison to the placebo group (Madar et al., 2016). The 
study recruited healthy adults of both genders, as opposed to the present study 
which included ID participants who may have greater reaction to iron therapy, due to 
their high physiological demands of iron. The study also did not include any iron 
intervention as opposed to the present study, hence, the difference in the 
observation. However, despite the differences, the study demonstrated no 
significant association between the increase in plasma 25(OH)D concentrations with 
any improvement in iron status biomarkers, which is in agreement with the present 
study.  
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A study carried out by Smith et al. (2016a) applied a similar study design as 
Bacchetta et al. (2013) to investigate the potential role of vitamin D in iron 
homeostasis using a bolus dose of vitamin D3 (250 000 IU) in 28 adults, but 
included not only plasma hepcidin concentrations, but also the measure of plasma 
pro-inflammatory cytokines. It was observed that plasma hepcidin concentration 
(geometric mean, 95% CI) significantly reduced by 73% at post-intervention in the 
vitamin D group (2.4, 0.8-7.4 ng/ml) compared to the placebo group (9.0, 4.8-16.7 
ng/ml) (p=0.04), consistent with the observation from Bacchetta et al. (2013) study. 
However, no significant increase in plasma ferritin or cytokine concentrations was 
observed between the groups (Smith et al., 2016a), indicating that vitamin D may 
directly affect hepcidin expression independent to the presence of inflammation 
(Smith et al., 2016a). Differences in the type of vitamin D supplements (daily vs 
bolus at 1 occasion), sample size (50 vs 7-28 participants), participants’ iron status 
background (ID vs healthy), and the higher dose (1500 IU vs 100 000-250 000 IU) 
used in Smith et al. (2016a) and Bacchetta et al. (2013) studies as opposed to the 
present study may have contributed to the difference in observed rate of hepcidin 
response following vitamin D supplementation. In addition, both of the specified 
studies, compared to the present study that was carried out in a specific population 
of women with low iron stores, measured the acute effect of a very high dose of 
vitamin D supplementation in a set of healthy participants as a pilot study. Despite 
the promising observation on the action of vitamin D on hepcidin suppression, which 
supports the hypothesised mechanism, it was suggested by Smith et al. (2016a) that 
a long-term study should be carried out to further validate the findings.  
The present study included the measurement of plasma PTH and VDBP 
concentrations as novel aspects of the study, aimed to investigate the potential 
underlying mechanism on vitamin D metabolism. Interestingly, the present study 
found that increased plasma VDBP concentrations were associated with 
improvement in iron status biomarkers. As yet, there is no existing evidence to 
support the findings and the link is still unclear. However, a cross-sectional study 
including data of 2073 male and female adults aged > 25 years who were recruited 
as part as population-based Canadian osteoporosis cohort study (Dastani et al., 
2014) observed a weak, but significant association between plasma 25(OH)D and 
VDBP concentrations (r=0.19, p<0.001). The connection observed in the Dastani et 
al. (2014) study is expected as VDBP is the carrier protein of 25(OH)D which is the 
active metabolite of vitamin D.  
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Based on those findings, in combination with observations in the present study, it 
was hypothesised that a significant effect may have been observed if a longer 
duration was applied in the present study for the upregulation of plasma VDBP 
concentrations to have an effect on the circulating 25(OH)D concentrations, and 
ultimately lead to greater improvement in iron status biomarkers. PTH was the only 
vitamin D biomarker that showed significant within-group changes following vitamin 
D supplementation. The mean (±S.D)  concentrations decreased to 6.81 ± 7.03 
pmol/l (interim) and 7.24 ± 7.84 pmol/l  (post-intervention) from 7.77 ± 8.11 
(baseline) in the intervention group, indicating good response to the vitamin D 
supplementation. However, the change was not associated with any improvement in 
the iron status biomarkers, which may have suggested that PTH is not involved in 
iron status regulation, via vitamin D mechanism of action. The findings in the present 
study are consistent with the findings of Madar et al. (2016) who did not observe any 
association between plasma PTH concentrations with the baseline concentration of 
haemoglobin and plasma ferritin. It was postulated that a decrease in haemoglobin 
concentration which caused a lower prevalence of anaemia, will only occur via the 
action of vitamin D if there is a very high concentration of PTH, which will normally 
be found in patients with bone marrow fibrosis (Madar et al., 2016). It was noted in 
the present study that plasma PTH concentrations were only slightly higher than the 
normal threshold at baseline and post-intervention in both groups, and this may not 
be sufficiently high enough to affect participants’ iron status biomarkers. Memon et 
al. (2013) carried out a cross-sectional study which included data of 10750 
participants in the USA aged > 18 years with a history of diabetes and hypertension, 
to compare the association between serum PTH and haemoglobin concentrations in 
diabetic and non-diabetic patients. It was observed that higher concentrations of 
serum PTH were associated with higher concentration of haemoglobin. This 
improvement in haemoglobin concentration was however, significant only in 
participants with diabetes (0.1. g/dl, 95% CI: 0.01-0.14, p<0.0001) but not in non-
diabetics (0.01 g/dl, 95 CI: -0.03-0.05, p=0.83) (Memon et al., 2013). This 
observation may be explained by the fact that production of the erythropoietin 
hormone is impaired in diabetic patients, proceeding to development of chronic 
kidney disease, hence the higher anaemia prevalence (Memon et al., 2013).  
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The significant finding observed within-group in the present study in the mean 
(±S.D)  haemoglobin concentration from 13.60 ± 1.15 g/dl (baseline) to 13.84 ± 0.98 
g/dl (post-intervention) in the vitamin D group, independent of intervention, following 
consumption of iron-fortified cereal is consistent with findings from a 6-month 
randomised controlled trial carried out in children by Barbosa, Taddei, Palma, 
Ancona-Lopez, and Braga (2012). The 24-week double-blind randomised controlled 
study was carried out in 324 Brazilian children aged 2-6 years, randomised into 2 
groups to consume iron-fortified rolls with ferrous sulphate (FS group) or unfortified 
rolls (control group). It was observed in the study that the increase in haemoglobin 
concentration was significantly higher at post-intervention in both groups, but no 
effect of intervention on iron status was observed. Mean (±S.D) haemoglobin 
concentration was reported to increase to 12.6 ± 1.1 g/dl (FS group) and 12.3 ± 1.1 
g/dl (control group) at post-intervention compared to baseline concentration of 11.7 
± 1.0 g/dl and 11.1 ± 1.1 g/dl in FS and control groups, respectively. The study also 
demonstrated that participants with lower baseline haemoglobin concentration (Hb < 
11 g/dl), exhibited a greater improvement in haemoglobin concentration, and is 
similar to that demonstrated in the present study. The increase in haemoglobin 
concentration (2 g/dl) was greater in participants with low haemoglobin 
concentration, as opposed to participants with a higher haemoglobin concentration 
in the FS group (0.6 g/dl) (p=0.0001). A similar observation was demonstrated in the 
control group, as the increase was higher in in participants with low haemoglobin 
concentration (2.1 g/dl), as opposed to participants with a higher haemoglobin 
concentration (0.5 g/dl) (Barbosa et al., 2012). It should, however be noted that the 
study is not comparable with the present study in terms of the population used, 
study duration and methods used to measure haemoglobin concentrations as the 
study used capillary blood samples as opposed to venous blood samples in the 
present study.  
It was previously demonstrated in a meta-analyses by Casgrain et al. (2012) that 
participants’ response to iron intervention vastly depends on their initial iron status, 
and that the improvement is greater in the anaemic participants, as the iron 
requirement is higher due to physiological demands. Additionally, a meta-analysis 
carried out in pool of 18 trials that investigated the effect of iron-fortified foods on 
haemoglobin concentration in children concluded that a longer duration of children 
receiving the fortified foods may result in a higher haemoglobin concentration (Athe, 
Rao, & Nair, 2014).  
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Gera et al. (2012) demonstrated that overall iron status was improved following iron 
fortification intervention, analysed in a meta-analysis carried out with the inclusion of 
60 iron fortification intervention studies. However, there was significant 
heterogeneity in the included trials, observed in the improvement of these following 
outcomes; serum ferritin (I2=95.6, p<0.001), transferrin saturation (I2=85, p<0.001), 
sTfR (I2=98.4, p<0.001), and TIBC (I2=81.4, p<0.001), except for serum iron 
(I2=41.6, p=0.128). This indicates inconsistencies in the improvement of iron status 
biomarkers observed in those 60 trials included in the meta-analysis. The index of 
heterogeneity (I2) of 75% is classified as high heterogeneity (Higgins, Thompson, 
Deeks, & Altman, 2003). Post-hoc sub analysis carried out in 33 of the included 
RCTs demonstrated that haemoglobin concentration had greater improvement in 
cereal-based studies, and is consistent with findings in the present study which used 
iron-fortified breakfast cereal. Lower response to haemoglobin concentration was 
however observed when the analyses included only adults (Gera et al., 2012).  
Existing literature investigating the effect of iron-fortified foods on iron status has 
yielded inconsistent findings. Table 5.3 summarises recent iron fortification studies 
that were carried out in various settings, reporting significant or non-significant 
improvement in iron status biomarkers, in comparison to the present study. 
192 
 
Table 5.3 Recent iron fortification studies using cereal and cereal-based products 
Study Population / Mean 
age (±SD) or range 
(years) 
Intervention/Duration Main findings  Remarks 
[1]  ID women (n=50) / 
27.4 ± 9.4 years 
Iron-fortified cereal  
8 weeks  
Mean (±S.D) Hb concentration 
was significantly higher at 
post-intervention in the vitamin 
D group (13.84 ± 0.98 g/dl) 
compared to placebo group 
(12.83 ± 1.25 g/dl) (p<0.05).  
  
Present study 
[2]  Children (n=112) / 
6-12 years 
Iron-fortified biscuits 
(high or low iron)  
4 months 
Mean (±S.D) Hb concentration 
was significantly higher at 
post-intervention in the high 
iron group (10.52 ± 0.81 g/dl) 
compared to low iron group 
(10.03 ± 0.73 g/dl) (p<0.01).   
 
The study showed Hb concentration can be increased 
in 4 months, but the present study showed that Hb 
concentration is increased at shorter duration of 8 
weeks. The high iron group received 30 mg of 
iron/serving of biscuits, whilst iron-fortified cereal used 
in the present study consist of 9 mg iron/serving and 
the study included only measurement of Hb to 
evaluate iron status.   
 
[3]  Children (n=47) /  
3-6 years 
A: Fortified biscuit 
(FS) 
B: Fortified biscuit 
(HIC) 
C: Placebo biscuit  
10 weeks 
Mean (±S.D) Hb concentration 
was significantly higher at 
post-intervention in A (14.9 ± 
0.2 g/dl) and B (14.7 ± 0.3 
g/dl) compared to placebo 
group (15.3 ± 0.3 g/dl) 
(p<0.05).  
 
The study recruited the participants in group C as non-
anaemic to make comparison with anaemic 
participants in group A and B, hence the higher Hb 
concentration at post-intervention. None of the other 
iron status biomarkers measured in the study (RBC, 
MCV, MCH, MCHC, and SF) was affected by the 
intervention, comparable to the present study. The 
study is limited with small sample size in each group. 
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[4]  Adolescents (n=71) 
/ 16-19 
12 weeks 
Iron-fortified or 
unfortified breakfast 
cereals  
 
Mean (±S.D) SF concentration 
was significantly higher at 
post-intervention in the 
intervention group (22.1 ± 16.7 
µg/l) compared to unfortified 
group (18.4 ± 11.6 µg/l) 
(p<0.001). 
 
The study found no effect of intervention on the other 
iron biomarkers including Hb, Hct and MCV, contrary 
to the present study. The participants in the study was 
not ID as opposed to the present study, but was 
recruited based on riboflavin status (EGRAC > 1.4 and 
Hb < 13.7 g/dl). The significant observation reported in 
the study may be due to a longer study duration, as 
opposed to 8 weeks in the present study. 
 
*[1] Present study (Chester, UK), [2] Bal, Nagesh, Surendra, Chiradoni, and Gomathy (2015) (India), [3] Quintero-Gutiérrez, González-Rosendo, Pozo, and Villanueva-Sánchez 
(2016) (Mexico), [4] Powers, Stephens, Russell, and Hill (2016) (United Kingdom) 
Hb: haemoglobin; SF: serum ferritin; RBC: red blood cell; MCV: mean corpuscular volume: MCH: mean corpuscular haemoglobin; MCHC: mean corpuscular haemoglobin 
concentration; FS: ferrous sulphate; HIC: haem iron concentrate; EGRAC: erythrocyte glutathione reductase activation coefficient 
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5.3.2 Clinical implications of findings  
Iron deficiency in the UK is currently 16% in premenopausal women with vitamin D 
deficiency prevalence of 8% during summer months and up to 39% during winter 
months in adults, therefore, these findings are clinically relevant. It was 
demonstrated in the present study that concurrent incidence of both VDD and ID 
exists in women with low iron stores, and vitamin D therapy (1500 IU) was shown to 
be effective in the recovery of both nutritional deficiencies to the normal levels. The 
recent UK SACN report on vitamin D proposed (i) a recommended threshold to 
define VDD (< 25 nmol/l) and (ii) reference nutrient intake of vitamin D (10 µg or 400 
IU/day) for the general population aged > 4 years.  
The present study demonstrated that with a 3.8-fold higher dose than the newly 
proposed RNI, vitamin D status of participants was improved from deficient to 
sufficient levels at the end of study, and with that improvement in vitamin D status, 
participants’ iron status was also improved. This shows the necessity of vitamin D 
supplementation, in addition to a healthy balanced diet with iron-rich foods, in the 
general population, or specifically for at-risk groups of ID. On the strength of 
findings, a higher RNI for vitamin D deserves consideration, taking into account the 
prevalence of ID also. The findings in this present study are of great importance at 
the healthcare level as the utilisation of vitamin D supplements may lead to the 
recovery of iron status but also vitamin D status. These findings have wider 
implications, especially in the countries where the concurrent incidence of vitamin D 
and iron deficiencies are common, and it was demonstrated in the present study that 
there was a concurrent incidence of both nutritional deficiencies.  
The present study was one of the few investigations carried out addressing the 
subject matter, and findings showed that not only iron status was improved following 
vitamin D supplementation, but also vitamin D status. In the UK, iron has been 
mandatorily added to white and brown flour since 1953 as a means of fortification 
(SACN, 2010), and with the novel insight of the role of vitamin D in upregulation of 
iron status, it may clinically useful if the most consumed foods by at-risk groups in 
the population are mandatorily or voluntarily fortified with both vitamin D and iron. 
This could be a potential alternative to therapeutic management of ID using oral 
supplements that will normally cause gastrointestinal discomfort and other adverse 
events, leading to unsuccessful iron status recovery. A longitudinal study carried out 
in 140 women age 20-55 years living in Surrey, UK showed that vitamin D deficiency 
is more prevalent in Asian women as opposed to Caucasian women across all 4 
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seasonal variations. The prevalence is particularly higher during winter season, with 
80.8% in Asian women as opposed to 10% in Caucasian women (Darling et al., 
2013), indicating that the magnitude of this nutritional problem is greater in specific 
population.  
The clinical aspects of findings in the present study may be particularly applied to 
the recovery of iron status in iron deficient population, through the use of vitamin D 
supplementation as a novel iron absorption enhancer. The recently proposed RNI of 
400 IU for vitamin D, however, was derived from RCTs that were focused on the 
prevention of risk to develop musculoskeletal health consequences. It was shown in 
the present study a higher dose of 1500 IU of vitamin D did not lead to replenished 
iron stores, thus, a higher RNI should be considered to take into account deficiency 
in iron. This is important not only for premenopausal women who require extra iron 
due to physiological demands and menstrual losses, but to young children and 
adolescents who needs iron for growth, cognitive and motor developments who are 
also prone to incidence of ID and VDD.  
The findings from the current study showed that iron-fortified breakfast cereals, 
which have been reported in the NDNS to contribute to the highest proportion of 
mean daily iron intake, are efficient in improving participants’ iron status. This could 
be a suitable alternative in the management of ID as opposed to the oral iron 
therapy that has poor adherence due to adverse gastrointestinal events, and vitamin 
D supplementation has not been shown to be associated with any adverse events in 
the present study or any existing body of literature. Vitamin D may be incorporated 
in the strategies of managing ID, and enriching diets with vitamin D, as an iron 
absorption enhancer, can be integrated in the dietary advice for general population 
at health care levels.  
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5.4 LIMITATIONS OF STUDY 
5.4.1 Experimental study 1 (Chapter 3) 
The present study was carried out in a cohort of healthy premenopausal women 
aged between 19-37 years, who were not regularly consuming nutritional 
supplements and did not report any known gastro-intestinal or metabolic illness 
which may interfere with iron absorption. Even though there was a small sample 
size in the present study, it was a controlled metabolic study and sufficiently 
powered. However, a higher number of participants may have yielded a better 
representation of the population. Women of childbearing-age were recruited for the 
present study as it has been suggested that this specific age group is an at-risk 
group that is susceptible to iron deficiency, due to combined factors of poor dietary 
intake, high physiological requirement, and menstrual losses (Murray-Kolb & Beard, 
2007). Future studies should include an additional iron deficient (plasma ferritin 
concentration < 15 µg/l) group, as plasma ferritin concentration has been shown to 
affect the rate of iron absorption. In addition, measuring plasma hepcidin 
concentration will be useful to establish the mechanism of how iron is regulated.  
The present study took place in controlled laboratory conditions and may not 
represent the actual dietary pattern of free-living participants. Future research could 
use a longer intervention period which includes specific frequency of tea 
consumption, consumed alongside typical dietary intake at household level, 
however, nutrient interactions may not be able be accounted for as a mixed diet 
contains combinations of potential enhancers or inhibitors. In addition, the present 
study included only 2 time intervals of tea consumption; simultaneously and 1-hour 
with the test meal, due to time and resource constraints. Future research should 
include more time intervals, possibly up to 2 or 3 hours, to investigate whether the 
iron absorption will continuously increase with longer time intervals. Despite its 
limitation, findings of the present study are suffice to initiate further investigations, 
particularly in the aspect of variability of time intervals.  
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5.4.2 Experimental study 2 (Chapter 4) 
The initial power calculation yielded a sample size of 31 participants/group to show 
a significant effect of intervention on iron status recovery. Due to time constraint, 
only 50 eligible participants were recruited (out of 62 who were eligible but did not 
agree to partake) to enrol in the study. However, it should be noted that the 
screening phase involved 186 women carried out in short period of time. The study 
did not include a specific measure of compliance for the iron-fortified breakfast 
cereal consumption (e.g; returning empty cereal container), however, the 3-day food 
diary provided at baseline and post-intervention returned by participants showed 
that the provided cereal were all consumed at breakfast, as suggested. The present 
study did not utilise the gold method (liquid chromatography-tandem mass 
spectrometry) in the measurement of the vitamin D active metabolite, circulating 
25(OH)D concentrations, due to time and resources constraints. An automated 
immunoanalyser with ready-to-use reagent strips and commercially available ELISA 
kits were used in the present study. However, the automated analyser used for the 
measurement of vitamin D is accredited with Vitamin D External Quality Assessment 
Scheme (DEQAS), to ensure that the measurement is corroborated with quality 
controls. In addition, findings in the present study may be not be able to be 
generalised to another study population, especially in the area where iron and 
vitamin D are not prevalent and cereal is not the most consumed breakfast to be 
suitable as a food fortification vehicle. However, the major strength of present study 
is the double-blind randomised controlled trial study design, carried out in a specific 
population of marginally low and low iron stores, which allows interpretation of 
findings to be extrapolated in clinical settings. The present study also measured 
vitamin D status biomarkers in order to provide information on the mechanism of 
action which was not measured in previous intervention studies, and included a 
measure of dietary intake to account for confounding factors that may affect the 
findings.  
Future studies should be carried out on a larger scale with a longer study duration, 
focusing on the at-risk groups such as children, pregnant, non-pregnant women and 
using a higher vitamin D3 dose in supplement form, to be able to observe a 
substantial effect on iron stores and hepcidin response. The inclusion of more 
specific vitamin D status biomarkers such as calcitriol should be considered in 
designing future studies. 
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5.5 FUTURE PERSPECTIVES OF STUDY 
Future studies should focus on investigations of iron absorption from the whole diet, 
administered for a longer duration to take into account adaptation responses and 
allowing a more accurate representative of absorption. Single meal studies have 
been demonstrated to have a pronounced effect on iron absorption (Armah, 
Carriquiry, Sullivan, Cook, & Reddy, 2013), however, the controlled laboratory 
environment method employed in the present study enabled monitoring of potential 
confounding factors that may affect iron absorption.  
With respect to iron absorption studies, future work should not only focus on dietary 
elements, but also non-dietary elements that may affect absorption, such as 
infection, or host-related factors such as body fat in relation to hepcidin expression. 
The investigation from the second part of the research is one of the few studies 
carried out to the best of our knowledge investigating the potential role of vitamin D 
in iron status regulation. Future directions should involve establishing the 
underpinning mechanism on the action of vitamin D on iron homeostasis, and the 
inclusion of additional vitamin D status biomarkers may improve the understanding 
of the mechanism. The investigations should address all the at-risk groups that are 
susceptible to both ID and VDD, across the world as these nutritional deficiencies 
are not only prevalent in the UK, but worldwide despite different implementations of 
various strategies to manage the issues.  
5.6 CONCLUSION  
It can be concluded in the first part of the research that tea containing polyphenol 
can be distinctly regarded as a potent inhibitor of non-haem iron absorption, and it is 
also evident that a 1-hour time interval between a cereal-based meal and tea 
consumption will counteract the inhibitory effect of tea on iron absorption. It was 
demonstrated in the present study that plasma hepcidin concentration was 
associated with iron absorption, strengthening the findings from previous studies 
that demonstrated the role of hepcidin as an iron regulator in iron homeostasis.  
The second part of the research concluded that breakfast cereal, used as a 
fortification vehicle, consumed daily as part of normal diet, is effective in the 
recovery of iron status indices. The key finding was that vitamin D, consumed daily 
in supplement form, at a dose of 1500 IU, was shown to be a novel potential iron 
absorption enhancer, lead to the recovery of haemoglobin concentrations and 
haematocrit levels in women with marginal and low iron stores. The finding in the 
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present study that shows baseline concentration of haemoglobin plays a role in 
dictating participants’ response to intervention strengthens the existing published 
literature. Both studies carried out as part of the research have provided new 
insights on how manipulating dietary elements can lead to improved iron absorption 
and overall iron status in premenopausal women. Figure 5.2 summarises both 
studies carried out, including outcomes and clinical implications of the research.  
 
 
Figure 5.2 Overall overview, outcomes and clinical implications of the studies 
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supplementation 
method 
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Roles of dietary elements in iron absorption  
INHIBITION EFFECT 
Tea containing polyphenol 
ENHANCEMENT EFFECT 
Vitamin D3 supplementation 
1-hour time interval between 
meal and tea increases iron 
absorption 
Recovery of iron status  
CLINICAL IMPLICATIONS: 
Better management of ID at healthcare level by practitioners and at population 
level by policy makers 
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Findings in both studies will be applicable for a nutrition-related practitioners or 
governing institutions for the purpose of: 
(i) prevention: dissemination of information to the general population on how to 
maximise iron absorption from the diet by manipulating the specified dietary 
components, and to maintain normal iron status;  
(ii) management and treatment: prescribing diet with vitamin D, to the individual with 
ID and VDD at healthcare levels in order to recover normal iron and vitamin D 
status; and  
(iii) regulation: reconsidering the RNI for both iron and vitamin D, taking into account 
the bioavailability (iron) and not only musculoskeletal health consequences but also 
ID (vitamin D). Regulation also includes the implementation of fortified iron/vitamin D 
food items to address the concurrent incidence of these nutritional deficiencies.  
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APPENDIX B 
EMAIL OF INVITATION TO PARTICIPANTS 
 
 
 
Dear Participants, 
 
INVESTIGATION INTO THE INHIBITORY EFFECTS OF TEA CONSUMPTION ON 
IRON BIOAVAILABILITY IN A COHORT OF HEALTHY UK WOMEN, USING A 
STABLE IRON ISOTOPE 
 
I am a PhD student from the Department of Clinical Sciences and Nutrition at 
University of Chester. I am inviting you to take part in my study which will investigate 
whether tea consumption effects how well we absorb iron, particularly in iron 
deficient “at risk” groups such as women. Iron tracers will be incorporated into meals 
in this study as they are one of the best methods for investigating how well iron is 
absorbed in human body and it is non-invasive.  With the findings, I hope to use the 
information to help individuals with impaired iron status to maximize their iron 
absorption, which ultimately helps in the improvement of their iron status.  
  
This invitation is especially for women between the ages of 19-40 years who: are 
healthy, non-pregnant or lactating, with no history of gastro-intestinal and metabolic 
disorders, have not donated blood in the past 2 to 6 months, and are not regularly 
taking nutritional supplements.  
 
If you fulfil the inclusion criteria and you decide to take part in this study, you will be 
required to attend clinics on 6 different occasions.  After an overnight fast, a 
baseline fasting blood sample will be drawn followed by the administration of the first 
test meal, in which 14 days post dosing, another blood sample will be drawn to 
measure the iron absorption. The same procedure will be repeated for the next 
clinics, where there will be another 2 test meals and a reference dose of iron.   
 
Detailed information on the study procedure will be provided, should you be 
interested to take part in this study.  
 
 
 
 
Yours sincerely, 
 
Salma Ahmad 
MPhil/PhD Student (Clinical Sciences and Nutrition) 
ironstudy@chester.ac.uk 
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APPENDIX C 
 
 
Participant information sheet 
 
INVESTIGATION INTO THE INHIBITORY EFFECTS OF TEA CONSUMPTION ON 
IRON BIOAVAILABILITY IN A COHORT OF HEALTHY UK WOMEN, USING A 
STABLE IRON ISOTOPE 
 
You are being invited to take part in a research study.  Before you decide, it is 
important for you to understand why the research is being carried out and what it will 
involve.  Please take time to read the following information carefully and discuss it 
with others if you wish.  Ask us if there is anything that is not clear or if you would 
like more information.  Take time to decide whether or not you wish to take part. 
Thank you for reading this. 
What is the purpose of the study? 
The study aims to find out whether tea consumption with or between meals will 
affect iron absorption in healthy childbearing-aged women. Iron tracers will be 
incorporated into meals in this study as they are one of the best methods for 
investigating how well iron is absorbed in human body and it is non-invasive.  The 
study is being carried out to find out whether consuming tea with a meal and 1 hour 
after meal will decrease iron absorption among the participants.  
Why have I been chosen? 
You have been chosen because you satisfy the inclusion criteria of the study which 
includes the following : female; between the ages of 19-40 years; healthy; non-
pregnant or lactating; with no history of gastro-intestinal and metabolic disorders; 
have not donated blood within the last 6 months and are not regularly taking 
nutritional supplements. 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form.  If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not 
affect you in any way. If you decide to withdraw at any time during the course of the 
study, samples collected so far may still be used in the study.  
What will happen to me if I take part? 
You will be asked to attend 6 clinics on 6 separate days where you will be expected 
to fast overnight for at least 10 hours prior to each session. There will be a time 
interval of 14 days between clinics, to allow the incorporation of the iron tracer into 
your system. Each clinic will last for approximately 45 minutes between 8 and 10 am 
in the morning, and participants will be asked not to consume any food or beverage 
4 hours after the test meals.  
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Participants will attend each clinic after an overnight fast, and 30 ml blood samples 
(5 teaspoons) will be collected at each clinic. 
 
Clinic 1 (Day 0): Participants will fill in a screening test questionnaire, followed by 
physical measurement of height and weight. If you satisfy the inclusion criteria, you 
will be invited to participate in the study and be asked to sign an informed consent 
form. Participants will be asked about their food consumption over the previous 24-
hours and will be required to complete a 3-day food diary after this clinic to reflect 
habitual intake. Participants will be given explanation on how to record the dietary 
intake and be required to bring the completed 3-day diary during Clinic 2. A baseline 
blood sample will be drawn and this will be followed by consumption of the control 
test meal. 
 
Clinic 2 (Day 14): Measurement of height and weight followed by a baseline blood 
sample and 24 hour food recall. This will be followed by consumption of the test 
meal II with tea given simultaneously with the test meal.  
 
Clinic 3 (Day 28): Measurement of height and weight followed by a baseline blood 
sample and 24 hour food recall. This will be followed by consumption of the test 
meal III with tea given 1 hour after the test meal.  
 
Clinic 4 (Day 42): Prior to the completion of the study, participants will be given 
another 3 days food diary which has to be completed before the clinic for another 
assessment of dietary intake. Measurement of height and weight followed by 
baseline blood sample and 24 hour food recall. This will be followed by consumption 
of the reference dose iron without any meal. 
 
Clinic 5 (Day 56): Measurement of height and weight followed by a final blood 
sample drawn to measure the incorporation of iron from the reference dose and 24 
hour food recall. 
 
The test meals will be administered as breakfast, where you will be given a 
standardised meal consisting oat porridge with one cup of tea with semi-skimmed 
milk, with additional sugar and sweetener if requested.  
 
What are the possible disadvantages and risks of taking part? 
There are no disadvantages foreseen in taking part in the study, however, you may 
experience slight discomfort and bruising due to the blood sampling procedures. 
The study will take a total of 56 days which may cause you inconvenience by having 
to attend 6 separate clinics. Unfortunately, it will not be possible to reimburse any 
travel or other expenses incurred in taking part in the study.  
What are the possible benefits of taking part? 
There are no direct benefits from taking part in the study, however you will be 
provided with a full dietary analysis and an iron status assessment. Dietary analysis 
will be performed by the researcher on completion of the study using dietary 
software.  The analysis will be based on the information you will have already 
provided us in your 3-day food diaries and 24 hour recalls during the course of the 
study and will thus require no further time input. We will provide information on your 
nutrient intake, in particular, iron intake, as well as information on your total energy, 
fat, carbohydrate and protein intake with a comparison to recommended values.  
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If the iron status assessment reveals a deficient iron status, with your consent, we 
will notify your GP of your involvement in the study and of any adverse findings. You 
will also be contributing to the development of knowledge on how to maximise iron 
absorption in the prevention of iron deficiency.  
What if something goes wrong? 
In the event of adverse findings during the course of the study, the researcher will 
contact your GP with permission. If you wish to complain or have any concerns 
about any aspect of the way you have been approached or treated during the 
course of this study, please contact Professor Sarah Andrew, Dean of the Faculty of 
Life Sciences, University of Chester, Parkgate Road, Chester, CH1 4BJ, 01244  
513055. 
Will my taking part in the study be kept confidential? 
All information which is collected about you during the course of the research will be 
kept strictly confidential and anonymised so that only the researcher carrying out the 
research will have access to such information. An 8ml plasma sample will be 
anonymised and stored in freezer located in the Clinical Laboratory in the 
Department of Clinical Sciences & Nutrition at the University of Chester. The 
samples will be retained for further research purposes after the completion of study, 
which will be subject to further ethical approval.  
What will happen to the results of the research study? 
The results will be written up into a dissertation for my PhD thesis. Individuals who 
participate will not be identified in any subsequent report or publication. After the 
completion of the study, a sheet summarising the findings of the study will be sent to 
the participants via post or email.  
Who is organising the research? 
The research is conducted as part of a PhD research project in Human Nutrition 
within the Department of Clinical Sciences & Nutrition at the University of Chester. 
The study is organised with supervision from the department, by Salma Ahmad, a 
PhD student. The academic supervisor for the study is a Senior Lecturer from 
Department of Clinical Sciences and Nutrition, Dr Sohail Mushtaq and he can be 
contacted at 01244513367 or s.mushtaq@chester.ac.uk. 
Who may I contact for further information? 
If you would like more information about the research before you decide whether or 
not you would be willing to take part, please contact: Salma Ahmad at 01244511198 
or email at ironstudy@chester.ac.uk. 
Thank you for your interest in this research. 
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APPENDIX D 
 
Title of Project: Investigation into the inhibitory effects of tea consumption on iron 
bioavailability in a cohort of healthy UK women, using a stable iron isotope. 
 
Name of Researcher:  Salma Ahmad 
Please initial box 
 
 
________________                 _________________              __________________ 
Name of Participant                               Date Signature 
___________________           _________________              __________________ 
Researcher                                              Date Signature 
 
1 for participant; 1 for researcher 
 
 
 
 
 
1. I confirm that I have read and understand the information sheet for 
the above study. I have had the opportunity to ask questions and 
have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason and without my legal 
rights being affected. 
 
3. (If appropriate) I understand that relevant sections of my medical 
notes and data collected during the study may be looked by 
individuals from University of Chester, from regulatory authorities or 
from the NHS Trust, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to 
my records. 
 
4.  (If appropriate) I agree to my General Practitioner being informed of 
my participation in the study. 
 
5.  I agree to the use of my blood samples in this research study. 
 
6. I agree to gift my blood samples (8 ml of plasma) to be stored and 
used  for a period of 5 years in future similar studies which have 
been given a favourable ethical opinion by a Research Ethics 
Committee.  
 
7. I agree to take part in the above study. 
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APPENDIX G 
 
 
 
 
 
 
  
Faculty of Life Sciences 
Research Ethics Committee 
frec@chester.ac.uk 
 
24/06/2015 
 
Salma Faeza Ahmed Fuzi 
Sibell Street 
Chester 
 
Dear Salma  
Study title: A double blind randomised controlled trial to investigate 
the effect of vitamin D3 supplementation on iron 
absorption and hepcidin response in iron deficient 
women 
FREC reference: 1078/15/SF/CSN 
Version number: 1  
Thank you for sending your application to the Faculty of Life Sciences Research 
Ethics Committee for review. 
I am pleased to confirm ethical approval for the above research, provided that you 
comply with the conditions set out in the attached document, and adhere to the 
processes described in your application form and supporting documentation.   
The final list of documents reviewed and approved by the Committee is as follows: 
Document                       Version Date 
Application Form                                   1 May 2015 
Appendix 1 – List of References 1 May 2015 
Appendix 2 – Summary CV for Lead Researcher 1 May 2015 
Appendix 3 – Email of invitation to participants 1 May 2015 
Letter(s) of invitation to participants 1 May 2015 
Appendix 4 – Participant Information Sheet [PIS] 2 May 2015 
Appendix 5 – Participant Consent Form 1 May 2015 
Appendix 6 – Risk Assessment 1 May 2015 
Appendix 7 – Copies of advertising materials 2 May 2015 
Appendix 8 – Questionnaire for screening test 1 May 2015 
Appendix 9 – Flow chart of study protocol 1 May 2015 
Appendix 10 – 3 day food diary dietary form 1 May 2015 
Response to FREC request for further information 
or clarification 
 May 2015 
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Please note that this approval is given in accordance with the requirements of 
English law only. For research taking place wholly or partly within other jurisdictions 
(including Wales, Scotland and Northern Ireland), you should seek further advice 
from the Committee Chair / Secretary or the Research and Knowledge Transfer 
Office and may need additional approval from the appropriate agencies in the 
country (or countries) in which the research will take place. 
 
With the Committee’s best wishes for the success of this project.  
 
Yours sincerely, 
 
 
 
Dr. Stephen Fallows 
Chair, Faculty Research Ethics Committee 
 
Enclosures: Standard conditions of approval.   
Cc. Supervisor/FREC Representative 
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APPENDIX I 
 
EMAIL INVITATION TO PARTICIPANTS  
 
Dear All,  
 
A STUDY TO INVESTIGATE THE EFFECT OF VITAMIN D3 SUPPLEMENTATION 
ON IRON STATUS IN IRON DEFICIENT WOMEN 
 
Would you like to know about how vitamin D can affect your iron status and how well 
your system is absorbing the iron food products that you consumed?  
 
If you are female and aged between the ages of 19-49 years and are: healthy, non-
pregnant or lactating, with no history of gastro-intestinal and metabolic disorders, 
have not donated blood in the past 6 months, and are not regularly taking nutritional 
supplements, I would like to invite you to take part in my PhD study which will 
investigate the effect of vitamin D supplementation consumed with iron fortified 
breakfast cereals to treat iron deficiency. Iron fortified breakfast cereals will be given 
to you to be consumed for 8 weeks, together with vitamin D supplements which 
have been shown to help increase iron status. With the findings, I hope to use the 
information to help individuals with impaired iron status to improve their iron status. 
 
If you are interested in partaking in the study, you will be asked to attend a 
screening clinic to assess if you are iron deficient, and I will contact you to inform 
about your iron levels. If you then fulfil the inclusion criteria and you decide to take 
part in this study, you will be asked to attend clinics on 3 separate occasions. 
Detailed information on the study procedure is provided in the attached Participant 
Information Sheet (PIS), should you be interested to take part in this study.  
 
All clinics will take place at the University of Chester Main Campus and upon 
completion of the study, you will be provided with a full dietary analysis and an iron 
status and vitamin D assessment, a £25 Amazon voucher as well as contributing to 
increasing our knowledge in this area of nutrition and health.  
 
Thank you for taking the time to read this email and if you would like to take part in 
the study or if you have any questions, I would very much like to hear from you. You 
can contact me at 01244511198 or email ironstudy@chester.ac.uk.  
 
 
 
Yours sincerely, 
 
Salma Ahmad 
MPhil/PhD Student (Clinical Sciences and Nutrition) 
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APPENDIX K 
 
Participant information sheet 
 
A STUDY TO INVESTIGATE THE EFFECT OF VITAMIN D3 SUPPLEMENTATION 
ON IRON STATUS IN IRON DEFICIENT WOMEN 
 
You are being invited to take part in a research study.  Before you decide, it is 
important for you to understand why the research is being carried out and what it will 
involve.  Please take time to read the following information carefully and discuss it 
with others if you wish.  Ask us if there is anything that is not clear or if you would 
like more information. Take time to decide whether or not you wish to take part. 
Thank you for reading this. 
What is the purpose of the study? 
The study aims to investigate about the effect of vitamin D supplementation 
consumed with iron fortified breakfast cereals to treat iron deficiency. Iron fortified 
breakfast cereals will be given to you to be consumed for 8 weeks, together with 
vitamin D supplements which have been shown to help increase iron status where 
there will be 3 clinics for blood sampling to assess the iron status.  
Why have I been chosen? 
You have been chosen because you satisfy the inclusion criteria of the study which 
includes the following: iron deficient; female; between the ages of 19-49 years; 
healthy; non-pregnant or lactating; with no history of gastro-intestinal and metabolic 
disorders; have not donated blood within the last 6 months and are not regularly 
taking nutritional supplements.  
Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not 
affect you in any way.  
What will happen to me if I take part? 
You will first be asked to attend a screening clinic to assess your eligibility to take 
part in the study. A 6 ml venous blood (1 teaspoon) will be drawn to assess full 
blood counts, including haemoglobin concentrations. A blood ferritin concentration, 
which is a measure of your iron status with a threshold of below 20.0 µg/L and 
vitamin D concentration of below 250 nmol/l will be used for inclusion. You will then 
have to fill in a screening test questionnaire that will provide information about your 
health status, drugs/medication/supplement usage, or recent occurrences of 
illness/trauma/injury, followed by physical measurement of height and weight. 
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If you satisfy the screening criteria, you will be randomly allocated into 2 groups; 
a) Fe group (iron fortified breakfast cereals and placebo) 
b) Vitamin D group (iron fortified breakfast cereals and vitamin D3) 
You will be asked to consume 60 grams of iron fortified breakfast cereals containing 
a total of 9 mg of iron daily for 8 weeks with either placebo or vitamin D3 according 
to your assigned group. You will be asked to consume the iron fortified breakfast 
cereals in the morning with 200 ml of ultra-high temperature (UHT) semi-skimmed 
milk daily for a period of 8 weeks. Please consume the vitamin D or placebo in the 
evening with 200 ml of water. Please maintain your dietary habits and physical 
activity and not to donate blood during the course of study. You will be asked to 
return the remaining supplements at the final clinic (week 8), and compliance will be 
estimated. 
You are required to attend 3 clinics on 3 separate days where you will be expected 
to fast overnight for at least 8 hours prior to each session. During the fasting period 
before each clinic, you are permitted to consume water only. There will be a time 
interval of 4 weeks between each clinic which each clinic will last for approximately 
20-30 minutes between 8 and 10 am in the morning. 
 
Clinic 1 (Week 0): Measurement of height and weight will be followed by a blood 
sample (30 ml). You will be required to complete a 3-day food diary after this clinic 
to reflect your habitual intake. 
 
Clinic 2 (Week 4): Measurement of weight will be followed by a blood sample (30 
ml). 
 
Clinic 3 (Week 8): Measurement of weight followed by a final blood sample (30 ml). 
You will be required to complete a 3-day food diary after this clinic to reflect your 
habitual intake.  
 
What are the possible disadvantages and risks of taking part? 
There are no disadvantages foreseen in taking part in the study, however, you may 
experience slight discomforts and bruising due to the blood sampling procedures. 
Unfortunately, it will not be possible to reimburse any travel or other expenses 
incurred in taking part in the study.  
What are the possible benefits of taking part? 
You will be provided with a full dietary analysis, iron and vitamin D status. Dietary 
analysis will be performed by the researcher on completion of the study using 
dietary analysis software. The analysis will be based on the information you will 
have already provided us in your 3-day food diaries during the course of the study 
and will thus require no further time input. We will provide you information on your 
nutrient intake, in particular, iron intake, as well as information on your total energy, 
fat, carbohydrate and protein intake with a comparison to recommended values. 
Upon completion of the study, you will also be given a £25 Amazon voucher. You 
will also be contributing to the development of knowledge on how to maximise iron 
absorption in the prevention of iron deficiency. 
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What if something goes wrong? 
If you wish to complain or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, please contact 
Professor Sarah Andrew, Dean of the Faculty of Life Sciences, University of 
Chester, Parkgate Road, Chester, CH1 4BJ, 01244  513055. 
Will my taking part in the study be kept confidential? 
All information which is collected about you during the course of the research will be 
kept strictly confidential and anonymised so that only the researcher carrying out the 
research will have access to such information. The blood sample will be anonymised 
and stored in freezer located in the Clinical Laboratory in the Department of Clinical 
Sciences & Nutrition at the University of Chester.  
What will happen to the results of the research study? 
The results will be written up into a dissertation for a PhD thesis and potential 
publications. Individuals who participate will not be identified in any subsequent 
report or publication. After the completion of the study, a sheet summarising the 
findings of the study will be sent to the participants via post or email.  
Who is organising the research? 
The research is conducted as part of a PhD research project in Human Nutrition 
within the Department of Clinical Sciences & Nutrition at the University of Chester. 
The study is organised with supervision from the department, by Salma Ahmad, a 
PhD student.  
Who may I contact for further information? 
If you would like more information about the research before you decide whether or 
not you would be willing to take part, please contact: Salma Ahmad at 01244511198 
or email at ironstudy@chester.ac.uk. 
 
Thank you for your interest in this research. 
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APPENDIX L 
PARTICIPANT CONSENT FORM 
 
 
 
TITLE OF PROJECT: A STUDY TO INVESTIGATE THE EFFECT OF VITAMIN D3 
SUPPLEMENTATION ON IRON STATUS IN IRON DEFICIENT WOMEN 
 
NAME OF RESEARCHER:  SALMA AHMAD 
Please initial box 
 
1.  I confirm that I have read and understand the information sheet for the 
above study. I have had the opportunity to ask questions and have 
had these answered satisfactorily.  
 
2.  I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason and without my legal 
rights being affected.  
 
3.  I agree to take part in the above study. 
 
 
4.  I agree to allow my blood samples to be stored for a period of 5 years 
for related nutritional studies.  
 
 
___________________             _________________                 _______________ 
Name of Participant                               Date    Signature 
 
___________________             _________________                  _______________ 
Researcher                                              Date    Signature 
 
 
 
1 for participant; 1 for researcher 
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APPENDIX M 
 
QUESTIONNAIRE FOR SCREENING TEST 
TITLE OF PROJECT:  
 
A STUDY TO INVESTIGATE THE EFFECT OF VITAMIN D3 SUPPLEMENTATION 
ON IRON STATUS IN IRON DEFICIENT WOMEN 
 
NAME OF RESEARCHER:  SALMA AHMAD 
Participant ID :  
Date :  
SECTION 1 : PERSONAL DETAILS 
1. Name : ______________________________________________________ 
2. Address : ______________________________________________________ 
3. Age  : ________________ years 
4. Date of birth : ___ day ___ month _____ year 
5. Ethnicity : Please (√) in the appropriate box. 
White Black Asian Other 
    
6. Contact No : ______________________________________________________ 
7. Email : ___________________________________________________________ 
 
SECTION 2 : SCREENING 
Please tick where appropriate.  
 
Question YES NO 
1. Are you pregnant?   
2. Are you lactating?   
3. Are you a vegetarian?   
4. Have you ever donated blood within the past 6 months?   
5. Are you regularly taking nutritional supplements?   
If yes, please state : 
 _________________________________________________ 
  
6. Do you have any gastro-intestinal or metabolic disorders?   
If yes, please state : 
 _________________________________________________ 
  
 
SECTION 3 : IRON DEFICIENCY SCREENING TEST VALUE 
1.  Serum Ferritin : ___________________________ µg/l 
2. Vitamin D  : ___________________________ nmol/l 
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APPENDIX N 
SAMPLE OF PLASMA CRP ELISA KIT CALIBRATION CURVE 
 
 
 
      4- & 5-Parameters-Logistics Curve Fit
All rights reserved A.Swart 2013
STEP 1 Set Extras/Macro/Security to medium (for SOLVER), close, reopen and activate
STEP 2 Enter the standard concentrations in the blue column [std] in the order of increasing concentration, for 0 set 0,0000001
STEP 3 Enter the corresponding standard readings in the yellow  column
STEP 4 Optional w eighting: set value of B for w eighting. For no w eighting set B = 0. 0 <-- enter value here
STEP 5 start optimizing by clicking f irst the 4-PL button. Note the goodness of f it: MAE and the distribution of error in the plot. 
Click the 5-PL button and compare the goodness of f it.
STANDARDS
[std] Reading Fit Recalc. Conc. % Recovery WSE         ERROR PLOT
0 0.006
0.78 0.1105 0.12115047 0.648513306 83.1427316 0.00011343 -0.0106505 0.0106505
1.56 0.184 0.18929757 1.501713526 96.2636876 2.8064E-05 -0.0052976 0.0052976
3.12 0.3685 0.33615788 3.458691296 110.85549 0.00104601 0.03234212 0.0323421
6.25 0.616 0.62807822 6.1152105 97.843368 0.00014588 -0.0120782 0.0120782
12.5 1.1045 1.12003617 12.27287368 98.1829894 0.00024137 -0.0155362 0.0155362
25 1.779 1.76223052 25.44458844 101.778354 0.00028122 0.01676948 0.0167695
50 2.363 2.36854917 49.63605648 99.272113 3.0793E-05 -0.0055492 0.0055492
8 8                       SUM OF WEIGHTED SQUARED ERRORS 0.00188677 error abs error
        PARAMETERS
3.228255676 (max) a rdg. of asymptotic maximum
-1.21117521 (slope) b slope at inversion point
22.17719949 (IC50) c concentration at inversion point (4-PL)
0.067257173 (min) d rdg. of asymptotic minimum
1 (sym f) s asymmetry factor (if  s = 1, f it is 4-PL)
R2 0.98079095 MEAN ABSOLUTE ERROR   (MAE) 0.01403189
0
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SAMPLE OF PLASMA HEPCIDIN ELISA KIT CALIBRATION CURVE 
 
 
 
 
SAMPLE OF PLASMA FERRITIN ELISA KIT CALIBRATION CURVE 
 
 
 
 
y = 1.2868x - 0.4
R² = 0.9686
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SAMPLE OF PLASMA PTH ELISA KIT CALIBRATION CURVE 
 
 
 
SAMPLE OF PLASMA STFR ELISA KIT CALIBRATION CURVE 
 
 
 
y = 0.0021x + 0.0179
R² = 0.9985
0.000
0.100
0.200
0.300
0.400
0.500
0.600
0.700
0 50 100 150 200 250 300 350
y = 0.0225x - 0.0885
R² = 0.9842
-0.500
0.000
0.500
1.000
1.500
2.000
0 10 20 30 40 50 60 70 80 90
 246 
 
SAMPLE OF PLASMA CRP ELISA KIT CALIBRATION CURVE 
 
 
 
 
      4- & 5-Parameters-Logistics Curve Fit
All rights reserved A.Swart 2013
STEP 1 Set Extras/Macro/Security to medium (for SOLVER), close, reopen and activate
STEP 2 Enter the standard concentrations in the blue column [std] in the order of increasing concentration, for 0 set 0,0000001
STEP 3 Enter the corresponding standard readings in the yellow  column
STEP 4 Optional w eighting: set value of B for w eighting. For no w eighting set B = 0. 0 <-- enter value here
STEP 5 start optimizing by clicking f irst the 4-PL button. Note the goodness of f it: MAE and the distribution of error in the plot. 
Click the 5-PL button and compare the goodness of f it.
STANDARDS
[std] Reading Fit Recalc. Conc. % Recovery WSE         ERROR PLOT
0 0.007 0.102206879
0.78 0.091 0.09215082 0.769544489 98.6595498 1.3244E-06 -0.0011508 0.0011508
1.56 0.170 0.17151969 1.538847366 98.6440619 4.0792E-06 -0.0020197 0.0020197
3.12 0.321 0.30780017 3.277749425 105.056071 0.00016129 0.01269983 0.0126998
6.25 0.518 0.53611968 5.979333526 95.6693364 0.00032832 -0.0181197 0.0181197
12.5 0.912 0.89985911 12.73635945 101.890876 0.0001474 0.01214089 0.0121409
25 1.436 1.44016768 24.88649743 99.5459897 1.737E-05 -0.0041677 0.0041677
50 2.164 2.16288283 50.02676109 100.053522 3.809E-07 0.00061717 0.0006172
8 8                       SUM OF WEIGHTED SQUARED ERRORS 0.00066016 error abs error
        PARAMETERS
5.959574321 (max) a rdg. of asymptotic maximum
-0.83395697 (slope) b slope at inversion point
97.49846412 (IC50) c concentration at inversion point (4-PL)
-0.01249464 (min) d rdg. of asymptotic minimum
1 (sym f) s asymmetry factor (if  s = 1, f it is 4-PL)
R2 0.98703420 MEAN ABSOLUTE ERROR   (MAE) 0.00727368
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SAMPLE OF PLASMA HEPCIDIN ELISA KIT CALIBRATION CURVE 
 
 
 
 
      4- & 5-Parameters-Logistics Curve Fit
All rights reserved A.Swart 2013
STEP 1 Set Extras/Macro/Security to medium (for SOLVER), close, reopen and activate
STEP 2 Enter the standard concentrations in the blue column [std] in the order of increasing concentration, for 0 set 0,0000001
STEP 3 Enter the corresponding standard readings in the yellow  column
STEP 4 Optional w eighting: set value of B for w eighting. For no w eighting set B = 0. 0 <-- enter value here
STEP 5 start optimizing by clicking f irst the 4-PL button. Note the goodness of f it: MAE and the distribution of error in the plot. 
Click the 5-PL button and compare the goodness of f it.
STANDARDS
[std] Reading Fit Recalc. Conc. % Recovery WSE         ERROR PLOT
0 0.014 1.012576899
15.6 0.028 0.02934311 14.04606525 90.0388798 3.3971E-06 -0.0018431 0.0018431
31.3 0.049 0.04937731 30.64496379 97.9072326 7.6967E-07 -0.0008773 0.0008773
62.5 0.100 0.09396465 66.17174837 105.874797 3.064E-05 0.00553535 0.0055353
125 0.190 0.1936688 122.8024281 98.2419425 1.346E-05 -0.0036688 0.0036688
250 0.416 0.41474956 250.67779 100.271116 1.5636E-06 0.00125044 0.0012504
500 0.897 0.89751925 499.7394405 99.9478881 2.6962E-07 -0.0005192 0.0005192
1000 1.918 1.91737732 1000.059613 100.005961 1.505E-08 0.00012268 0.0001227
8 8                       SUM OF WEIGHTED SQUARED ERRORS 0.00005012 error abs error
        PARAMETERS
25.80904625 (max) a rdg. of asymptotic maximum
-1.16695828 (slope) b slope at inversion point
8737.704141 (IC50) c concentration at inversion point (4-PL)
0.013341699 (min) d rdg. of asymptotic minimum
1 (sym f) s asymmetry factor (if  s = 1, f it is 4-PL)
R2 0.99637292 MEAN ABSOLUTE ERROR   (MAE) 0.00197385
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SAMPLE OF PLASMA VDBP ELISA KIT CALIBRATION CURVE 
 
 
 
 
      4- & 5-Parameters-Logistics Curve Fit
All rights reserved A.Swart 2013
STEP 1 Set Extras/Macro/Security to medium (for SOLVER), close, reopen and activate
STEP 2 Enter the standard concentrations in the blue column [std] in the order of increasing concentration, for 0 set 0,0000001
STEP 3 Enter the corresponding standard readings in the yellow  column
STEP 4 Optional w eighting: set value of B for w eighting. For no w eighting set B = 0. 0 <-- enter value here
STEP 5 start optimizing by clicking f irst the 4-PL button. Note the goodness of f it: MAE and the distribution of error in the plot. 
Click the 5-PL button and compare the goodness of f it.
STANDARDS
[std] Reading Fit Recalc. Conc. % Recovery WSE         ERROR PLOT
0 0.004 5.264749467
15.6 0.054 0.05489397 15.3382294 98.3219833 1.9431E-06 -0.001394 0.001394
31.3 0.140 0.14479055 30.42329003 97.1990097 2.799E-05 -0.0052906 0.0052906
62.5 0.361 0.34717069 64.44176323 103.106821 0.00017767 0.01332931 0.0133293
125 0.797 0.80516612 123.9415457 99.1532365 6.6686E-05 -0.0081661 0.0081661
250 1.836 1.83397867 250.1761483 100.070459 2.3144E-06 0.00152133 0.0015213
6 6                       SUM OF WEIGHTED SQUARED ERRORS 0.00027660 error abs error
        PARAMETERS
141.2072717 (max) a rdg. of asymptotic maximum
-1.18288391 (slope) b slope at inversion point
9657.271296 (IC50) c concentration at inversion point (4-PL)
-0.01547738 (min) d rdg. of asymptotic minimum
1 (sym f) s asymmetry factor (if  s = 1, f it is 4-PL)
R2 0.99068715 MEAN ABSOLUTE ERROR   (MAE) 0.00594026
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SAMPLE OF PLASMA 25(OH)D ELISA KIT CALIBRATION CURVE 
 
 
 
 
      4- & 5-Parameters-Logistics Curve Fit
All rights reserved A.Swart 2013
STEP 1 Set Extras/Macro/Security to medium (for SOLVER), close, reopen and activate
STEP 2 Enter the standard concentrations in the blue column [std] in the order of increasing concentration, for 0 set 0,0000001
STEP 3 Enter the corresponding standard readings in the yellow  column
STEP 4 Optional w eighting: set value of B for w eighting. For no w eighting set B = 0. 0 <-- enter value here
STEP 5 start optimizing by clicking f irst the 4-PL button. Note the goodness of f it: MAE and the distribution of error in the plot. 
Click the 5-PL button and compare the goodness of f it.
STANDARDS
[std] Reading Fit Recalc. Conc. % Recovery WSE         ERROR PLOT
0 2.159 2.15539905 1.2967E-05 0.00360095 0.0036009
2.5 1.549 1.57924467 2.725566408 109.022656 0.00091474 -0.0302447 0.0302447
5 1.352 1.31356386 4.554135124 91.0827025 0.00147734 0.03843614 0.0384361
15 0.846 0.84906719 15.11482554 100.765504 9.4076E-06 -0.0030672 0.0030672
35 0.522 0.54722164 38.10340258 108.866865 0.00063613 -0.0252216 0.0252216
70 0.385 0.3699375 65.25720245 93.2245749 0.00022688 0.0150625 0.0150625
150 0.244 0.2425661 148.3418635 98.8945757 2.0561E-06 0.0014339 0.0014339
7 7                       SUM OF WEIGHTED SQUARED ERRORS 0.00327952 error abs error
        PARAMETERS
2.15539905 (max) a rdg. of asymptotic maximum
0.827140397 (slope) b slope at inversion point
7.986407072 (IC50) c concentration at inversion point (4-PL)
0.073477083 (min) d rdg. of asymptotic minimum
1 (sym f) s asymmetry factor (if  s = 1, f it is 4-PL)
R2 0.97198598 MEAN ABSOLUTE ERROR   (MAE) 0.01672386
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APPENDIX O 
 
 
 
TITLE OF PROJECT: INVESTIGATION INTO THE INHIBITORY EFFECTS OF 
TEA CONSUMPTION ON IRON BIOAVAILABILITY IN A COHORT OF HEALTHY 
UK WOMEN, USING A STABLE IRON ISOTOPE 
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We would like you to keep his diary of everything you eat and drink over 3 
consecutive days. Please do not change your habits because you are keeping this 
record.  
 
Instructions: 
 Record your eating & drinking as you go, not from memory. Remember to include 
foods/drinks consumed between meals or at night. 
 Ensure you write the day, time, description of meal or drink, amount and preparation 
method as well as brand of product or recipe as appropriate.  
 Homemade dishes: Record the name of the recipe, ingredients with the amounts & 
cooking method. These can be recorded on the page at the back of the diary.  Take-
aways/restaurant: Including as much information as you can eg; vegetable curry with 
chickpeas, onions, aubergine. 
 Please ensure you record the portion size of the food you eat—there is a guide 
overleaf to aid you with this. 
 Remember to include any added sugar in drinks/food, salt during cooking or at table 
and table sauces.  
 Ensure you note details of cooking method—grilled, fried (in oil/butter), steamed, 
boiled etc. 
 If foods come with added vitamins or minerals please write this down. 
 Do write down any exercise participated in during each day. Include the  nature of 
exercise (eg swimming) and length of time. 
 Make a note in the margin if there is any wastage and the quantity. 
 
Physical Activity: 20mins household chores (mopping, hovering) 20min slow jog 
 
Guide to Portion Sizes: 
For foods, quantity can be described using: 
Household measures: eg 1 tsp of sugar, 2 thick slices of bread, 1/2 cup gravy.  
Weights from labels: eg 125g pot yoghurt, 420g tin baked beans 
Number of items: 4 fish fingers, 1 regular sized doughnut 
For drinks, quantity can be described using: 
The size of the glass (eg large glass ) or the volume (300ml) 
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Use the example below to assist you with completing your food diary 
 Day: Monday                  Date: 21st October 
  
Time Location Description of food/drink  
consumed  
Brand Amount/  
Portion Size 
 7.50am Home Bran flakes with semi 
skimmed milk. Banana 
Tesco Bran Flakes. 1 cup cereal,  
1/2 cup milk 
1/2 banana 
12.30pm Work Sandwich 
Tuna 
Light mayo  
Tomato 
Flapjack 
Hovis wholemeal,  
Tesco tuna 
Tesco mayo,   
Homemade 
flapjack (See 
recipe, serves 15) 
2 medium 
slices. 
1 can tuna 
2 tbsp. mayo 
1 tomato 
2 servings 
flapjack 
  
 
Guide to help with information required to complete your food diary. 
Food/Drink Description/Preparation Portion Size/Quantity 
Bacon Back, middle, streaky, smoked, un-
smoked.  Fried in oil/ grilled 
Number of rashers 
Beefburger Homemade (ingredients), from packet 
(brand name), with or without bread roll 
Number, large or small, grams 
Butter, Margerine Give full product name Thick/average/thin spread, 
spoons 
Cheese Name, brand & type eg cheddar, low 
fat 
Number of slices, thick or thin 
cut 
Milk Type semi, skimmed, UHT, Soya Pints, glass (size of volume), 
cup. For on cereal: 
little/normal/drowned. For in 
tea/coffee: little/some/lot 
Salad Ingredients, what sort of dressing (oil, 
mayonnaise) 
Amount of each component (eg 
number of tomatoes, slices 
cucumber, tablespoons of 
dressing) 
Savoury snacks 
in packets 
What sort; Cheddars, walkers, give 
brand name 
Size, packet weight, number 
Soup What sort, brand name, canned, 
packet, instant, homemade 
Tablespoons, mug, bowl (small, 
medium, large) 
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Pasta Type (eg fresh, dried, white, 
wholemeal, canned, in sauce, type of 
filling) 
Tablespoons (or how much dry 
pasta used per portion) 
Vegetables What sort, how cooked, added 
butter/oil/sauce 
Tablespoons, number of florets, 
weight from tins 
 
Typical quantities of drinks in various containers measured in ml 
  Small 
glass 
Average 
glass 
Large 
glass 
Vending 
cup 
Cup Mug 
Soft drinks 150 200 300       
Wine 125 175 250       
Hot drinks       170 190 260 
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Day:     Date : 
 
Time Location Description of food / drink 
consumed 
Brand Amount/Quantity 
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Day:     Date : 
 
Time Location Description of food / drink 
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Day:     Date : 
 
Time Location Description of food / drink 
consumed 
Brand Amount/Quantity 
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Recipes 
For any homemade meals/snacks please write down the ingredients used, 
quantities and preparation method in the space provided. 
—————————————————————————————————————
—————————————————————————————————————
—————————————————————————————————————
—————————————————————————————————————
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APPENDIX P 
IRON STUDY 
24 HOUR RECALL FORM 
Participant ID  
Clinic                 
Date  
Which day of the week does this record?  
Sun  Mon  Tues  Weds  Thurs  Fri  Sat  
  
Is this a typical day?  
 
 
Time Location Description of food / drink 
consumed 
Brand Amount/Quantity 
          
          
          
          
     
     
 
Yes  No  
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APPENDIX Q 
 
 
TITLE OF PROJECT: A STUDY TO INVESTIGATE THE EFFECT OF VITAMIN 
D3 SUPPLEMENTATION ON IRON STATUS IN IRON DEFICIENT WOMEN 
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We would like you to keep his diary of everything you eat and drink over 3 
consecutive days. Please do not change your habits because you are keeping this 
record.  
 
Instructions: 
 Record your eating & drinking as you go, not from memory. Remember to include 
foods/drinks consumed between meals or at night. 
 Ensure you write the day, time, description of meal or drink, amount and preparation 
method as well as brand of product or recipe as appropriate.  
 Homemade dishes: Record the name of the recipe, ingredients with the amounts & 
cooking method. These can be recorded on the page at the back of the diary.  Take-
aways/restaurant: Including as much information as you can eg; vegetable curry with 
chickpeas, onions, aubergine. 
 Please ensure you record the portion size of the food you eat—there is a guide 
overleaf to aid you with this. 
 Remember to include any added sugar in drinks/food, salt during cooking or at table 
and table sauces.  
 Ensure you note details of cooking method—grilled, fried (in oil/butter), steamed, 
boiled etc. 
 If foods come with added vitamins or minerals please write this down. 
 Do write down any exercise participated in during each day. Include the nature of 
exercise (eg swimming) and length of time. 
 Make a note in the margin if there is any wastage and the quantity. 
 
Physical Activity: 20mins household chores (mopping, hovering) 20min slow jog 
 
Guide to Portion Sizes: 
For foods, quantity can be described using: 
Household measures: eg 1 tsp of sugar, 2 thick slices of bread, 1/2 cup gravy.  
Weights from labels: eg 125g pot yoghurt, 420g tin baked beans 
Number of items: 4 fish fingers, 1 regular sized doughnut 
For drinks, quantity can be described using: 
The size of the glass (eg large glass ) or the volume (300ml) 
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Use the example below to assist you with completing your food diary 
 Day: Monday                  Date: 21st October 
  
Time Location Description of food/drink  
consumed  
Brand Amount/  
Portion Size 
 7.50am Home Bran flakes with semi 
skimmed milk. Banana 
Tesco Bran Flakes. 1 cup cereal,  
1/2 cup milk 
1/2 banana 
12.30pm Work Sandwich 
Tuna 
Light mayo  
Tomato 
Flapjack 
Hovis wholemeal,  
Tesco tuna 
Tesco mayo,   
Homemade 
flapjack (See 
recipe, serves 15) 
2 medium 
slices. 
1 can tuna 
2 tbsp. mayo 
1 tomato 
2 servings 
flapjack 
  
 
Guide to help with information required to complete your food diary. 
Food/Drink Description/Preparation Portion Size/Quantity 
Bacon Back, middle, streaky, smoked, un-
smoked.  Fried in oil/ grilled 
Number of rashers 
Beefburger Homemade (ingredients), from packet 
(brand name), with or without bread roll 
Number, large or small, grams 
Butter, Margerine Give full product name Thick/average/thin spread, 
spoons 
Cheese Name, brand & type eg cheddar, low 
fat 
Number of slices, thick or thin 
cut 
Milk Type semi, skimmed, UHT, Soya Pints, glass (size of volume), 
cup. For on cereal: 
little/normal/drowned. For in 
tea/coffee: little/some/lot 
Salad Ingredients, what sort of dressing (oil, 
mayonnaise) 
Amount of each component (eg 
number of tomatoes, slices 
cucumber, tablespoons of 
dressing) 
Savoury snacks 
in packets 
What sort; Cheddars, walkers, give 
brand name 
Size, packet weight, number 
Soup What sort, brand name, canned, 
packet, instant, homemade 
Tablespoons, mug, bowl (small, 
medium, large) 
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Pasta Type (eg fresh, dried, white, 
wholemeal, canned, in sauce, type of 
filling) 
Tablespoons (or how much dry 
pasta used per portion) 
Vegetables What sort, how cooked, added 
butter/oil/sauce 
Tablespoons, number of florets, 
weight from tins 
 
Typical quantities of drinks in various containers measured in ml 
  Small 
glass 
Average 
glass 
Large 
glass 
Vending 
cup 
Cup Mug 
Soft drinks 150 200 300       
Wine 125 175 250       
Hot drinks       170 190 260 
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Day:     Date : 
 
Time Location Description of food / drink 
consumed 
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Recipes 
For any homemade meals/snacks please write down the ingredients used, 
quantities and preparation method in the space provided. 
—————————————————————————————————————
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APPENDIX R 
Investigation into the inhibitory effects of tea consumption on iron 
bioavailability in a cohort of healthy UK women, using a stable iron isotope 
(57Fe). 
Salma Faeza, AHMAD FUZI1 2; Sohail, MUSHTAQ1 
1Department of Clinical Sciences & Nutrition, University of Chester, United Kingdom 
2Department of Nutrition & Dietetics, Universiti Putra Malaysia, Malaysia 
 
Tea can inhibit iron absorption but it is unclear whether time of consumption in 
relation to a meal influences bioavailability. The present study assessed the effect of 
time variability of tea consumption on iron absorption from a test meal in non-
pregnant women using a 57Fe tracer. Twelve women (mean age (± SD): 24.8 ± 6.9 
years) were given a standardised breakfast extrinsically labelled with 4mg 57Fe on 3 
occasions with a 14 day time interval between each test meal. The isotope was 
administered with: (a) water (b) tea simultaneously (c) tea 1 hour after the meal. A 
reference dose was also administered (3mg 57Fe with 35mg ascorbate) without a 
test meal. Fasted blood samples were collected and iron absorption was estimated 
by the erythrocyte iron incorporation method, assuming 80% absorption. Mean iron 
absorption (± SD) was 5.69 ± 8.5%, 3.57 ± 4.2% and 5.73 ± 5.4% (test meals a,b 
and c, respectively). Mean iron absorption was found to be 2.2% higher when tea 
was consumed 1 hour after test meals (p = 0.05). Mean total iron absorbed was also 
found to be 0.043mg higher when tea was consumed 1 hour after the meal (p= 
0.049). This study demonstrates that consuming tea separately from a meal may 
attenuate the inhibition effect thus increasing iron absorption. This may have 
implications for those who are iron deficient.  
 
KEYWORDS: Iron deficiency; Iron bioavailability; Tea 
 
